WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, December 14, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L13	L12 AND 3D6	129
☐	L12	Alzheimers disease	38299
☐	L11	L10 AND 3D6	28
☐	L10	530/387.1,387.3,388.1,388.15.CCLS.	4742
☐	L9	Yednock.IN.	49
☐	L8	Yednock-T.IN.	10
☐	L7	Yednock-Ted.IN.	7
☐	L6	Saldanha.IN.	163
☐	L5	Saldanha-J.IN.	12
☐	L4	Saldanha-Jose.IN.	17
☐	L3	Basi.IN.	62
☐	L2	Basi-G.IN.	6
☐	L1	(Basi-Guriq.IN.)	6

END OF SEARCH HISTORY

h e b b cg b chh e f c e c ch

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for 3D6 Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1 - 43 of 43 One page.

1: Scragg JL, Fearon IM, Boyle JP, Ball SG, Varadi G, Peers C. Related Articles, Links

Alzheimer's amyloid peptides mediate hypoxic up-regulation of L-type Ca2+ channels.
FASEB J. 2004 Oct 19; [Epub ahead of print]
PMID: 15494446 [PubMed - as supplied by publisher]

2: Oldoni I, Weiblen R, Inkelmann MA, Flores EF. Related Articles, Links

Production and characterization of monoclonal antibodies to a Brazilian bovine herpesvirus type 5.
Braz J Med Biol Res. 2004 Feb;37(2):213-21. Epub 2004 Jan 30.
PMID: 14762576 [PubMed - indexed for MEDLINE]

3: Nguyen TH, Loux N, Dagher I, Vons C, Carey K, Briand P, Hadchouel M, Franco D, Jouanneau J, Schwall R, Weber A. Related Articles, Links

Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met.
Cancer Gene Ther. 2003 Nov;10(11):840-9.
PMID: 14605670 [PubMed - indexed for MEDLINE]

4: Liu X, Zhen Y. Related Articles, Links

Antitumor effects of monoclonal antibody Fab' fragment-containing immunoconjugates.
Chin Med Sci J. 2002 Mar;17(1):1-6.
PMID: 12894876 [PubMed - indexed for MEDLINE]

5: Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT. Related Articles, Links

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.
J Neurosci. 2002 Sep 15;22(18):7873-8.
PMID: 12223540 [PubMed - indexed for MEDLINE]

6: Elmore LW, Domson K, Moore JR, Kornstein M, Burks RT. Related Articles, Links

Expression of c-kit (CD117) in benign and malignant human endometrial epithelium.
Arch Pathol Lab Med. 2001 Jan;125(1):146-51.
PMID: 11151069 [PubMed - indexed for MEDLINE]

7: Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E. Related Articles, Links

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.
Amyloid. 2000 Dec;7(4):245-58.
PMID: 11132093 [PubMed - indexed for MEDLINE]

8: Wang W, Zhou J, Xu L, Zhen Y. Related Articles, Links

Antineoplastic effect of intracellular expression of a single-chain antibody

h cb h g e e e fcg e ch b e

directed against type IV collagenase.
J Environ Pathol Toxicol Oncol. 2000;19(1-2):61-8.
PMID: 10905509 [PubMed - indexed for MEDLINE]

9: Cavacini LA, Wisnewski A, Peterson JE, Montefiori D, Emes C, Duval M, Kingsbury G, Wang A, Scadden D, Posner MR. Related Articles, Links

A human anti-HIV autoantibody enhances EBV transformation and HIV infection.
Clin Immunol. 1999 Dec;93(3):263-73.
PMID: 10600338 [PubMed - indexed for MEDLINE]

10: Jackson LR, Trudel LJ, Fox JG, Lipman NS. Related Articles, Links

Monoclonal antibody production in murine ascites. II. Production characteristics.
Lab Anim Sci. 1999 Feb;49(1):81-6.
PMID: 10090099 [PubMed - indexed for MEDLINE]

11: Zhou YY, Li CL. Related Articles, Links

Spin-triplet contribution to zero-field splittings for 3d4 and 3d6 ions at tetragonal sites.
Phys Rev B Condens Matter. 1993 Dec 1;48(22):16489-16499. No abstract available.
PMID: 10008231 [PubMed - as supplied by publisher]

12: Jiang CY, Du ML, Zhou YY. Related Articles, Links

Contributions to zero-field splitting from spin triplets of 3d4 and 3d6 ions in tetragonal symmetry.
Phys Rev B Condens Matter. 1994 Jul 1;50(2):949-954. No abstract available.
PMID: 9975761 [PubMed - as supplied by publisher]

13: Cavacini LA, Emes CL, Wisnewski AV, Power J, Lewis G, Montefiori D, Posner MR. Related Articles, Links

Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.
AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1271-80.
PMID: 9764911 [PubMed - indexed for MEDLINE]

14: Kunert R, Ruker F, Katinger H. Related Articles, Links

Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5.
AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1115-28.
PMID: 9737583 [PubMed - indexed for MEDLINE]

15: Duperray A, Languino LR, Plescia J, McDowall A, Hogg N, Craig AG, Berendt AR, Altieri DC. Related Articles, Links

Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging.
J Biol Chem. 1997 Jan 3;272(1):435-41.
PMID: 8995280 [PubMed - indexed for MEDLINE]

16: Woodside DG, Teague TK, McIntyre BW. Related Articles, Links

Specific inhibition of T lymphocyte coactivation by triggering integrin beta 1 reveals convergence of beta 1, beta 2, and beta 7 signaling pathways.
J Immunol. 1996 Jul 15;157(2):700-6.
PMID: 8752919 [PubMed - indexed for MEDLINE]

17: Stigler RD, Ruker F, Katinger D, Elliott G, Hohne W, Henklein P, Ho JX, Keeling K, Carter DC, Nugel E, et al. Related Articles, Links

Interaction between a Fab fragment against gp41 of human

h cb h g e e e fcg e ch b e

immunodeficiency virus 1 and its peptide epitope: characterization using a peptide epitope library and molecular modeling.
Protein Eng. 1995 May;8(5):471-9.
PMID: 8532669 [PubMed - indexed for MEDLINE]

18: Chen YH, Susanna A, Bock G, Steindl F, Katinger H, Dierich MP. Related Articles, Links

HIV-1 gp41 shares a common immunologic determinant with human T, B and monocyte cell lines.
Immunol Lett. 1994 Mar;39(3):219-22.
PMID: 7518416 [PubMed - indexed for MEDLINE]

19: Unterluggauer F, Doblhoff-Dier O, Tauer C, Jungbauer A, Gaida T, Reiter M, Schmatz C, Zach N, Katinger H. Related Articles, Links

Stable, continuous large-scale production of human monoclonal HIV-1 antibody using a computer-controlled pilot plant.
Biotechniques. 1994 Jan;16(1):140-7.
PMID: 8136128 [PubMed - indexed for MEDLINE]

20: Salem RR, Wolf BC, Sears HF, Lavin PT, Ravikumar TS, DeCoste D, D'Emilia JC, Herlyn M, Schlom J, Gottlieb LS, et al. Related Articles, Links

Expression of colorectal carcinoma-associated antigens in colonic polyps.
J Surg Res. 1993 Sep;55(3):249-55.
PMID: 8412106 [PubMed - indexed for MEDLINE]

21: Marschang P, Gurtler L, Totsch M, Thielens NM, Arlaud GJ, Hittmair A, Katinger H, Dierich MP Related Articles, Links

HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells.
AIDS. 1993 Jul;7(7):903-10.
PMID: 7689323 [PubMed - indexed for MEDLINE]

22: Reisbach G, Bartke I, Kempkes B, Kostka G, Ellwart J, Birner A, Thalmeier K, Mailhammer R, Bornkamm GW, Ullrich A, et al. Related Articles, Links

Characterization of hemopoietic cell populations from human cord blood expressing c-kit.
Exp Hematol. 1993 Jan;21(1):74-9.
PMID: 7678090 [PubMed - indexed for MEDLINE]

23: Borth N, Heider R, Assadian A, Katinger H. Related Articles, Links

Growth and production kinetics of human x mouse and mouse hybridoma cells at reduced temperature and serum content.
J Biotechnol. 1992 Sep;25(3):319-31.
PMID: 1382458 [PubMed - indexed for MEDLINE]

24: Churn SB, Yaghmai A, Povlishock J, Rafiq A, DeLorenzo RJ. Related Articles, Links

Global forebrain ischemia results in decreased immunoreactivity of calcium/calmodulin-dependent protein kinase II.
J Cereb Blood Flow Metab. 1992 Sep;12(5):784-93.
PMID: 1324253 [PubMed - indexed for MEDLINE]

25: Cloeckaert A, Zygmunt MS, de Wergifosse P, Dubray G, Limet JN. Related Articles, Links

Demonstration of peptidoglycan-associated Brucella outer-membrane proteins by use of monoclonal antibodies.
J Gen Microbiol. 1992 Jul;138 (Pt 7):1543-50.
PMID: 1380979 [PubMed - indexed for MEDLINE]

26: Groopman JD, Skipper PL, Donahue PR, Trudel LJ, Wildschutte M, Kadlubar FF, Tannenbaum SR. Related Articles, Links

Monoclonal antibodies and rabbit antisera recognizing 4-aminobiphenyl--

h cb h g e e e fcg e ch b e

DNA adducts and application to immunoaffinity chromatography.
Carcinogenesis. 1992 Jun;13(6):917-22.
PMID: 1600611 [PubMed - indexed for MEDLINE]

☐ **27:** Ruker F, Ebert V, Kohl J, Steindl F, Riegler H, Katinger H. Related Articles, Links

Expression of a human monoclonal anti-HIV-1 antibody in CHO cells.
Ann N Y Acad Sci. 1991 Dec 27;646:212-9.
PMID: 1809191 [PubMed - indexed for MEDLINE]

☐ **28:** Kohl J, Ruker F, Himmler G, Razazzi E, Katinger H. Related Articles, Links

Cloning and expression of an HIV-1 specific single-chain Fv region fused to Escherichia coli alkaline phosphatase.
Ann N Y Acad Sci. 1991 Dec 27;646:106-14.
PMID: 1809181 [PubMed - indexed for MEDLINE]

☐ **29:** Ohsako S, Kurohmaru M, Nishida T, Hayashi Y. Related Articles, Links

Analysis of various antigens in golden hamster testis by monoclonal antibodies.
J Vet Med Sci. 1991 Dec;53(6):969-74.
PMID: 1790231 [PubMed - indexed for MEDLINE]

☐ **30:** Larcher C, Broker M, Huemer HP, Solder B, Schulz TF, Hofbauer JM, Wachter H, Dierich MP. Related Articles, Links

Characterization of monoclonal antibodies to human immunodeficiency virus type 1 gp41 by HIV-1 polypeptides expressed in Escherichia coli.
FEMS Microbiol Immunol. 1990 Sep;2(2):103-10.
PMID: 1701654 [PubMed - indexed for MEDLINE]

☐ **31:** Wolf BC, Salem RR, Sears HF, Horst DA, Lavin PT, Herlyn M, Iizkowitz SH, Schlom J, Steele GD Jr. Related Articles, Links

The expression of colorectal carcinoma-associated antigens in the normal colonic mucosa. An immunohistochemical analysis of regional distribution.
Am J Pathol. 1989 Jul;135(1):111-9.
PMID: 2476033 [PubMed - indexed for MEDLINE]

☐ **32:** Lipoldova M, Boylston AW, Yssel H, Owen MJ. Related Articles, Links

T-cell receptor V beta 5 usage defines reactivity to a human T-cell receptor monoclonal antibody.
Immunogenetics. 1989;30(3):162-8.
PMID: 2476387 [PubMed - indexed for MEDLINE]

☐ **33:** Miyazaki H, Kozutsumi H, Kato T, Hoshi S, Tamura S, Kubota M, Suzuki T. Related Articles, Links

Production of monoclonal antibodies against human erythropoietin and their use in the purification of human urinary erythropoietin.
J Immunol Methods. 1988 Oct 26;113(2):261-7.
PMID: 2459256 [PubMed - indexed for MEDLINE]

☐ **34:** Hodges RS, Heaton RJ, Parker JM, Molday L, Molday RS. Related Articles, Links

Antigen-antibody interaction. Synthetic peptides define linear antigenic determinants recognized by monoclonal antibodies directed to the cytoplasmic carboxyl terminus of rhodopsin.
J Biol Chem. 1988 Aug 25;263(24):11768-75.
PMID: 2457026 [PubMed - indexed for MEDLINE]

☐ **35:** Borst J, Spits H, Voordouw A, de Vries E, Boylston A, de Vries JE. Related Articles, Links

A family of T-cell receptor molecules expressed on T-cell clones with different specificities for allomajor histocompatibility antigens.
Hum Immunol. 1986 Dec;17(4):426-42.

h cb h g e e e fcg e ch b e

PMID: 2432049 [PubMed - indexed for MEDLINE]

36: Yssel H, Blanchard D, Boylston A, De Vries JE, Spits H. Related Articles, Links

T cell clones which share T cell receptor epitopes differ in phenotype, function and specificity.
Eur J Immunol. 1986 Oct;16(10):1187-93.
PMID: 2429845 [PubMed - indexed for MEDLINE]

37: Boylston AW, Borst J, Yssel H, Blanchard D, Spits H, de Vries JE. Related Articles, Links

Properties of a panel of monoclonal antibodies which react with the human T cell antigen receptor on the leukemic line HPB-ALL and a subset of normal peripheral blood T lymphocytes.
J Immunol. 1986 Jul 15;137(2):741-4.
PMID: 2424978 [PubMed - indexed for MEDLINE]

38: Hicks D, Molday RS. Related Articles, Links

Differential immunogold-dextran labeling of bovine and frog rod and cone cells using monoclonal antibodies against bovine rhodopsin.
Exp Eye Res. 1986 Jan;42(1):55-71.
PMID: 2420630 [PubMed - indexed for MEDLINE]

39: Borst J, Boylston AW, de Vries JE, Spits H. Related Articles, Links

Human T cell lines differing in phenotype and specificity are reactive with the same anti-idiotypic antibody.
J Immunol. 1986 Jan;136(2):601-8.
PMID: 2416817 [PubMed - indexed for MEDLINE]

40: Boylston AW, Cosford P. Related Articles, Links

Growth of normal human T lymphocytes induced by monoclonal antibody to the T cell antigen receptor.
Eur J Immunol. 1985 Jul;15(7):738-42.
PMID: 3874082 [PubMed - indexed for MEDLINE]

41: Liu YS, Tobias RJ, Zurawski VR Jr. Related Articles, Links

A more specific, simpler radioimmunoassay for carcinoembryonic antigen, with use of monoclonal antibodies.
Clin Chem. 1985 Feb;31(2):191-5.
PMID: 3967348 [PubMed - indexed for MEDLINE]

42: Uede T, Ibayashi Y, Koda H, Kikuchi K. Related Articles, Links

Construction of rat-mouse T-cell hybridomas that constitutively produce rat IL-2.
Hybridoma. 1985 Summer;4(2):103-14.
PMID: 3874144 [PubMed - indexed for MEDLINE]

43: MacKenzie D, Molday RS. Related Articles, Links

Organization of rhodopsin and a high molecular weight glycoprotein in rod photoreceptor disc membranes using monoclonal antibodies.
J Biol Chem. 1982 Jun 25;257(12):7100-5.
PMID: 7085619 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

h cb h g e e e fcg e ch b e

Welcome to STN International! Enter x:x
* * * * * * * * * * Welcome to STN International * * * * * * * * * *
* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:05:02 ON 14 DEC 2004

=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:05:12 ON 14 DEC 2004

FILE 'ANABSTR' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:05:12 ON 14 DEC 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 15:05:12 ON 14 DEC 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:05:12 ON 14 DEC 2004

FILE 'CAPLUS' ENTERED AT 15:05:12 ON 14 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:05:12 ON 14 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve

FILE 'DRUGB' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:05:12 ON 14 DEC 2004

FILE 'FOMAD' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:05:12 ON 14 DEC 2004

FILE 'HEALSAFE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemi

FILE 'LIFESCI' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:05:12 ON 14 DEC 2004

FILE 'MEDLINE' ENTERED AT 15:05:12 ON 14 DEC 2004

FILE 'NIOSHTIC' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:05:12 ON 14 DEC 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 15:05:12 ON 14 DEC 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:05:12 ON 14 DEC 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 15:05:12 ON 14 DEC 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'PS' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 15:05:12 ON 14 DEC 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 15:05:12 ON 14 DEC 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:05:12 ON 14 DEC 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 15:05:12 ON 14 DEC 2004

```
FILE 'WPIFV' ENTERED AT 15:05:12 ON 14 DEC 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S Alzheimers disease
  14 FILES SEARCHED...
  25 FILES SEARCHED...
  46 FILES SEARCHED...
  65 FILES SEARCHED...
L1        44391 ALZHEIMERS DISEASE

=> S 3D6
  62 FILES SEARCHED...
L2         2889 3D6

=> S L2 AND antibody
  25 FILES SEARCHED...
  65 FILES SEARCHED...
L3          681 L2 AND ANTIBODY

=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4           374 DUP REM L3 (307 DUPLICATES REMOVED)

=> D L4 1-374

L4    ANSWER 1 OF 374  BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
      DUPLICATE 1
AN    2004-22931  BIOTECHDS
TI    New humanized   ***antibodies***   that recognize beta amyloid peptides,
      useful for preventing or treating amyloidogenic diseases, such as
      Alzheimer's disease;
         production and isolation of a humanized   ***antibody***   specific
         for beta amyloid protein useful for Alzheimer disease immunotherapy
AU    BASI G; SALDANHA J W; YEDNOCK T
PA    NEURALAB LTD; WYETH
PI    WO 2004080419 23 Sep 2004
AI    WO 2004-S 7503 12 Mar 2004
PRAI  US 2003-388389 12 Mar 2003; US 2003-388389 12 Mar 2003
DT    Patent
LA    English
OS    WPI: 2004-668880 [65]

L4    ANSWER 2 OF 374  CAPLUS  COPYRIGHT 2004 ACS on STN DUPLICATE 2
AN    2004:372930  CAPLUS
DN    140:390303
TI    Humanized   ***antibodies***   specific to .beta.-amyloid peptide for
      treating amyloidogenic disease such as Alzheimer's disease
IN    Basi, Guriq; Saldanha, Jose; Yednock, Ted
PA    Elan Pharmaceuticals, Inc., USA
SO    U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 10,942.
      CODEN: USXXCO
DT    Patent
LA    English
FAN.CNT 8
      PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
      ---------------     ----   --------    --------------------     --------
PI    US 2004087777        A1    20040506    US 2003-388389           20030312
      US 2003165496        A1    20030904    US 2001-10942            20011206
      US 2004171815        A1    20040902    US 2003-703713           20031107
      US 2004171816        A1    20040902    US 2003-704070           20031107
      WO 2004080419        A2    20040923    WO 2004-US7503           20040312
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
```

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 2000-251892P	P	20001206
	US 2001-10942	A2	20011206
	US 1998-80970P	P	19980407
	US 1998-201430	A2	19981130
	US 1999-322289	A2	19990528
	US 2000-580015	A2	20000526
	US 2003-388389	A1	20030312

L4 ANSWER 3 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 3
AN 10740339 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Bard Frederique; Schenk Dale B; Yednock Theodore
PA Neuralab Ltd BM (66431)
PI US 2004247591 A1 20041209
AI US 2004-890070 20040712
RLI US 2000-580018 20000526 CONTINUATION 6761888
FI US 2004247591 20041209
US 6761888
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 46
GI 25 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific monoclonal ***antibody*** ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific monoclonal 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund' adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of AP-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for

derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice for the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.
FIG. 16: Mean titer of mice treated with polyclonal ***antibody*** to A beta .
FIG. 17: Mean titer of mice treated with monoclonal ***antibody*** 10D5 to A beta .
FIG. 18: Mean titer of mice treated with monoclonal ***antibody*** 2F12 to A beta .
FIG. 19: Epitope Map: Restricted N-terminal Response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10920M shows a representative N-terminal restricted response to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide which was used as immunizing antigen.
FIG. 20: Epitope Map: Non-restricted N-terminal response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10975F shows a representative non-restricted N-terminal response. Reactivity is seen against the two peptides N-terminal and one peptide C-terminal to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide.

L4 ANSWER 4 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 4
AN 10740338 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Bard Frederique; Schenk Dale B; Yednock Theodore
PA Neuralab Ltd BM (66431)
PI US 2004247590 A1 20041209
AI US 2004-889999 20040713
RLI US 2000-580018 20000526 CONTINUATION 6761888
FI US 2004247590 20041209
US 6761888
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 6
GI 25 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific monoclonal ***antibody*** ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific monoclonal 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following

1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund' adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice for the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.
FIG. 16: Mean titer of mice treated with polyclonal ***antibody*** to A beta .
FIG. 17: Mean titer of mice treated with monoclonal ***antibody*** 10D5 to A beta .
FIG. 18: Mean titer of mice treated with monoclonal ***antibody*** 2F12 to A beta .
FIG. 19: Epitope Map: Restricted N-terminal Response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10920M shows a representative N-terminal restricted response to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide which was used as immunizing antigen.
FIG. 20: Epitope Map: Non-restricted N-terminal response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10975F shows a representative non-restricted N-terminal response. Reactivity is seen against the two peptides N-terminal and one peptide C-terminal to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide.

L4 ANSWER 5 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 5
AN 10733914 IFIPAT;IFIUDB;IFICDB
TI USE OF ***ANTIBODIES*** HAVING HIGH AFFINITY FOR SOLUBLE AB TO TREAT CONDITIONS AND DISEASES RELATED TO ASS
IN Bales Kelly Renee; Paul Steven Marc
PA Unassigned Or Assigned To Individual (68000)
PPA ELI LILLY AND CO (Probable)
PI US 2004241164 A1 20041202
AI US 2002-487326 20020814
WO 2002-US21324 20020814
20020814 PCT 371 date
20020814 PCT 102(e) date
PRAI US 2001-313576P 20010817 (Provisional)
US 2002-383851P 20020528 (Provisional)

DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 18
GI 9 Figure(s).
FIG. 1. Object recognition memory performance 24 hours after administration of m266 anti-A beta ***antibody*** . The recognition index is the percentage of time spent exploring a novel object during trial 2 (test trial). Both saline- and control IgGtreated tg mice performed at chance levels (recognition index=50%), whereas m266-treated tg mice and WT mice significantly performed above chance (t-test analysis). Values are means+-SEM; ** means p<0.0001 vs. saline- and IgG-treated tg groups; ## means p<0.0001 vs. wild type (WT) mice.
FIG. 2. Plasma A beta 40 and A beta 42 levels 24 hours after administration of m266. Plasma levels correlated with object recognition memory performance. (A) Plasma levels of both peptides are markedly increased in APPV717F tg mice acutely administered m266, compared to saline or control IgG-treated tg mice. Values are means +-SEM; (B) Bivariate scattergrams showing highly significant correlation between plasma levels of A beta and the object recognition memory performance.
FIG. 3. Apparatus used for holeboard spatial learning assay.
FIG. 4. Acute A beta ***antibody*** treatment improved reference memory in APPV717F mice.
FIG. 5. Acute A beta ***antibody*** treatment decreased total errors in APPV717F mice.
FIG. 6. Correlation between Log (A beta flux) and Log (affinity of various anti-A beta ***antibodies*** for soluble A beta).
FIG. 7. Lack of correlation between Log (A beta flux) and Log (affinity of various anti-A beta ***antibodies*** for insoluble A beta).
FIG. 8. Object recognition memory performance 24 hours after administration of 266 or ***3D6*** anti-A beta ***antibody*** . (* means p<0. 05 vs. saline or IgG, *** means p<0.001 vs. saline or IgG).
FIG. 9. Correlation between Log (A beta flux) and Log (affinity of various anti-A beta ***antibodies*** for soluble A beta using altered BIAcore method).

L4 ANSWER 6 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 6
AN 10721615 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 2004228865 A1 20041118
AI US 2004-816380 20040331
RLI US 2000-724102 20001128 CONTINUATION 6787139
US 1998-201430 19981130 DIVISION 6787523
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 2004228865 20041118
US 6787139
US 6787523
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 64
GI 19 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The

group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups. FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment

L4 ANSWER 7 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 7
AN 10711897 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 2004219146 A1 20041104
AI US 2004-828548 20040419
RLI US 1999-322289 19990528 CONTINUATION PENDING
US 1998-201430 19981130 CONTINUATION-IN-PART 6787523
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 2004219146 20041104
US 6787523
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 140
GI 23 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific monoclonal ***antibody*** ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific monoclonal 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown

horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the. 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund' adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice for the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.
FIG. 16: Mean titer of mice treated with polyclonal ***antibody*** to A beta .
FIG. 17: Mean titer of mice treated with monoclonal ***antibody*** 10D5 to A beta .
FIG. 18: Mean titer of mice treated with monoclonal ***antibody*** 2F12 to A beta .

L4 ANSWER 8 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 8
AN 10668156 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 2004175394 A1 20040909
AI US 2004-815391 20040331
RLI US 1998-201430 19981130 CONTINUATION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 2004175394 20040909
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 72
GI 20 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.

the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.

FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.

FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.

FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.

FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.

FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.

FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.

FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.

FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).

FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.

FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.

FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.

FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.

FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.

FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.

FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.

FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.

FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.

FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment

L4 ANSWER 9 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 9
AN 10664579 IFIPAT;IFIUDB;IFICDB
TI HUMANIZED ***ANTIBODIES*** THAT RECOGNIZE BETA AMYLOID PEPTIDE
IN Basi Guriq; Schenk Dale B
PA Unassigned Or Assigned To Individual (68000)

PI	US 2004171816 A1	20040902		
AI	US 2003-704070	20031107		
RLI	US 2003-388389	20030312	CONTINUATION	PENDING
	US 1998-201430	19981130	CONTINUATION-IN-PART	PENDING
	US 1999-322289	19990528	CONTINUATION-IN-PART	PENDING
	US 2000-580015	20000526	CONTINUATION-IN-PART	PENDING
	US 2001-10942	20011206	CONTINUATION-IN-PART	PENDING
PRAI	US 1998-80970P	19980407	(Provisional)	
	US 2000-251892P	20001206	(Provisional)	

DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 24
GI 10 Figure(s).
FIG. 1 depicts an alignment of the amino acid sequences of the light chain of mouse ***3D6*** , humanized ***3D6*** , Kabat ID 109230 and germline A19 ***antibodies*** . CDR regions are indicated by arrows. Bold italics indicate rare murine residues. Bold indicates packing (VH+VL) residues. Solid fill indicates canonical/CDR interacting residues. Asterisks indicate residues selected for backmutation in humanized ***3D6*** , version 1.
FIG. 2 depicts an alignment of the amino acid sequences of the heavy chain of mouse ***3D6*** , humanized ***3D6*** , Kabat ID 045919 and germline VH3-23 ***antibodies*** . Annotation is the same as for FIG. 1.
FIG. 3 graphically depicts the A beta binding properties of ***3D6*** , chimeric ***3D6*** and 10D5. FIG. 3A is a graph depicting binding of A beta to chimeric ***3D6*** (PK1614) as compared to murine ***3D6*** . FIG. 3B is a graph depicting competition of biotinylated ***3D6*** versus unlabeled ***3D6*** , PK1614 and 10D5 for binding to A beta .
FIG. 4 depicts a homology model of ***3D6*** VH and VL, showing alphacarbon backbone trace. VH is shown in as a stippled line, and VL is shown as a solid line. CDR regions are indicated in ribbon form.
FIG. 5 graphically depicts the A beta binding properties of chimeric ***3D6*** and humanized ***3D6*** . FIG. 5A depicts ELISA results measuring the binding of humanized 3D6v1 and chimeric ***3D6*** to aggregated A beta . FIG. 5B depicts ELISA results measuring the binding of humanized 3D6v1 and humanized 3D6v2 to aggregated A beta .
FIG. 6 is a graph quantitating the binding of humanized ***3D6*** and chimeric ***3D6*** to A beta plaques from brain sections of PDAPP mice.
FIG. 7 is a graph showing results of a competitive binding assay testing the ability of humanized ***3D6*** versions 1 and 2, chimeric ***3D6*** , murine ***3D6*** , and 10D5 to compete with murine ***3D6*** for binding to A beta .
FIG. 8 graphically depicts of an ex vivo phagocytosis assay testing the ability of humanized 3D6v2, chimeric ***3D6*** , and human IgG to mediate the uptake of A alpha by microglial cells.
FIG. 9 depicts an alignment of the 10D5 VL and ***3D6*** VL amino acid sequences. Bold indicates residues that match 10D5 exactly.
FIG. 10 depicts an alignment of the 10D5 VH and ***3D6*** VH amino acid sequences. Bold indicates residues that match 10D5 exactly.

L4 ANSWER 10 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 10
AN 10664578 IFIPAT;IFIUDB;IFICDB
TI HUMANIZED ***ANTIBODIES*** THAT RECOGNIZE BETA AMYLOID PEPTIDE
IN Basi Guriq; Schenk Dale B; Yednock Ted
PA Unassigned Or Assigned To Individual (68000)
PI US 2004171815 A1 20040902
AI US 2003-703713 20031107
RLI US 2003-388389 20030312 CONTINUATION PENDING
US 1998-201430 19981130 CONTINUATION-IN-PART PENDING
US 1999-322289 19990528 CONTINUATION-IN-PART PENDING
US 2000-580015 20000526 CONTINUATION-IN-PART PENDING
US 2001-10942 20011206 CONTINUATION-IN-PART PENDING
PRAI US 1998-80970P 19980407 (Provisional)
US 2000-251892P 20001206 (Provisional)
FI US 2004171815 20040902
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 30
GI 10 Figure(s).
FIG. 1 depicts an alignment of the amino acid sequences of the light chain of mouse ***3D6*** , humanized ***3D6*** , Kabat ID 109230 and germline A19 ***antibodies*** . CDR regions are indicated by arrows. Bold italics indicate rare murine residues. Bold indicates packing (VH+VL) residues. Solid fill indicates canonical/CDR interacting residues. Asterisks indicate residues selected for backmutation in humanized ***3D6*** , version 1.
FIG. 2 depicts an alignment of the amino acid sequences of the heavy chain of mouse ***3D6*** , humanized ***3D6*** , Kabat ID 045919 and germline VH3-23 ***antibodies*** . Annotation is the same as for FIG.

FIG. 3 graphically depicts the A beta binding properties of ***3D6*** , chimeric ***3D6*** and 1D5. FIG. 3A is a graph depicting binding of A beta to chimeric ***3D6*** (PK1614) as compared to murine ***3D6*** . FIG. 3B is a graph depicting competition of biotinylated ***3D6*** versus unlabeled ***3D6*** , PK1614 and 10D5 for binding to A beta .
FIG. 4 depicts a homology model of ***3D6*** VH and VL, showing alphacarbon backbone trace. VH is shown in as a stippled line, and VL is shown as a solid line. CDR regions are indicated in ribbon form.
FIG. 5 graphically depicts the A beta binding properties of chimeric ***3D6*** and humanized ***3D6*** . FIG. 5A depicts ELISA results measuring the binding of humanized 3D6v1 and chimeric ***3D6*** to aggregated A beta . FIG. 5B depicts ELISA results measuring the binding of humanized 3D6v1 and humanized 3D6v2 to aggregated A beta .
FIG. 6 is a graph quantitating the binding of humanized ***3D6*** and chimeric ***3D6*** to A beta plaques from brain sections of PDAPP mice.
FIG. 7 is a graph showing results of a competitive binding assay testing the ability of humanized ***3D6*** versions 1 and 2, chimeric ***3D6*** , murine ***3D6*** , and 10D5 to compete with murine ***3D6*** for binding to A beta .
FIG. 8 graphically depicts of an ex vivo phagocytosis assay testing the ability of humanized 3D6v2, chimeric ***3D6*** , and human IgG to mediate the uptake of A beta by microglial cells.
FIG. 9 depicts an alignment of the 10D5 VL and ***3D6*** VL amino acid sequences. Bold indicates residues that match 10 D5 exactly.
FIG. 10 depicts an alignment of the 10D5 VH and ***3D6*** VH amino acid sequences. Bold indicates residues that match 10D5 exactly.

L4 ANSWER 11 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 11
AN 10663406 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 2004170641 A1 20040902
AI US 2004-815353 20040331
RLI US 2000-723927 20001128 CONTINUATION PENDING
US 1998-201430 19981130 DIVISION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 2004170641 20040902
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 29
GI 20 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.

and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment

L4 ANSWER 12 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 12
AN 10658886 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 2004166119 A1 20040826
AI US 2004-816529 20040331
RLI US 1998-201430 19981130 CONTINUATION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 2004166119 20040826
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 38
GI 20 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization.

each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment

L4 ANSWER 13 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 13
AN 10650548 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 2004157779 A1 20040812
AI US 2004-816022 20040331
RLI US 1998-201430 19981130 CONTINUATION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 2004157779 20040812
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 80
GI 20 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.

immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

L4 ANSWER 14 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 14
AN 10575540 IFIPAT;IFIUDB;IFICDB
TI HUMANIZED ***ANTIBODIES*** THAT RECOGNIZE BETA AMYLOID PEPTIDE
IN Basi Guriq; Saldanha Jose (GB)
PA Elan Pharmaceuticals Inc (49246)
PI US 2004082762 A1 20040429
AI US 2003-388214 20030312
PRAI US 2002-363751P 20020312 (Provisional)
FI US 2004082762 20040429
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 115
GI 9 Figure(s).
FIGS. 1A-B depicts an alignment of the amino acid sequences of the light chain of mouse 12B4 (mature peptide, SEQ ID NO:2), humanized 12B4 (mature peptide, SEQ ID NO:6), Kabat ID 005036 (mature peptide, SEQ ID NO:32) and germline A19 (X63397, mature peptide, SEQ ID NO:30) ***antibodies*** . CDR regions are stippled and overlined. The single backmutation of a human right-arrow mouse residue is indicated by the asterisk. The importance of the shaded residues is shown in the legend. Numbered from the first methionine, not Kabat numbering.
FIGS. 2A-B depicts an alignment of the amino acid sequences of the heavy chain of mouse 12B4 (mature peptide, SEQ ID NO:4), humanized 12B4 (version 1) (mature peptide, SEQ ID NO:8), Kabat ID 000333 (mature peptide, SEQ ID NO:34), and germline VH4-39 and VH4-61 ***antibodies*** (mature peptides, SEQ ID NOs: 38 and 36, respectively). Annotation is the same as for FIG. 1. Numbered from the first methionine, not Kabat numbering.
FIGS. 3A-D depicts the nucleotide and amino acid sequence for humanized 12B4VLv1 compared with chimeric 12B4VL (identical variable region sequences as murine 12B4VL, SEQ ID NOs: 1 and 2, respectively); germline A19 sequences (SEQ ID NOs: 29 and 30, respectively); and Kabid ID 005036

FIGS. 4A-D depicts the nucleotide and amino acid sequence for humanized 12B4VHv1 compared with chimeric 12B4VH (identical variable region sequences as murine 12B4VH, SEQ ID NOs: 3 and 4, respectively); Kabat ID 000333 (SEQ ID NOs: 33 and 34, respectively); and germline VH4-61 (SEQ ID NOs: 35 and 36, respectively).
FIG. 5 graphically depicts the ELISA results from two independent experiments measuring the binding of chimeric 12B4, ***3D6*** , and chimeric ***3D6*** to A beta (panels A and B, respectively).
FIG. 6 graphically depicts competitive ELISA binding confirming functional activity of 12B4 and chimeric 12B4 as compared to ***3D6*** , chimeric ***3D6*** , and 10D5. Chimeric 12B4 (open triangles) competes with equa potency with its non biotinylated murine counterpart (open inverted triangles) for binding of biotinylated murine 12B4 to A beta 1-42 peptide.
FIG. 7 graphically depicts an ex vivo phagocytosis assay testing the ability of chimeric 12B4, ***3D6*** , and human IgG1 to mediate the uptake of A beta by microglial cells on PDAPP brain sections.
FIG. 8 graphically depicts the results from two independent ex vivo phagocytosis assays (panels A and B, respectively) testing the ability of chimeric 12B4, humanized ***3D6*** , and human IgG1 to mediate the uptake of A beta by microglial cells on AD brain sections.
FIG. 9 is a schematic representation of the PCR-mediated assembly of humanized 12B4, version 1. FIG. 9A depicts the assembly of the VL regions. FIG. 9B depicts the assembly of the VH regions.

L4 ANSWER 15 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 15
AN 10574435 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Athena Neurosciences Inc (33043)
PI US 2004081657 A1 20040429
AI US 2003-429216 20030502
RLI US 1998-201430 19981130 CONTINUATION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 2004081657 20040429
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 63
GI 15 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.

AN1792-treated (upper panel) or PBS-treated (lower panel).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIG. 15: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 with different adjuvants.

L4 ANSWER 16 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 16
AN 04124526 IFIPAT;IFIUDB;IFICDB
TI N-TERMINAL AMYLOID-BETA ***ANTIBODIES***
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 6787637 B1 20040907
AI US 2000-724551 20001128
RLI US 2000-580018 20000526 CONTINUATION PENDING
US 1999-322289 19990528 CONTINUATION-IN-PART 6761888
FI US 6787637 20040907
US 6761888
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 7
GI 18 Drawing Sheet(s), 25 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific monoclonal ***antibody*** ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific monoclonal 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund' adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image

beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/OS21 treatment groups.
FIG. 16: Mean titer of mice treated with polyclonal ***antibody*** to A beta .
FIG. 17: Mean titer of mice treated with monoclonal ***antibody*** 10D5 to A beta .
FIG. 18: Mean titer of mice treated with monoclonal ***antibody*** 2F12 to A beta .
FIG. 19: Epitope Map: Restricted N-terminal Response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10920M shows a representative N-terminal restricted response to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide which was used as immunizing antigen.
FIG. 20: Epitope Map: Non-restricted N-terminal response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10975F shows a representative non-restricted N-terminal response. Reactivity is seen against the two peptides N-terminal and one peptide C-terminal to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide.

L4 ANSWER 17 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 17
AN 04124414 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 6787523 B1 20040907
AI US 1998-201430 19981130
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 6787523 20040907
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 24
GI 13 Drawing Sheet(s), 15 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.

area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (upper panel) or PBS-treated (lower panel).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIG: 15: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 with different adjuvants.

L4 ANSWER 18 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 18
AN 04124037 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PI US 6787144 B1 20040907
AI US 2000-723762 20001128
RLI US 1998-201430 19981130 DIVISION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 6787144 20040907
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 24
GI 13 Drawing Sheet(s), 19 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4,

FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (upper panel) or PBS-treated (lower panel).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values, for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN19792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

L4 ANSWER 19 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 19
AN 04124036 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 6787143 B1 20040907
AI US 2000-724477 20001128
RLI US 1998-201430 19981130 DIVISION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 6787143 20040907
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 24
GI 13 Drawing Sheet(s), 19 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative

values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (upper panel) or PBS-treated (lower panel).
FIG. 11: Total beta To levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN19792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

L4 ANSWER 20 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 20
AN 04124033 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 6787140 B1 20040907
AI US 2000-724489 20001128
RLI US 1998-201430 19981130 DIVISION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 6787140 20040907
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 43
GI 13 Drawing Sheet(s), 19 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated

grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (upper panel) or PBS-treated (lower panel).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-15E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice for the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

L4 ANSWER 21 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 21
AN 04124032 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 6787139 B1 20040907
AI US 2000-724102 20001128
RLI US 1998-201430 19981130 DIVISION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 6787139 20040907
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 70
GI 13 Drawing Sheet(s), 19 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.

of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

L4 ANSWER 22 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 22
AN 04124031 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 6787138 B1 20040907
AI US 2000-723927 20001128
RLI US 1998-201430 19981130 DIVISION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 6787138 20040907
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 36
GI 13 Drawing Sheet(s), 15 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity

computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.

FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.

FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.

FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.

FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.

FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.

FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.

FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.

FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (upper panel) or PBS-treated (lower panel).

FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.

FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.

FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.

FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.

FIGS. 15A-15E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.

FIG. 15A: The values for mice for the PBS-treated control group and the untreated control group.

FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.

FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.

FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.

FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

L4 ANSWER 23 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 23
AN 04095913 IFIPAT;IFIUDB;IFICDB
TI PASSIVE IMMUNIZATION TREATMENT OF ALZHEIMER'S DISEASE
IN Schenk Dale B
PI US 6761888 B1 20040713
AI US 2000-580018 20000526
FI US 6761888 20040713
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 36
GI 18 Drawing Sheet(s), 25 Figure(s).

FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.

FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of

with the A beta-specific monoclonal ***antibody*** ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.

FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific monoclonal 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.

FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.

FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.

FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.

FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.

FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.

FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.

FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).

FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund' adjuvant.

FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.

FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.

FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.

FIGS. 15 A E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.

FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.

FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.

FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.

FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.

FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

FIG. 16: Mean titer of mice treated with polyclonal ***antibody*** to A beta .

FIG. 17: Mean titer of mice treated with monoclonal ***antibody*** 10D5 to A beta .

FIG. 18: Mean titer of mice treated with monoclonal ***antibody*** 2F12 to A beta .

FIG. 19: Epitope Map: Restricted N-terminal Response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10920M shows a representative N-terminal restricted response to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide which was used as immunizing antigen.

FIG. 20: Epitope Map: Non-restricted N-terminal response. Day 175 serum

overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10975F shows a representative non-restricted N-terminal response. Reactivity is seen against the two peptides N-terminal and one peptide C-terminal to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide.

L4 ANSWER 24 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 24
AN 04082931 IFIPAT;IFIUDB;IFICDB
TI HUMANIZED AND CHIMERIC N-TERMINAL AMYLOID BETA- ***ANTIBODIES***
IN Bard Frederique; Schenk Dale B; Yednock Theodore
PA Neuralab Ltd BM (66431)

PI	US 6750324 B1	20040615		
AI	US 2000-724552	20001128		
RLI	US 2000-580018	20000526	CONTINUATION	PENDING
	US 1998-201430	19981130	CONTINUATION-IN-PART	PENDING
	US 1999-322289	19990528	CONTINUATION-IN-PART	PENDING
PRAI	US 1997-67740P	19971202	(Provisional)	
	US 1998-80970P	19980407	(Provisional)	
FI	US 6750324	20040615		

DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 12
GI 18 Drawing Sheet(s), 25 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific monoclonal ***antibody*** ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific monoclonal 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund' adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.

treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.
FIG. 16: Mean titer of mice treated with polyclonal ***antibody*** to A beta .
FIG. 17: Mean titer of mice treated with monoclonal ***antibody*** 10D5 to A beta .
FIG. 18: Mean titer of mice treated with monoclonal ***antibody*** 2F12 to A beta .
FIG. 19: Epitope Map: Restricted N-terminal Response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10920M shows a representative N-terminal restricted response to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide which was used as immunizing antigen.
FIG. 20: Epitope Map: Non-restricted N-terminal response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10975F shows a representative non-restricted N-terminal response. Reactivity is seen against the two peptides N-terminal and one peptide C-terminal to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide.

L4 ANSWER 25 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 25
AN 04075252 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)

PI	US 6743427 B1	20040601		
AI	US 2000-724961	20001128		
RLI	US 2000-580015	20000526	CONTINUATION	PENDING
	US 1998-201430	19981130	CONTINUATION-IN-PART	PENDING
	US 1999-322289	19990528	CONTINUATION-IN-PART	PENDING
PRAI	US 1997-67740P	19971202	(Provisional)	
	US 1998-80970P	19980407	(Provisional)	
FI	US 6743427	20040601		

DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 19
GI 18 Drawing Sheet(s),
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific monoclonal ***antibody*** ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific monoclonal 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.

immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund' adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.
FIG. 16: Mean titer of mice treated with polyclonal ***antibody*** to A beta .
FIG. 17: Mean titer of mice treated with monoclonal ***antibody*** 10D5 to A beta .
FIG. 18: Mean titer of mice treated with monoclonal ***antibody*** 2F12 to A beta .
FIG. 19: Epitope Map: Restricted N-terminal Response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10920M shows a representative N-terminal restricted response to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide which was used as immunizing antigen.
FIG. 20: Epitope Map: Non-restricted N-terminal response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10975F shows a representative non-restricted N-terminal response. Reactivity is seen against the two peptides N-terminal and one peptide C-terminal to the peptide DAEFRHDSGY (SEQ ID NO:9) which covers amino acids 1-10 of the AN1792 peptide.

L4 ANSWER 26 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 26
AN 04049335 IFIPAT;IFIUDB;IFICDB
TI METHODS OF INHIBITING T CELL PROLIFERATION OR IL-2 ACCUMULATION WITH CTLA4-SPECIFIC ***ANTIBODIES*** ; INDUCE ANTIGEN SPECIFIC APOPTOSIS IN ACTIVATED T CELLS; LIGANDS WITH MONOCLONAL ANTI-CTLA4 ***ANTIBODY*** THAT BINDS TO AN EPITOPE OF CTLA4
IN Freeman Gordon J; Gray Gary S; Greenfield Edward; Gribben John G; Jellis Cindy L; Nadler Lee M; Rennert Paul
PA Dana-Farber Cancer Institute Inc
Repligen Corp
(10790, 11804)
PI US 6719972 B1 20040413
AI US 1994-253783 19940603

DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 11
GI 2 Drawing Sheet(s), 4 Figure(s).
FIG. 1A is a graphic representation of T cell responses (proliferation, IL-2 production or apoptosis) by activated DR7specific T cell clones upon rechallenge with antigen (t-DR7) and the indicated second signals, demonstrating induction of apoptosis by an anti-CTLA4 monoclonal ***antibody*** (mAb).
FIG. 1B is a graphic representation of T cell responses (proliferation, IL-2 production or apoptosis) by normal peripheral blood CD4+ T cell blasts upon rechallenge with antiCD3 and the indicated second signals, demonstrating induction of apoptosis by an anti-CTLA4 mAb.
FIG. 2A is a graphic representation of T cell responses (proliferation, IL-2 production or apoptosis) by activated DR7specific T cell clones upon rechallenge with cells expressing antigen alone (t-DR7) or cells expressing both antigen and either B7-1 (tDR7/B7-1) or B7-2 (tDR7/B7-2), demonstrating that neither B7-1 nor B7-2 induces antigen apoptosis.
FIG. 2B is a graphic representation of T cell responses (proliferation, IL-2 production or apoptosis) by activated DR7specific T cell clones upon rechallenge with the indicated cells together with the indicated mAbs or fusion proteins, demonstrating that antigen specific apoptosis is induced by a non-B7-1, non-B7-2 CTLA4 binding ligand.

L4 ANSWER 27 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 27
AN 04038728 IFIPAT;IFIUDB;IFICDB
TI TRANSGENIC MOUSE ASSAY TO DETERMINE THE EFFECT OF A BETA ***ANTIBODIES*** AND A BETA FRAGMENTS ON ALZHEIMER'S DISEASE CHARACTERISTICS; ADMINISTERING AGENT TO INDUCE IMMUNE RESPONSE AGAINST AMYLOID DEPOSIT; DRUG SCREENING, VACCINES
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 6710226 B1 20040323
AI US 2000-723384 20001127
RLI US 1999-322289 19990528 CONTINUATION PENDING
US 1998-201430 19981130 CONTINUATION-IN-PART PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 6710226 20040323
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 32
GI 16 Drawing Sheet(s), 22 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific monoclonal ***antibody*** ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific monoclonal 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in

FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS-and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (upper panel) or PBS-treated (lower panel).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund' adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice for the PBS-treated control group and the untreadted control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.
FIG. 16: Mean titer of mice treated with polyclonal ***antibody*** to A beta .
FIG. 17: Mean titer of mice treated with monoclonal ***antibody*** 10D5 to A beta .
FIG. 18: Mean titer of mice treated with monoclonal ***antibody*** 2F12 to A beta .

L4 ANSWER 28 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN
AN 04158057 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 6818218 B2 20041116
US 2004166119 A1 20040826
AI US 2004-816529 20040331
RLI US 1998-201430 19981130 CONTINUATION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 6818218 20041116
DT Utility; Granted Patent - Utility, with Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 38
GI 13 Drawing Sheet(s), 20 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the

(GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).
FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.
FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.
FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.
FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

L4 ANSWER 29 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN
AN 04147593 IFIPAT;IFIUDB;IFICDB
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk Dale B
PA Neuralab Ltd BM (66431)
PI US 6808712 B2 20041026
US 2004170641 A1 20040902
AI US 2004-815353 20040331
RLI US 2000-723927 20001128 CONTINUATION PENDING
US 1998-201430 19981130 DIVISION PENDING
PRAI US 1997-67740P 19971202 (Provisional)
US 1998-80970P 19980407 (Provisional)
FI US 6808712 20041026
DT Utility; Granted Patent - Utility, with Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 29
GI 13 Drawing Sheet(s), 20 Figure(s).
FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area

their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.

FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.

FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.

FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.

FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.

FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.

FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.

FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (FIG. 10A) or PBS-treated (FIG. 10B).

FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.

FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.

FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.

FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.

FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.

FIG. 15A: The values for mice in the PBS-treated control group and the untreated control group.

FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPLtreatment groups.

FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.

FIG. 15D: The values for mice in the AN1792/Thimerosol and AN1792/alum treatment groups.

FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

L4 ANSWER 30 OF 374 USPATFULL on STN
AN 2004:315202 USPATFULL
TI Lactam compound
IN Koenig, Thomas Mitchell, Camby, IN, UNITED STATES
Audia, James Edmund, Zionsville, IN, UNITED STATES
Mitchell, David, Indianapolis, IN, UNITED STATES
McDaniel, Stacey Leigh, Martinsville, IN, UNITED STATES
Buccilli, Lynne Ann, Indianapolis, IN, UNITED STATES
Engel, Gary Lowell, Greenwood, IN, UNITED STATES
Aikins, James Abraham, Pendleton, IN, UNITED STATES
PI US 2004248878 A1 20041209
AI US 2003-415548 A1 20030428 (10)
WO 2001-US27795 20011102
PRAI US 2000-249656P 20001117 (60)
DT Utility
FS APPLICATION
LN.CNT 2013
INCL INCLM: 514/212.070
INCLS: 540/523.000
NCL NCLM: 514/212.070
NCLS: 540/523.000

ICM: A61K031-55

L4 ANSWER 31 OF 374 USPATFULL on STN
AN 2004:314559 USPATFULL
TI Modulation of Abeta levels by beta-secretase BACE2
IN Cordell, Barbara, Palo Alto, CA, UNITED STATES
Schimmoller, Frauke, Menlo Park, CA, UNITED STATES
Liu, Yu-Wang, Santa Clara, CA, UNITED STATES
Quon, Diana Hom, Redwood City, CA, UNITED STATES
PI US 2004248231 A1 20041209
AI US 2003-749714 A1 20031231 (10)
RLI Division of Ser. No. US 2001-886143, filed on 20 Jun 2001, GRANTED, Pat. No. US 6713276
PRAI US 2000-215729P 20000628 (60)
DT Utility
FS APPLICATION
LN.CNT 1814
INCL INCLM: 435/023.000
NCL NCLM: 435/023.000
IC [7]
ICM: C12Q001-37

L4 ANSWER 32 OF 374 USPATFULL on STN
AN 2004:314422 USPATFULL
TI Magneto-optical bio-discs and systems including related methods
IN Coombs, James Howard, Irvine, CA, UNITED STATES
Phan, Brigitte Chau, Irvine, CA, UNITED STATES
Valencia, Ramoncito Magpantay, Aliso Viejo, CA, UNITED STATES
PI US 2004248093 A1 20041209
AI US 2002-307263 A1 20021127 (10)
RLI Continuation-in-part of Ser. No. US 2002-99266, filed on 14 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-997741, filed on 27 Nov 2001, PENDING
PRAI US 2000-253283P 20001127 (60)
US 2000-253958P 20001128 (60)
US 2001-272525P 20010301 (60)
US 2002-355644P 20020205 (60)
US 2002-356982P 20020213 (60)
US 2002-358479P 20020219 (60)
US 2002-372007P 20020411 (60)
US 2002-388132P 20020612 (60)
US 2002-408227P 20020904 (60)
DT Utility
FS APPLICATION
LN.CNT 6281
INCL INCLM: 435/006.000
INCLS: 435/287.200
NCL NCLM: 435/006.000
NCLS: 435/287.200
IC [7]
ICM: C12Q001-68
ICS: C12M001-34

L4 ANSWER 33 OF 374 USPATFULL on STN
AN 2004:313942 USPATFULL
TI Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease
IN Wang, Chang Yi, Harbor, NY, UNITED STATES
PI US 2004247612 A1 20041209
AI US 2004-861614 A1 20040604 (10)
RLI Division of Ser. No. US 2001-865294, filed on 25 May 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 1731
INCL INCLM: 424/185.100
INCLS: 530/324.000; 530/325.000; 530/326.000
NCL NCLM: 424/185.100
NCLS: 530/324.000; 530/325.000; 530/326.000
IC [7]
ICM: A61K039-00
ICS: C07K014-47

L4 ANSWER 34 OF 374 USPATFULL on STN
AN 2004:308171 USPATFULL
TI Degraded agonist ***antibody***

Tscuchiya, Masayuki, Gotemba-shi, JAPAN
Uno, Shinsuke, Gotemba-shi, JAPAN
Ohtomo, Toshihiko, Gotemba-shi, JAPAN
Yabuta, Naohiro, Niihari-gun, JAPAN
Tsunoda, Hiroyuki, Niihari-gun, JAPAN
PI US 2004242847 A1 20041202
AI US 2003-399585 A1 20030418 (10)
WO 2001-JP9260 20011022
PRAI JP 2000-321821 20001020
JP 2000-321822 20001020
JP 2001-277314 20011009
WO 2001-JP1912 20011203
WO 2001-JP3288 20010417
DT Utility
FS APPLICATION
LN.CNT 5568
INCL INCLM: 530/387.300
NCL NCLM: 530/387.300
IC [7]
ICM: C07K016-44

L4 ANSWER 35 OF 374 USPATFULL on STN
AN 2004:306970 USPATFULL
TI Peptides mimicking a cryptic epitope of gp41 hiv-1
IN Stiegler, Gabriela M, Fels am Wagram, AUSTRIA
Kunert, Renate, Deutsch-Wagram, AUSTRALIA
Katinger, Hermann, Vienna, AUSTRALIA
PI US 2004241641 A1 20041202
AI US 2004-485525 A1 20040318 (10)
WO 2002-EP10070 20020909
PRAI US 2001-318091P 20010907 (60)
DT Utility
FS APPLICATION
LN.CNT 1007
INCL INCLM: 435/005.000
INCLS: 424/148.100; 530/388.350; 530/387.200
NCL NCLM: 435/005.000
NCLS: 424/148.100; 530/388.350; 530/387.200
IC [7]
ICM: C12Q001-70
ICS: C07K016-00; C12P021-08; A61K039-42

L4 ANSWER 36 OF 374 USPATFULL on STN
AN 2004:292174 USPATFULL
TI Methods of detecting neurological disorders
IN Mucke, Lennart, San Francisco, CA, UNITED STATES
Palop, Jorge J., San Francisco, CA, UNITED STATES
PI US 2004229258 A1 20041118
AI US 2004-809777 A1 20040324 (10)
PRAI US 2003-457200P 20030324 (60)
DT Utility
FS APPLICATION
LN.CNT 1817
INCL INCLM: 435/006.000
INCLS: 514/012.000
NCL NCLM: 435/006.000
NCLS: 514/012.000
IC [7]
ICM: C12Q001-68
ICS: A61K038-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 37 OF 374 USPATFULL on STN
AN 2004:287882 USPATFULL
TI Method for identifying Alzheimer's disease therapeutics using transgenic animal models
IN Games, Kate Dora, Belmont, CA, UNITED STATES
Schenk, Dale Bernard, Burlingame, CA, UNITED STATES
McConlogue, Lisa Claire, San Francisco, CA, UNITED STATES
Seubert, Peter Andrew, San Francisco, CA, UNITED STATES
Rydel, Russell E., Belmont, CA, UNITED STATES
PI US 2004226054 A1 20041111
AI US 2003-746473 A1 20031223 (10)
RLI Continuation of Ser. No. US 1998-149718, filed on 8 Sep 1998, GRANTED, Pat. No. US 6717031 Continuation-in-part of Ser. No. US 1996-659797,

1995-486538, filed on 7 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1996-660487, filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-480653, filed on 7 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1995-486538, filed on 7 Jun 1995, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4401
INCL INCLM: 800/012.000
NCL NCLM: 800/012.000
IC [7]
ICM: A01K067-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 38 OF 374 USPATFULL on STN
AN 2004:285752 USPATFULL
TI Compositions and methods for non-invasive imaging of soluble beta-amyloid
IN Montalto, Michael Christopher, Colonie, NY, UNITED STATES
Agdeppa, Eric Dustin, Latham, NY, UNITED STATES
Siclovan, Tiberiu Mircea, Rexford, NY, UNITED STATES
Williams, Amy Casey, Clifton Park, NY, UNITED STATES
PI US 2004223912 A1 20041111
AI US 2003-431202 A1 20030507 (10)
DT Utility
FS APPLICATION
LN.CNT 497
INCL INCLM: 424/001.490
INCLS: 424/009.600; 530/391.100
NCL NCLM: 424/001.490
NCLS: 424/009.600; 530/391.100
IC [7]
ICM: A61K051-00
ICS: A61K049-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 39 OF 374 USPATFULL on STN
AN 2004:285749 USPATFULL
TI Compositions and methods for non-invasive imaging of soluble beta-amyloid
IN Montalto, Michael Christopher, Albany, NY, UNITED STATES
Agdeppa, Eric Dustin, Latham, NY, UNITED STATES
Siclovan, Tiberiu Mircea, Rexford, NY, UNITED STATES
Williams, Amy Casey, Clifton Park, NY, UNITED STATES
PI US 2004223909 A1 20041111
AI US 2003-747715 A1 20031226 (10)
RLI Continuation-in-part of Ser. No. US 2003-431202, filed on 7 May 2003, PENDING
DT Utility
FS APPLICATION
LN.CNT 1027
INCL INCLM: 424/001.110
INCLS: 424/009.600; 548/495.000; 549/055.000; 549/467.000
NCL NCLM: 424/001.110
NCLS: 424/009.600; 548/495.000; 549/055.000; 549/467.000
IC [7]
ICM: A61K051-00
ICS: A61K049-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 374 USPATFULL on STN
AN 2004:280221 USPATFULL
TI Novel nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
Weng, Gezhi, Piedmont, CA, UNITED STATES
Boyle, Bryan J., San Francisco, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
PI US 2004219521 A1 20041104
AI US 2002-128558 A1 20020422 (10)
RLI Continuation-in-part of Ser. No. WO 2000-US35017, filed on 22 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-552317, filed on 25 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING Continuation-in-part of Ser. No. WO 2001-US2623, filed on 25 Jan 2001, PENDING Continuation-in-part of Ser. No. US

PRAI WO 2000-US35017 20001222
WO 2001-US2623 20010125
WO 2001-US3800 20010205
WO 2001-US4927 20010226
WO 2001-US4941 20010305
WO 2001-US8631 20010330
WO 2001-US8656 20010418
US 2001-339453P 20011211 (60)
DT Utility
FS APPLICATION
LN.CNT 13159
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 41 OF 374 USPATFULL on STN
AN 2004:260156 USPATFULL
TI Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific ***antibodies***
IN Gribben, John G., Brookline, MA, UNITED STATES
Freeman, Gordon J., Brookline, MA, UNITED STATES
Nadler, Lee M., Newton, MA, UNITED STATES
Rennert, Paul D., Holliston, MA, UNITED STATES
Jellis, Cindy L., Londonderry, NH, UNITED STATES
Greenfield, Edward, Randolph, MA, UNITED STATES
Gray, Gary S., Brookline, MA, UNITED STATES
PI US 2004202650 A1 20041014
AI US 2003-732847 A1 20031209 (10)
RLI Division of Ser. No. US 1994-253783, filed on 3 Jun 1994, GRANTED, Pat. No. US 6719972
DT Utility
FS APPLICATION
LN.CNT 2874
INCL INCLM: 424/131.100
INCLS: 424/144.100
NCL NCLM: 424/131.100
NCLS: 424/144.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 42 OF 374 USPATFULL on STN
AN 2004:248295 USPATFULL
TI Anti-abeta ***antibodies***
IN Jia, Audrey Yunhua, Union City, CA, UNITED STATES
Tsurushita, Naoya, Palo Alto, CA, UNITED STATES
Vasquez, Maximiliano J., Palo Alto, CA, UNITED STATES
PI US 2004192898 A1 20040930
AI US 2004-487322 A1 20040217 (10)
WO 2002-US21322 20020814
PRAI US 2001-313224P 20010817 (60)
DT Utility
FS APPLICATION
LN.CNT 1798
INCL INCLM: 530/388.100
NCL NCLM: 530/388.100
IC [7]
ICM: C07K016-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 43 OF 374 USPATFULL on STN
AN 2004:227000 USPATFULL
TI Therapeutic monoclonal ***antibodies*** that neutralize botulinum neurotoxins
IN Marks, James D., Kensington, CA, UNITED STATES
Amersdorfer, Peter, San Diego, CA, UNITED STATES
PA The Regents of the University of Carlifornia (U.S. corporation)
PI US 2004175385 A1 20040909
AI US 2003-632706 A1 20030801 (10)
RLI Continuation-in-part of Ser. No. US 1998-144886, filed on 31 Aug 1998,

PRAI US 2002-400721P 20020801 (60)
DT Utility
FS APPLICATION
LN.CNT 6069
INCL INCLM: 424/164.100
INCLS: 435/007.320; 530/388.400
NCL NCLM: 424/164.100
NCLS: 435/007.320; 530/388.400
IC [7]
ICM: A61K039-40
ICS: G01N033-554; G01N033-569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 44 OF 374 USPATFULL on STN
AN 2004:191870 USPATFULL
TI Animals comprising human hepatocellular tissue
IN Kay, Mark A., Los Altos, CA, UNITED STATES
Ohashi, Kazuo, Palo Alto, CA, UNITED STATES
PI US 2004148646 A1 20040729
AI US 2003-636510 A1 20030806 (10)
RLI Continuation of Ser. No. US 2000-614658, filed on 12 Jul 2000, GRANTED, Pat. No. US 6660905
PRAI US 1999-143897P 19990714 (60)
DT Utility
FS APPLICATION
LN.CNT 1504
INCL INCLM: 800/014.000
INCLS: 800/006.000
NCL NCLM: 800/014.000
NCLS: 800/006.000
IC [7]
ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 45 OF 374 USPATFULL on STN
AN 2004:189753 USPATFULL
TI Prevention and treatment of synucleinopathic disease
IN Schenk, Dale B., Burlingame, CA, UNITED STATES
Masliah, Eliezer, San Diego, CA, UNITED STATES
PI US 2004146521 A1 20040729
AI US 2003-698099 A1 20031031 (10)
RLI Continuation-in-part of Ser. No. US 2000-585817, filed on 1 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-580015, filed on 26 May 2000, PENDING
PRAI US 2002-423012P 20021101 (60)
US 1999-137010P 19990601 (60)
DT Utility
FS APPLICATION
LN.CNT 3102
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 46 OF 374 USPATFULL on STN
AN 2004:152192 USPATFULL
TI Succinoyl aminopyrazoles and related compounds
IN Tung, Jay S., Belmont, CA, UNITED STATES
Guinn, Ashley C., Santa Monica, CA, UNITED STATES
Thorsett, Eugene D., Half Moon Bay, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
PI US 2004116414 A1 20040617
AI US 2003-434528 A1 20030507 (10)
PRAI US 2002-378795P 20020507 (60)
DT Utility
FS APPLICATION
LN.CNT 2133
INCL INCLM: 514/227.500
INCLS: 514/237.500; 514/255.010; 514/372.000; 514/389.000; 514/406.000; 514/563.000; 514/575.000; 544/059.000; 544/162.000; 544/386.000; 548/318.500; 548/368.100; 548/138.000; 562/450.000; 562/623.000
NCL NCLM: 514/227.500
NCLS: 514/237.500; 514/255.010; 514/372.000; 514/389.000; 514/406.000; 514/563.000; 514/575.000; 544/059.000; 544/162.000; 544/386.000;

IC [7]
ICM: A61K031-54
ICS: A61K031-537; A61K031-495; A61K031-433; A61K031-4152
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 47 OF 374 USPATFULL on STN
AN 2004:139422 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Thompson, Richard C., Frankfort, IN, UNITED STATES
Wilkie, Stephen, Indianapolis, IN, UNITED STATES
Stack, Douglas R., Fishers, IN, UNITED STATES
Vanmeter, Eldon E., Greenwood, IN, UNITED STATES
Shi, Qing, Carmel, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Martinsville, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2004106598 A1 20040603
AI US 2003-392332 A1 20030320 (10)
RLI Division of Ser. No. US 1999-338191, filed on 22 Jun 1999, GRANTED, Pat. No. US 6569851
PRAI US 1998-160067P 19980622 (60)
DT Utility
FS APPLICATION
LN.CNT 12955
INCL INCLM: 514/212.030
INCLS: 514/424.000; 514/327.000; 514/580.000; 514/588.000
NCL NCLM: 514/212.030
NCLS: 514/424.000; 514/327.000; 514/580.000; 514/588.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 48 OF 374 USPATFULL on STN
AN 2004:138990 USPATFULL
TI Non-invasive measurement of analytes
IN Workman, Jerome James, JR., Brookline, MA, UNITED STATES
Lambert, Christopher Robert, Hudson, MA, UNITED STATES
PI US 2004106163 A1 20040603
AI US 2003-617915 A1 20030710 (10)
PRAI US 2002-425488P 20021112 (60)
US 2003-438837P 20030109 (60)
DT Utility
FS APPLICATION
LN.CNT 3737
INCL INCLM: 435/014.000
NCL NCLM: 435/014.000
IC [7]
ICM: C12Q001-54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 49 OF 374 USPATFULL on STN
AN 2004:120070 USPATFULL
TI Degraded tpo agonist ***antibody***
IN Tsuchiya, Masayuki, Shizuoka-ken, JAPAN
Ohtomo, Toshihiko, Shizuoka-ken, JAPAN
Yabuta, Naohiro, Ibaraki, JAPAN
Tsunoda, Hiroyuki, Ibaraki, JAPAN
Orita, Tetsuro, Ibaraki, JAPAN
PI US 2004091475 A1 20040513
AI US 2003-399518 A1 20030417 (10)
WO 2001-JP9259 20011022
PRAI JP 2000-321821 20001020
JP 2001-277314 20010912
DT Utility
FS APPLICATION

INCL INCLM: 424/132.100
INCLS: 530/387.300
NCL NCLM: 424/132.100
NCLS: 530/387.300
IC [7]
ICM: A61K039-395
ICS: C07K016-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 50 OF 374 USPATFULL on STN
AN 2004:108368 USPATFULL
TI Novel glyphosate N-acetyltransferase (GAT) genes
IN Castle, Linda A., Mountain View, CA, UNITED STATES
Siehl, Dan, Menlo Park, CA, UNITED STATES
Giver, Lorraine, Sunnyvale, CA, UNITED STATES
Minshull, Jeremy, Los Altos, CA, UNITED STATES
Ivy, Cristina, Encinitas, CA, UNITED STATES
Chen, Yong Hong, Foster City, CA, UNITED STATES
Patten, Phillip A., Menlo Park, CA, UNITED STATES
Gorton, Rebecca, Irvine, CA, UNITED STATES
Duck, Nicholas B., Apex, NC, UNITED STATES
McCutchen, Billy Fred, Clive, IA, UNITED STATES
Kemble, Roger, Wake Forest, NC, UNITED STATES
PA Verdia, Inc. (U.S. corporation)
Pioneer Hi-Bred International, Inc. (U.S. corporation)
PI US 2004082770 A1 20040429
AI US 2003-427692 A1 20030430 (10)
RLI Continuation-in-part of Ser. No. US 2001-4357, filed on 29 Oct 2001, PENDING
PRAI US 2002-377719P 20020430 (60)
US 2002-377175P 20020501 (60)
US 2000-244385P 20001030 (60)
DT Utility
FS APPLICATION
LN.CNT 7542
INCL INCLM: 536/023.200
INCLS: 435/069.100; 435/006.000; 435/193.000; 435/320.100; 435/419.000
NCL NCLM: 536/023.200
NCLS: 435/069.100; 435/006.000; 435/193.000; 435/320.100; 435/419.000
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-10; C12N005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 51 OF 374 USPATFULL on STN
AN 2004:101757 USPATFULL
TI Lactam compound
IN Koenig, Thomas Mitchell, Camby, IN, UNITED STATES
Mitchell, David, Indianapolis, IN, UNITED STATES
Nissen, Jeffrey Scott, Indianapolis, IN, UNITED STATES
PI US 2004077627 A1 20040422
AI US 2003-415057 A1 20030903 (10)
WO 2001-US27796 20011102
DT Utility
FS APPLICATION
LN.CNT 1843
INCL INCLM: 514/212.070
INCLS: 540/523.000
NCL NCLM: 514/212.070
NCLS: 540/523.000
IC [7]
ICM: A61K031-55
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 52 OF 374 USPATFULL on STN
AN 2004:77121 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES

John, Varghese, San Fancisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianpolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
Mcdaniel, Stacey L., Indianapolis, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2004058900 A1 20040325
AI US 2003-336767 A1 20030106 (10)
RLI Division of Ser. No. US 2001-915342, filed on 27 Jul 2001, PENDING
Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25655
INCL INCLM: 514/183.000
INCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000; 514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000
NCL NCLM: 514/183.000
NCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000; 514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000
IC [7]
ICM: A61K031-553
ICS: A61K031-55; A61K031-554; A61K031-551; A61K031-5513; A61K031-473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 53 OF 374 USPATFULL on STN
AN 2004:76615 USPATFULL
TI Agonist ***antibodies***
IN Fukishima, Naoshi, Gotemba-shi, Shizuoka-ken, JAPAN
Tsuchiya, Masayuki, Gotemba-shi, Shizuoka-ken, JAPAN
Oheda, Masayoshi, Gotemba-shi, Shizuoka-ken, JAPAN
Uno, Shinsuke, Gotemba-shi, Shizuoka-ken, JAPAN
Kikuchi, Yasufumi, Gotemba-shi,Shizuoka-ken, JAPAN
Ohtomo, Toshihiko, Gotemba-shi, Shizuoka-ken, JAPAN
PI US 2004058393 A1 20040325
AI US 2003-257864 A1 20030624 (10)
WO 2001-JP3288 20010417
PRAI JP 2000-115246 20000417
JP 2000-321821 20001020
JP 2000-321822 20001020
WO 2001-JP1912 20010312
DT Utility
FS APPLICATION
LN.CNT 4382
INCL INCLM: 435/007.200
INCLS: 530/388.250
NCL NCLM: 435/007.200
NCLS: 530/388.250
IC [7]
ICM: G01N033-53
ICS: G01N033-567; C07K016-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 54 OF 374 USPATFULL on STN
AN 2004:63731 USPATFULL
TI Novel nucleic acids and secreted polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Yang, Yonghong, San Jose, CA, UNITED STATES
Weng, Gezhi, Piedmont, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Ren, Feiyan, Cupertino, CA, UNITED STATES
Xue, Aidong, Sunnyvale, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Wehrman, Tom, Stanford, CA, UNITED STATES
Ghosh, Malabika J., Sunnyvale, CA, UNITED STATES
Wang, Dunrui, Poway, CA, UNITED STATES
Zhao, Qing A., San Jose, CA, UNITED STATES

PI US 2004048249 A1 20040311
AI US 2002-112944 A1 20020328 (10)
RLI Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-496914, filed on 3 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-515126, filed on 28 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-519705, filed on 7 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-540217, filed on 31 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-552929, filed on 18 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-577408, filed on 18 May 2000, ABANDONED
PRAI US 2001-306971P 20010721 (60)
DT Utility
FS APPLICATION
LN.CNT 23809
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000; 530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000; 530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 55 OF 374 USPATFULL on STN
AN 2004:63342 USPATFULL
TI ***Antibodies*** to human mcp-1
IN Hiestand, Peter, Allscwil, SWITZERLAND
Hofstetter, Hans, Riehen, SWITZERLAND
Payne, Trevor Glyn, Nedlands, AUSTRALIA
Urfer, Roman, Foster City, CA, UNITED STATES
Di Padova, Franco E, Birsfelden, SWITZERLAND
PI US 2004047860 A1 20040311
AI US 2003-312022 A1 20030718 (10)
WO 2001-EP7468 20010629
PRAI GB 2000-1638 20000630
DT Utility
FS APPLICATION
LN.CNT 1372
INCL INCLM: 424/144.100
INCLS: 530/388.220
NCL NCLM: 424/144.100
NCLS: 530/388.220
IC [7]
ICM: A61K039-395
ICS: C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 56 OF 374 USPATFULL on STN
AN 2004:58174 USPATFULL
TI Novel nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Asundi, Vinod, Foster City, CA, UNITED STATES
Wehrman, Tom, Stanford, CA, UNITED STATES
Ren, Feiyan, Cupertino, CA, UNITED STATES
Zhou, Ping, Cupertino, CA, UNITED STATES
Zhao, Qing A., San Jose, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Xue, Aidong, Sunnyvale, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Wang, Dunrui, Poway, CA, UNITED STATES
PI US 2004044181 A1 20040304
AI US 2003-363616 A1 20030715 (10)
WO 2001-US27093 20010831
DT Utility
FS APPLICATION
LN.CNT 17667
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500

NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 57 OF 374 USPATFULL on STN
AN 2004:57970 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2004043977 A1 20040304
AI US 2003-336687 A1 20030106 (10)
RLI Division of Ser. No. US 2001-915362, filed on 27 Jul 2001, GRANTED, Pat. No. US 6541466 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25738
INCL INCLM: 514/183.000
INCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000; 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000; 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000; 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000; 514/662.000; 564/454.000
NCL NCLM: 514/183.000
NCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000; 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000; 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000; 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000; 514/662.000; 564/454.000
IC [7]
ICM: A61K031-5513
ICS: A61K031-551; A61K031-55; A61K031-4706; A61K031-473; A61K031-445; A61K031-366; A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 58 OF 374 USPATFULL on STN
AN 2004:57416 USPATFULL
TI Humanized ***antibodies*** that sequester Abeta peptide
IN Holtzman, David M., St. Louis, MO, UNITED STATES
DeMattos, Ronald, Noblesville, IN, UNITED STATES
Bales, Kelly R., Indianapolis, IN, UNITED STATES
Paul, Steven M., Carmel, IN, UNITED STATES
Tsurushita, Naoya, Palo Alto, CA, UNITED STATES
Vasquez, Maximiliano, Palo Alto, CA, UNITED STATES
PI US 2004043418 A1 20040304
AI US 2002-226435 A1 20020821 (10)
DT Utility
FS APPLICATION
LN.CNT 2136
INCL INCLM: 435/007.100
INCLS: 530/388.150; 424/133.100

NCLS: 530/388.150; 424/133.100
IC [7]
ICM: A61K039-395
ICS: G01N033-53; C07K016-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 59 OF 374 USPATFULL on STN
AN 2004:18840 USPATFULL
TI Differential diagnosis of neurodegeneration
IN VanMechelen, Eugeen, Nazareth Eke, BELGIUM
Vanderstichele, Hugo, Gent, BELGIUM
Van De Voorde, Andre, Lokeren, BELGIUM
PA INNOGENETICS N.V. (non-U.S. corporation)
PI US 2004014142 A1 20040122
AI US 2003-445366 A1 20030522 (10)
RLI Division of Ser. No. US 2000-720707, filed on 29 Dec 2000, ABANDONED A 371 of International Ser. No. WO 1999-EP4483, filed on 29 Jun 1999, UNKNOWN
PRAI EP 1998-870148 19980703
EP 1998-870236 19981103
EP 1999-870069 19990409
DT Utility
FS APPLICATION
LN.CNT 2706
INCL INCLM: 435/007.100
INCLS: 435/007.200
NCL NCLM: 435/007.100
NCLS: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 60 OF 374 USPATFULL on STN
AN 2004:7845 USPATFULL
TI Hydroxyalkanoyl aminopyrazoles and related compounds
IN Tung, Jay S., Belmont, CA, UNITED STATES
Guinn, Ashley C., Pacifica, CA, UNITED STATES
Thorsett, Gene, Half Moon Bay, CA, UNITED STATES
Pleiss, Mike A., Sunnyvale, CA, UNITED STATES
PI US 2004006085 A1 20040108
AI US 2003-355700 A1 20030131 (10)
PRAI US 2002-353214P 20020201 (60)
DT Utility
FS APPLICATION
LN.CNT 1738
INCL INCLM: 514/249.000
INCLS: 514/253.010; 514/254.110; 514/317.000; 514/278.000; 514/316.000; 514/363.000; 514/400.000; 514/419.000; 514/464.000; 514/534.000; 514/616.000; 514/406.000; 544/360.000; 544/353.000; 544/386.000; 514/255.010; 544/377.000; 546/186.000; 546/020.000; 548/138.000; 548/328.500; 548/367.400; 560/155.000; 564/155.000; 514/389.000; 548/318.100
NCL NCLM: 514/249.000
NCLS: 514/253.010; 514/254.110; 514/317.000; 514/278.000; 514/316.000; 514/363.000; 514/400.000; 514/419.000; 514/464.000; 514/534.000; 514/616.000; 514/406.000; 544/360.000; 544/353.000; 544/386.000; 514/255.010; 544/377.000; 546/186.000; 546/020.000; 548/138.000; 548/328.500; 548/367.400; 560/155.000; 564/155.000; 514/389.000; 548/318.100
IC [7]
ICM: A61K031-498
ICS: A61K031-495; A61K031-496; A61K031-4747; A61K031-4545; A61K031-433; A61K031-4172; A61K031-4152; A61K031-165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 61 OF 374 USPATFULL on STN
AN 2004:310056 USPATFULL
TI Protein/(poly)peptide libraries
IN Achim, Knappik, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Pack, Peter, Munchen, GERMANY, FEDERAL REPUBLIC OF
Liming, Ge, Munchen, GERMANY, FEDERAL REPUBLIC OF
Simon, Moroney, Munchen, NEW ZEALAND
Andreas, Pluckthun, Zurich, SWITZERLAND
PA Morphosys AG, Munich, GERMANY, FEDERAL REPUBLIC OF (non-U.S.

PI US 6828422 B1 20041207
AI US 2000-490324 20000124 (9)
RLI Division of Ser. No. US 1998-25769, filed on 18 Feb 1998, now patented, Pat. No. US 6300064 Continuation of Ser. No. WO 1996-EP3647, filed on 19 Aug 1996
PRAI EP 1995-113021 19950818
DT Utility
FS GRANTED
LN.CNT 8990
INCL INCLM: 530/380.000
INCLS: 530/386.000; 530/387.100; 530/387.300; 530/350.000; 435/006.000; 435/069.700; 435/069.100
NCL NCLM: 530/380.000
NCLS: 530/386.000; 530/387.100; 530/387.300; 530/350.000; 435/006.000; 435/069.700; 435/069.100
IC [7]
ICM: C07K016-00
ICS: C12P021-08; C12P021-06; C12Q001-68
EXF 530/350; 530/380; 530/386; 530/387.1; 530/387.3; 435/6; 435/69.7; 435/69.1

L4 ANSWER 62 OF 374 USPATFULL on STN
AN 2004:65895 USPATFULL
TI Protein/(poly)peptide libraries
IN Knappik, Achim, Grarelfing, GERMANY, FEDERAL REPUBLIC OF
Pack, Peter, Munchen, GERMANY, FEDERAL REPUBLIC OF
Ge, Liming, Munchen, GERMANY, FEDERAL REPUBLIC OF
Moroney, Simon, Munchen, GERMANY, FEDERAL REPUBLIC OF
Pluckthun, Andreas, Zurich, SWITZERLAND
PA Morphosys AG, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6706484 B1 20040316
AI US 2000-490153 20000124 (9)
RLI Division of Ser. No. US 1998-25769, filed on 18 Feb 1998 Continuation of Ser. No. WO 1996-EP3647, filed on 19 Aug 1996
PRAI EP 1995-113021 19950818
DE 1997-U29702923 19970219
DT Utility
FS GRANTED
LN.CNT 8910
INCL INCLM: 435/007.100
INCLS: 435/069.100; 435/069.300; 435/069.700; 435/320.100; 536/023.100; 530/350.000
NCL NCLM: 435/007.100
NCLS: 435/069.100; 435/069.300; 435/069.700; 435/320.100; 530/350.000; 536/023.100
IC [7]
ICM: C12P021-06
ICS: G01N033-53; C07K001-00
EXF 435/69.1; 435/69.3; 435/69.7; 435/320.1; 435/7.1; 435/DIG.2; 435/DIG.15; 435/DIG.47; 536/23.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 63 OF 374 USPATFULL on STN
AN 2004:59929 USPATFULL
TI ***Antibodies*** to vertebrate serrate proteins and fragments
IN Ish-Horowicz, David, Oxford, UNITED KINGDOM
Henrique, Domingos Manuel Pinto, Oxford, UNITED KINGDOM
Lewis, Julian Hart, Oxford, UNITED KINGDOM
Myat, Anna Mary, Oxford, UNITED KINGDOM
Fleming, Robert J., Rochester, NY, United States
Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
Mann, Robert S., Hamden, CT, United States
Gray, Grace E., New Haven, CT, United States
PA Yale University, New Haven, CT, United States (U.S. corporation)
Imperial Cancer Research Technology, Ltd., London, UNITED KINGDOM (non-U.S. corporation)
PI US 6703489 B1 20040309
AI US 1998-195524 19981119 (9)
RLI Division of Ser. No. US 1996-611729, filed on 6 Mar 1996, now patented, Pat. No. US 6004924 Continuation-in-part of Ser. No. US 1995-400159, filed on 7 Mar 1995, now patented, Pat. No. US 5869282
DT Utility
FS GRANTED
LN.CNT 6515
INCL INCLM: 530/399.000

424/141.100; 424/156.100; 536/023.100; 536/023.530; 536/024.500
NCL NCLM: 530/399.000
NCLS: 424/130.100; 424/141.100; 424/156.100; 530/387.100; 530/388.100; 530/388.850; 530/389.100; 536/023.100; 536/023.530; 536/024.500
IC [7]
ICM: A61K038-24
ICS: A61K039-395; C07K016-00; C12P021-06; C07H021-04
EXF 530/387.1; 530/399; 530/388.1; 530/388.85; 530/389.1; 424/130.1; 424/141.1; 424/156.1; 536/23.1; 536/23.53; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 64 OF 374 USPATFULL on STN
AN 2004:46723 USPATFULL
TI Protein/(poly)peptide libraries
IN Knappik, Achim, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Pack, Peter, Munchen, GERMANY, FEDERAL REPUBLIC OF
Ge, Liming, Munchen, GERMANY, FEDERAL REPUBLIC OF
Moroney, Simon, Munchen, GERMANY, FEDERAL REPUBLIC OF
Pluckthun, Andreas, Zurich, GERMANY, FEDERAL REPUBLIC OF
PA Morphosys AG, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6696248 B1 20040224
AI US 2000-490070 20000124 (9)
RLI Division of Ser. No. US 1998-25769, filed on 18 Feb 1998, now patented, Pat. No. US 6300064 Continuation of Ser. No. WO 1996-EP3647, filed on 19 Aug 1996
PRAI EP 1995-1130210 19950818
DE 1997-U29702923 19970219
DT Utility
FS GRANTED
LN.CNT 9073
INCL INCLM: 435/006.000
INCLS: 435/320.100; 536/023.100; 536/024.100; 536/024.500
NCL NCLM: 435/006.000
NCLS: 435/320.100; 536/023.100; 536/024.100; 536/024.500
IC [7]
ICM: C12Q001-68
ICS: C12N015-00; C12N015-63; C07H021-04
EXF 435/6; 435/320.1; 435/DIG.1; 536/23.1; 536/24.1; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 65 OF 374 USPATFULL on STN
AN 2004:21609 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palastine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6683075 B1 20040127
AI US 2003-336806 20030106 (10)
RLI Division of Ser. No. US 2001-915564, filed on 27 Jul 2001 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997
PRAI US 1996-64851P 19961223 (60)
DT Utility

LN.CNT 19986
INCL INCLM: 514/220.000
INCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/517.000; 540/518.000
NCL NCLM: 514/220.000
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/517.000; 540/518.000
IC [7]
ICM: A61K031-55
ICS: C07D487-04; C07D243-12; C07D243-24; C07D487-00
EXF 540/496; 540/497; 540/498; 540/499; 540/504; 540/517; 540/518; 514/220; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 66 OF 374 USPATFULL on STN
AN 2004:21475 USPATFULL
TI Anti-cryptosporidium parvum preparations
IN Riggs, Michael W., Tucson, AZ, United States
Perryman, Lance E., Cary, NC, United States
PA North Carolina State University, Raleigh, NC, United States (U.S. corporation)
PI US 6682737 B1 20040127
AI US 2000-557324 20000425 (9)
RLI Continuation of Ser. No. US 1997-828943, filed on 27 Mar 1997, now patented, Pat. No. US 6110463
PRAI US 1996-14410P 19960329 (60)
US 1996-21465P 19960710 (60)
DT Utility
FS GRANTED
LN.CNT 1356
INCL INCLM: 424/151.100
INCLS: 424/157.100; 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/329.000; 435/342.000; 530/388.600; 530/389.100; 530/822.000; 530/832.000
NCL NCLM: 424/151.100
NCLS: 424/157.100; 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/329.000; 435/342.000; 530/388.600; 530/389.100; 530/822.000; 530/832.000
IC [7]
ICM: A61K039-395
ICS: A61K035-20; C07K016-20; C12N005-20
EXF 424/130.1; 424/151.1; 424/184.1; 424/265.1; 424/266.1; 424/269.1; 424/535; 424/807; 424/157.1; 435/7.22; 435/70.21; 435/452; 435/329; 435/342; 435/947; 530/388.6; 530/389.1; 530/395; 530/822; 530/832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 67 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 28
AN 2004:175867 BIOSIS
DN PREV200400177964
TI Production and characterization of monoclonal ***antibodies*** to a Brazilian bovine herpesvirus type 5.
AU Oldoni, I.; Weiblen, R.; Inkelmann, M. A.; Flores, E. F. [Reprint Author]
CS Departamento de Medicina, Veterinaria Preventiva, Universidade Federal de Santa Maria, 97105-900, Santa Maria, RS, Brazil
flores@ccr.ufsm.br
SO Brazilian Journal of Medical and Biological Research, (February 2004) Vol. 37, No. 2, pp. 213-221. print.
CODEN: BJMRDK. ISSN: 0100-879X.
DT Article
LA English
ED Entered STN: 31 Mar 2004
Last Updated on STN: 31 Mar 2004

L4 ANSWER 68 OF 374 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:978925 SCISEARCH
GA The Genuine Article (R) Number: 867NS
TI Alzheimer's amyloid peptides mediate hypoxic up-regulation of L-type Ca2+ channels
AU Scragg J L; Fearon I M; Boyle J P; Ball S G; Varadi G; Peers C (Reprint)
CS Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England (Reprint); Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada

SO FAŠEB JOURNAL, (OCT 2004) Vol. 18, No. 13.
Publisher: FEDERATION AMER SOC EXP BIOL, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA.
ISSN: 0892-6638.
DT Article; Journal
LA English
REC Reference Count: 42
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 69 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 29
AN 2003:919088 CAPLUS
DN 140:234388
TI Anti-collagenase IV monoclonal ***antibody*** ***3D6*** and lidamycin for diagnosing and treating colon and other digestive tract neoplasm
IN Zhen, Yongsu; Wang, Fengqiang; Li, Liang; Liu, Xiujun; Shang, Baiyang
PA Institute of Medical and Biological Technology, Chinese Academy of Medical Sciences, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 16 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1389472	A	20030108	CN 2002-125314	20020724
PRAI CN 2002-125314		20020724		

L4 ANSWER 70 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 30
AN 10421072 IFIPAT;IFIUDB;IFICDB
TI HUMANIZED ***ANTIBODIES*** THAT RECOGNIZE BETA AMYLOID PEPTIDE; ALZHEIMER'S DISEASE
IN Basi Guriq; Saldanha Jose (GB); Yednock Ted
PA Elan Pharmaceuticals Inc (49246)
PI US 2003165496 A1 20030904
AI US 2001-10942 20011206
PRAI US 2000-251892P 20001206 (Provisional)
FI US 2003165496 20030904
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 158
GI 10 Figure(s).
FIG. 1 depicts an alignment of the amino acid sequences of the light chain of mouse ***3D6*** , humanized ***3D6*** , Kabat ID 109230 and germline A19 ***antibodies*** . CDR regions are indicated by arrows. Bold italics indicate rare murine residues. Bold indicates packing (VH+VL) residues. Solid fill indicates canonical/CDR interacting residues. Asterisks indicate residues selected for backmutation in humanized ***3D6*** , version 1.
FIG. 2 depicts an alignment of the amino acid sequences of the heavy chain of mouse ***3D6*** , humanized ***3D6*** , Kabat ID 045919 and germline VH3-23 ***antibodies*** . Annotation is the same as for FIG. 1.
FIG. 3 graphically depicts the A beta binding properties of ***3D6*** , chimeric ***3D6*** and 10D5. FIG. 3A is a graph depicting binding of A beta to chimeric ***3D6*** (PK1614) as compared to murine ***3D6*** . FIG. 3B is a graph depicting competition of biotinylated ***3D6*** versus unlabeled ***3D6*** , PK1614 and 10D5 for binding to A beta .
FIG. 4 depicts a homology model of ***3D6*** VH and VL, showing alphacarbon backbone trace. VH is shown in as a stippled line, and VL is shown as a solid line. CDR regions are indicated in ribbon form.
FIG. 5 graphically depicts the A beta binding properties of chimeric ***3D6*** and humanized ***3D6*** . FIG. 5A depicts ELISA results measuring the binding of humanized 3D6v1 and chimeric ***3D6*** to aggregated A beta . FIG. 5B depicts ELISA results measuring the binding of humanized 3D6v1 and humanized 3D6v2 to aggregated A beta .
FIG. 6 is a graph quantitating the binding of humanized ***3D6*** and chimeric ***3D6*** to A beta plaques from brain sections of PDAPP mice.
FIG. 7 is a graph showing results of a competitive binding assay testing the ability of humanized ***3D6*** versions 1 and 2, chimeric ***3D6*** , murine ***3D6*** , and 10D5 to compete with murine ***3D6*** for binding to A beta .

ability of humanized 3D6v2, chimeric ***3D6*** , and human IgG to mediate the uptake of A beta by microglial cells.
FIG. 9 depicts an alignment of the 10D5 VL and ***3D6*** VL amino acid sequences. Bold indicates residues that match 10D5 exactly.
FIG. 10 depicts an alignment of the 10D5 VH and ***3D6*** VH amino acid sequences. Bold indicates residues that match 10D5 exactly.

L4 ANSWER 71 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 31
AN 10374168 IFIPAT;IFIUDB;IFICDB
TI HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF; USE OF ANTAGONISTS IN THERAPY OR DIAGNOSIS OF PARTICULAR PATHOLOGICAL CONDITIONS IN MAMMALS, INCLUDING CANCER
IN Schwall Ralph H; Tabor Kelly H
PA Unassigned Or Assigned To Individual (68000)
PI US 2003118587 A1 20030626
AI US 2002-232408 20020903
RLI WO 1996-US8094 19960531 Section 371 PCT Filing PENDING
US 1998-952235 19980217 CONTINUATION 6207152
US 2000-669971 20000926 CONTINUATION 6468529
FI US 2003118587 20030626
US 6207152
US 6468529
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 40
GI 14 Figure(s).
FIGS. 1A and 1B show the amino acid sequences (and encoding nucleotides) for the light chain (FIG. 1A) and heavy chain (FIG. 1B), respectively, of monoclonal ***antibody*** 5D5 Fab.
FIG. 2 is a graph showing the inhibition of HGF binding to c-MetIgG fusion protein by monoclonal ***antibody*** 1A3.3.13.
FIG. 3 is a bar diagram showing the stimulatory effect of monoclonal ***antibodies*** ***3D6*** , 6G1. and 1A3.3.13 on human mammary epithelial cells in a proliferation assay.
FIG. 4 is a bar diagram showing the stimulatory effect of monoclonal ***antibodies*** ***3D6*** , 05-237 and 05-238 on mink lung cells in a proliferation assay.
FIG. 5 is a bar diagram showing the inhibitory effect of monoclonal ***antibody*** 1A3.3.13 Fab fragments on BaF3-hmet.8 cells in a proliferation assay.
FIGS. 6A and 6B are FACS analysis graphs showing binding specificity of monoclonal ***antibody*** 5D5 to BaF3-hmet.8 cells expressing c-Met.
FIG. 7 is a graph showing the inhibition of HGF binding to c-MetIgG fusion protein by monoclonal ***antibody*** 5D5 and by 5D5 Fab.
FIGS. 8A and 8B are graphs showing the inhibitory effect of 5D5 Fab on BaF3-hmet.8 cells in a proliferation assay.
FIG. 9 is a graph showing the inhibitory effect of 5D5 Fab on a human breast carcinoma cell line (MDA-MB-435) which expresses cMet.
FIGS. 10A and 10B are bar diagrams showing the inhibitory effect of 5D5 Fab on c-Met tyrosine phosphorylation.
FIGS. 11A-11C are graphs comparing inhibitory effects of NK1 (FIG. 11A), 5D5 Fab (FIG. 11B), and 5D5 Fab and rhuHGF (FIG. 11C) on BaF3-hmet.8 cells in a proliferation assay conducted in the presence or absence of heparin.
FIG. 12 is a restriction map of plasmid p5D5 containing the discistronic operon for expression of the chimer 5D5 Fab.
FIG. 13 is a graph showing the inhibition of HGF binding to cMet-IgG fusion protein by recombinant 5D5 Fab.
FIGS. 14A-14D art graphs comparing the inhibitory effect of recombinant 5D5 Fab and recombinant anti-VEGF Fab (control Fab) on BaF3-hmet.8 cells in a proliferation assay conducted in the presence or absence of heparin.

L4 ANSWER 72 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 32
AN 10264702 IFIPAT;IFIUDB;IFICDB
TI IN VIVO MULTIPHOTON DIAGNOSTIC DETECTION AND IMAGING OF A NEURODEGENERATIVE DISEASE
IN Bacskai Brian; Christie Richard; Hyman Bradley T; Webb Watt W; Zipfel Warren R
PA Unassigned Or Assigned To Individual (68000)
PI US 2003009104 A1 20030109
AI US 2001-1643 20011031
PRAI US 2000-245306P 20001102 (Provisional)
FI US 2003009104 20030109
DT Utility; Patent Application - First Publication

APPLICATION
CLMN 34
GI 25 Figure(s).

FIGS. 1A-C show different embodiments for imaging neurodegenerative disease in accordance with the present invention. FIG. 1A illustrates the manner in which a patient's skull is imaged. In FIG. 1B, imaging is carried out with a spectroscopic system. FIG. 1 C illustrates imaging with a single mode optical fiber and terminal lens.

FIGS. 2A-E show the preparation of a skull for in vivo imaging. FIG. 2A shows the gross appearance of skull through dissecting microscope prior to imaging. The pial vasculature is visible through the intact but thinned region of skull. Anterior and midline sutures are also visible in the image. Scale marks are spaced 1 mm apart. FIG. 2B is a schematic diagram of the microscope objective during imaging. The thinned area of skull is bathed in a pool of artificial cerebrospinal fluid (light gray), retained by a ring of bone wax (dark gray). A small break is made in the lateral wall of the thinned area to allow for thioflavine S entry. FIG. 2C is the in vivo visualization of thioflavine S-positive ("ThioS") amyloid in a 15-month old Tg2576 mouse. Single optical section near the surface of the skull. Thioflavine S-positive amyloid angiopathy is visible ringing the pial arteriole in this image. The fainter autofluorescence of the skull bone is visible in the lower right comer, and the fibrous autofluorescence of the dura is visible as a band at lower right. FIG. 2D shows another optical section from the same z-series as in FIG. 2C, but 50 mu m deeper into the brain, showing a thioflavine S-positive amyloid deposit in layer 1 of the mouse cortex. FIG. 2E shows the perpendicular volume rendering of the entire stack of images, with the skull visible at the top, the amyloid-encrusted pial vessel just beneath, and the thioflavine S-positive plaque deep in the living brain. The autofluorescent dura can also be seen as a faint layer between the vessel and the skull. The approximate levels of optical sections shown in FIGS. 2C and 2D are represented by dotted lines. The scale bars in FIGS. 2C-E are 25 mu m.

FIGS. 3A-C confirm the thioflavine S-positive structures were indeed senile plaques. This was demonstrated by applying thioflavine S and an anti-amyloid-beta monoclonal ***antibody*** , cy3labeled 10D5 (Elan Pharmaceuticals, South San Francisco, Calif.) , to the surface of a fixed but intact Tg2576 brain. In FIG. 3A, the fluorescence emission in the range 380-480 nm shows Thioflavine S staining the amyloid core of a plaque about 40 mu m deep into the brain. In FIG. 3B, emission in the 560-650 nm range shows the Cy3-10 D5 staining of the same A beta surrounding the thioflavine S positive core. Scale bar =10 mu m. FIG. 3C shows glial fibrillary acidic protein immunoreactivity in a section through the area imaged by multiphoton microscopy 2 days previously. Sparse immunoreactive astrocytes, not substantially different from adjacent (non-imaged) cortex, suggest minimal tissue response to imaging. Scale=100 mu m.

FIGS. 4A-E show the in vivo imaging of thioflavine S positive amyloid deposition in a Tg2576 mouse. FIG. 4A is a 3 x 3 montage of 60 x fields acquired on initial imaging day. Optical sections were obtained every 2 micrometers for a distance of 200 micrometers from the inner surface of the skull; images were aligned in the x, y, and z axes, then projected onto a single image revealing amyloid angiopathy and senile plaques. Scale bar=100 mu m. FIG. 4B shows the in vivo imaging of a thioflavine S-positive plaque approximately 40 mu m deep to the skull surface. This image is a single optical section through the body of the plaque. Scale bar=10 mu m. FIG. 4C shows the same plaque as in FIG. 4B, reimaged two days later under identical imaging conditions. FIG. 4D is a single optical section showing thioflavine S-positive amyloid angiopathy associated with a pial arteriole. Scale bar=20 mu m. FIG. 4E shows the same arteriole imaged in FIG. 4D after two days.

FIGS. 5A-B show the analysis of variability of plaque measurements. In FIG. 5A, the percent change (average +/standard deviation) for all plaque measurements binned into 0.5month groups shows no trend in either the average measure or the variability of measurement over the time interval examined. N's for each measurement are noted above the standard deviation bars. FIG. 5B is a linear regression plot of initial measurement and subsequent measurement for all time intervals, showing tight correlation for all plaque sizes. The slope of the line approaches unity (0.98) with a correlation coefficient (R2=0.89).

FIG. 6 shows a subpopulation of plaques change size over time. The images are 2-channel volume rendered stacks of thioflavine S plaques (red) and fluorescein angiograms (green) taken from the same animal at the initial imaging session (left images) and 104 days later (right images). Four clearly imaged plaques can be seen in these volumes, labeled A-D. The

stacks, and appears slightly different in the images here and in FIG. 7, because the image stacks are not exactly coincident at their initial depth. The graph below represents the percent change in diameter for each plaque. The plaques labeled A and B increase in size by about 50%, plaque C remains the same size, and plaque D decreases by 40%. Scale bar=20 mu m.

FIGS. 7A-B show the appearance of a novel plaque in the imaged region. FIG. 7A is a volume rendering of a set of 3 plaques during an initial imaging session. FIG. 7B is a volume rendering of the same region, imaged 64 days later, showing the initial plaques joined by a novel thicflavine S-positive plaque. The fibrous autofluorescence at lower left is dura mater. Scale bar=50 mu m.

FIG. 8 is a simplified schematic representation of the experimental paradigm. An anesthetized mouse is placed in a head-open device that is then mounted on the stage of a multiphoton microscope. Texas red-labeled dextran is injected in the tail vein as an angiographic contrast agent. ThioflavineS is applied to the surface of the brain through an open craniotomy. After thioflavine-S is washed out, imaging reveals both microvascular anatomy and amyloid deposits.

FIG. 9 shows examples of the co-occurrence of amyloid angiopathy and microvascular anatomy. A semiquantitative rating scale (none, mild, moderate, severe) was employed as illustrated in this figure.

FIG. 10 shows the measurement of vessel diameter. A random start point was placed, and then the diameter of vessels measured every thirty micrometers thereafter throughout the image series. At each measuring point, the diameter of the vessel as well as the presence or absence of amyloid was noted.

FIG. 11 shows the measurement of vessel diameter as noted with regard to FIG. 10. There is a significant difference between amyloid-containing and non-amyloid-containing vessels for mild (n=11), moderate (n=10) and severe (n=6) vessels.

*=p less-than 0.01.

FIG. 12 shows an example of mild amyloid angiopathy occurring near the branch points of vesssels. The method for measuring distance is illustrated with an overlay of random points from which the distance from the nearest branch point is measured.

FIG. 13 shows the distance af amyloid deposits from nearest branch point. Measurements were carried out as described with reference to FIG. 12. The significant differences were seen in both mild (n=75 vessel segments, p less-than 0.005) and moderate (n=73 vessel segments, p less-than 0.005) vessels, with amyloid tending to occur near branch points. A smaller difference, not reaching statistical significance was seen in severely affected vessels (n=59).

FIG. 14 shows the thioS positive amyloid angiopathy in the Tg2576 mouse. The intact fixed brain of a 16 month old Tg2576 mouse was stained with thioS (0.005%) and imaged using twophoton excitation at 750 nm. This image is a montage of 4 x 8 zseries collected with a 20 x objective. The midline of the brain is at the top of the figure, and the brain was oriented with the anterior pole to the left. Extreme curvature at the lateral edge of the brain interfered with montage generation, distorting the lowermost portion of the image. The middle cerebral artery emerges from behind the lateral edge of the brain on the right, and courses towards the midline. ThioS positive vessel-associated amyloid, as well as superficial parenchymal thioS-positive plaques are clearly visible. Surface venules are seen as negatively stained background profiles. Scale bar(upper right)=600 mu m.

FIGS. 15A-B shows that the overexpression of mutant amyloid precursor protein ("APP") does not disrupt smooth muscle cells independent of amyloid deposition. Phalloidin-labeled smooth muscle cells in young (6 month) Tg2576 animals are arranged neatly around the circumference of the vessel, with no apparent space between adjacent cells. FIG. 15A shows the phalloidinstained smooth muscle cells in a pial vessel from a Tg-animal. FIG. 15B shows smooth muscle cells in a pial vessel of a Tg+ animal. Scale bar=20 mu m.

FIGS. 16A-F show the effect of amyloid deposition on smooth muscle cells in 14 month old and 22 month old Tg2567 animals. FIG. 16A shows phalloidin-labeled smooth muscle cells in the wall of a pial arteriole in a 14 month old Tg2576 animal. FIG. 16B shows thioS-positive amyloid surrounding the vessels. Smooth muscle cells are clearly disrupted in areas of amyloid deposition as compared to unaffected regions of the same vessel. Smooth muscle cells surrounded by amyloid are disorganized and isolated, though there is no apparent loss of cells along the length of the vessel. FIG. 16D shows smooth muscle cell staining in a 24 month old Tg2576 animal. FIG. 16E shows thioSpositive amyloid surrounding the vessel. At this age, overt loss of smooth muscle cells along the length

Regions of the vessel unaffected by amyloid, however, retain normal smooth muscle cell organization. (See FIG. 16C and F). Superimposed color images showing both phalliodin and thio S staining. Scale bar=20 mu m.

FIG. 17 shows the quantitation of smooth muscle cell density in amyloid-laden versus amyloid-free vessels in 14 mo and 24 mo Tg2576 mice. Smooth muscle cell linear density was measured as described. Density was measured in affected and unaffected vessels from both age groups. The 24 month old amyloid-laden set of vessels has significantly smaller smooth muscle cell density (p less-than 0.01, ANOVA) than either the amyloid-free vessels from the same animal or amyloid-free vessels from younger transgenic and non-transgenic animals.

FIG. 18 shows the response of pial vessels to ACh and SNP. Maximal percent dilation in response to ACh (10-6M) and SNP (0. 5 x 10-6M) in 14 month old Tg+ (n=4 of 5, one outlier excluded) and Tg-(n=3 of 3) mice. Bars are mean +/-SD. *, p less-than 0. 05 by ANOVA.

FIGS. 19A-D show the in vivo imaging of amyloid-beta deposits in 20 month old homozygous PDAPP mice. Reconstructions of stacks of Z series images taken at 5 micron steps with a 20X objective (FIGS. 19A-B) and 2 micron steps with a 60 x objective (FIGS. 19C-D) starting from just below the cortical surface to approximately 150 microns below the surface. Amyloid beta is visualized with a dilute solution of fluorescein labeled monoclonal ***antibody*** 10D5. (FIGS. 19A and C) Initial imaging session shows numerous 10D5 immunoreactive amyloidbeta plaques in the neuropil and associated with vessels in one representative animal (FIGS. 19B and D). Three days later exactly the same sites were re-imaged with fluorescein10D5. Surprisingly, very little of the neuropil amyloid-beta remains, directly showing reversal of previously existing amyloid-beta deposits. Note that the vessel associated amyloid-beta is not clearly altered. Magnification bar=50 mu m in FIGS. 19A and B, 25 mu m in FIGS. 19C and D.

FIGS. 20A-D ascertain whether the apparent clearance of amyloidbeta was due to application of an anti-amyloid beta ***antibody*** or to the surgical preparation, imaging, and other nonspecific factors by replacing 10D5 in the first imaging session with 16B5, a monoclonal ***antibody*** directed against human tau that does not cross react with rodent tau (Sobey et al., "Effect of Nitric Oxide and Potassium Channel Agonists and Inhibitors on Basilar Artery Diameter," Am J Physiol 72:H256-H262 (1997), which is hereby incorporated by reference), and used thioflavine S as the imaging agent. FIGS. 20A and 20B, respectively, show a thioflavine S positive plaque in the first imaging session and 3 days after application of 10D5. FIG. 20C depicts a thioflavine S positive plaque in a 16B5 treated animal does not change 3 days later (FIG. 20D). Magnification bar=20 mu m.

FIGS. 21A-B show the histological analysis of imaged brains from 20 mo. old homozygous PDAPP mice using directly labeled ***antibody*** ***3D6*** , showing an extraordinarily high level of amyloidbeta deposits throughout the cortex and hippocampal formation. There was a marked diminution of amyloid-beta staining at the site of 10D5 application. FIG. 21A depicts the immunostaining with biotinylated ***3D6*** , an anti-amyloid-beta monoclonal ***antibody*** that has a distinct epitope (aa 1-5) compared to 10D5 (aa 3-6), which shows a 100-200 micron deep area that was essentially devoid of diffuse amyloid-beta deposits, in contrast to the intense deposits found in adjacent sections or medial or lateral to the site. FIG. 21B shows that there were no changes in ***3D6*** immunoreactive amyloid-beta plaques observed after initial treatment with 16B5 application. Magnification bar=200 mu m.

FIGS. 22A-B show that marked local microglial activation, as assessed with biotin labeled tomato lectin (Sigma Chemical Co., St. Louis, Mo.), occurred three days after skull preparation and imaging in both (FIG. 22A) the 10D5 and (FIG. 22B) the 16B5 groups. Magnification bar=200 mu m.

FIGS. 23A-B show confocal thin optical sections (0.2 micron) that were reconstructed to illustrate the intimate relationship of microglia with remaining amyloid-beta three days after treatment with 10D5-fluorescein. FIG. 23A depicts luorescein labeled tomato lectin, which detects microglia, and biotin labeled ***3D6*** detected with Cy3 avidin, which detects amyloidbeta . A marked microglial response surrounding remaining amyloid-beta plaques was deserved. As indicated in FIG. 23B, distal to the site, for example in temporal lobe, the association of microglia with amyloid-beta is much more modest. Magnification bar=20 mu m.

FIG. 24A shows the autofluorescence of neurofibrillary tangles and lipofusion droplets from post-mortem brain tissue in a human Alzheimer's Disease patient. FIG. 24B shows the fluorescence of neurofibrillary tangles from post-mortem brain tissue in a human Alzheimer's Disease

demonstrates the fluorescence in FIG. 24A is attributable to the tau protein. !

L4 ANSWER 73 OF 374 USPATFULL on STN DUPLICATE 33
AN 2003:271511 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
PI US 2003191119 A1 20031009
US 6767918 B2 20040727
AI US 2002-314221 A1 20021209 (10)
RLI Division of Ser. No. US 2001-984834, filed on 31 Oct 2001, PENDING Continuation of Ser. No. US 1999-303655, filed on 3 May 1999, GRANTED, Pat. No. US 6333351 Continuation of Ser. No. US 1997-976179, filed on 21 Nov 1997, GRANTED, Pat. No. US 6117901
PRAI US 1996-98551P 19961122 (60)
DT Utility
FS APPLICATION
LN.CNT 3753
INCL INCLM: 514/227.800
INCLS: 514/357.000; 514/235.500; 514/563.000; 514/616.000
NCL NCLM: 514/361.000
NCLS: 514/359.000; 514/374.000; 514/378.000; 514/432.000; 514/438.000; 548/128.000; 548/235.000; 548/247.000; 549/013.000; 549/019.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-44; A61K031-198; A61K031-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 74 OF 374 USPATFULL on STN DUPLICATE 34
AN 2003:232567 USPATFULL
TI Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Shi, Qing, Carmel, IN, UNITED STATES
PI US 2003162768 A1 20030828
US 6696438 B2 20040224
AI US 2002-317081 A1 20021212 (10)
RLI Division of Ser. No. US 1999-338180, filed on 22 Jun 1999, GRANTED, Pat. No. US 6528505
PRAI US 1998-160067P 19980622 (60)
US 1998-155238P 19980930 (60)
DT Utility
FS APPLICATION
LN.CNT 7196
INCL INCLM: 514/211.050
INCLS: 514/212.050; 514/212.070; 514/220.000; 514/221.000; 540/490.000; 540/496.000; 540/500.000; 540/504.000
NCL NCLM: 514/220.000
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/517.000; 540/518.000
IC [7]
ICM: A61K031-554
ICS: A61K031-553; A61K031-55; A61K031-5513; A61K031-551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 75 OF 374 USPATFULL on STN DUPLICATE 35
AN 2003:220259 USPATFULL
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, UNITED STATES
Thompson, Richard C., Frankfort, IN, UNITED STATES
Wilkie, Stephen C., Indianapolis, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES

Huffman, George W., Carmel, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
PI US 2003153550 A1 20030814
US 6774125 B2 20040810
AI US 2002-267017 A1 20021007 (10)
RLI Division of Ser. No. US 1999-337484, filed on 21 Jun 1999, GRANTED, Pat. No. US 6509331
PRAI US 1998-155265P 19980622 (60)
DT Utility
FS APPLICATION
LN.CNT 6533
INCL INCLM: 514/211.050
INCLS: 514/221.000; 514/220.000; 514/212.040; 514/212.050; 514/151.000; 540/490.000; 540/496.000; 540/500.000; 540/522.000; 540/523.000; 540/520.000
NCL NCLM: 514/220.000
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/517.000; 540/518.000
IC [7]
ICM: A61K031-655
ICS: A61K031-55; A61K031-553; A61K031-5513; A61K031-551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 76 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:617008 CAPLUS
TI Cloning of anti-type IV collagenase single-chain ***antibody*** fusion with lidamycin protein subunit Lida-protein (LDP) in yeast
IN Zhen, Yongsu; Tang, Yong
PA Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 18 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1403577	A	20030319	CN 2001-131299	20010906

PRAI CN 2001-131299 20010906

L4 ANSWER 77 OF 374 USPATFULL on STN
AN 2003:330543 USPATFULL
TI Immunological methods and compositions for the treatment of Alzheimer's disease
IN St. George-Hyslop, Peter H., Toronto, CANADA
McLaurin, JoAnne, Toronto, CANADA
PA Hospital for Sick Children and University of Toronto (non-U.S. corporation)
PI US 2003232758 A1 20031218
AI US 2003-411544 A1 20030410 (10)
PRAI US 2002-373914P 20020419 (60)
DT Utility
FS APPLICATION
LN.CNT 2487
INCL INCLM: 514/012.000
INCLS: 530/324.000; 435/069.100; 435/320.100; 435/325.000; 536/023.100
NCL NCLM: 514/012.000
NCLS: 530/324.000; 435/069.100; 435/320.100; 435/325.000; 536/023.100
IC [7]
ICM: A61K038-17
ICS: C07K014-47; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 78 OF 374 USPATFULL on STN
AN 2003:325042 USPATFULL
TI Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
IN Audia, James E., Indianapolis, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Folmer, Beverly K., Newark, DE, UNITED STATES
Huffman, George W., Carmel, IN, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES

Porter, Warren J., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Wu, Jing, San Mateo, CA, UNITED STATES
Eid, Clark Norman, Cheshire, CT, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
PI US 2003229024 A1 20031211
AI US 2002-309569 A1 20021203 (10)
RLI Continuation of Ser. No. US 2001-789487, filed on 20 Feb 2001, PENDING
Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED, Pat. No. US 6191166
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
DT Utility
FS APPLICATION
LN.CNT 14968
INCL INCLM: 514/017.000
INCLS: 514/018.000; 514/019.000; 530/328.000; 530/329.000; 530/330.000; 530/331.000
NCL NCLM: 514/017.000
NCLS: 514/018.000; 514/019.000; 530/328.000; 530/329.000; 530/330.000; 530/331.000
IC [7]
ICM: A61K038-08
ICS: A61K038-06; A61K038-05; C07K007-08; C07K007-06; C07K005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 79 OF 374 USPATFULL on STN
AN 2003:318635 USPATFULL
TI Novel nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Yang, Yonghong, San Jose, CA, UNITED STATES
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
Weng, Gezhi, Piedmont, CA, UNITED STATES
Ma, Yunqing, Santa Clara, CA, UNITED STATES
PI US 2003224379 A1 20031204
AI US 2002-243552 A1 20020912 (10)
RLI Continuation-in-part of Ser. No. WO 2000-US35017, filed on 22 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-552317, filed on 25 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING
PRAI WO 2001-US2623 20010125
WO 2001-US3800 20010205
WO 2001-US4927 20010226
WO 2001-US4941 20010305
WO 2001-US8631 20010330
WO 2001-US8656 20010416
WO 2001-US14827 20010516
US 2001-322511P 20010913 (60)
DT Utility
FS APPLICATION
LN.CNT 13810
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-47; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 80 OF 374 USPATFULL on STN
AN 2003:271536 USPATFULL
TI Compounds, compositions and methods for modulating beta-amyloid production
IN Connop, Bruce P., Vancouver, CANADA
Grant, Amelia, Vancouver, CANADA
MacDonald, David, Surrey, CANADA
Nathwani, Parimal S., Burnaby, CANADA
Reiner, Peter B., Vancouver, CANADA

PA Active Pass Pharmaceuticals, Inc., Vancouver, CANADA (non-U.S. corporation)
PI US 2003191144 A1 20031009
AI US 2002-325667 A1 20021219 (10)
RLI Continuation-in-part of Ser. No. US 2002-170224, filed on 12 Jun 2002, PENDING
PRAI US 2001-309257P 20010731 (60)
US 2001-297845P 20010612 (60)
DT Utility
FS APPLICATION
LN.CNT 3629
INCL INCLM: 514/269.000
NCL NCLM: 514/269.000
IC [7]
ICM: A61K031-513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 81 OF 374 USPATFULL on STN
AN 2003:214379 USPATFULL
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Thompson, Richard C,, Frankfort, IN, UNITED STATES
Wilkie, Stephen C., Indianapolis, IN, UNITED STATES
Stack, Douglas R., Fishers, IN, UNITED STATES
Shi, Qing, Carmel, IN, UNITED STATES
PI US 2003149022 A1 20030807
AI US 2002-326081 A1 20021223 (10)
RLI Division of Ser. No. US 1999-338121, filed on 22 Jun 1999, PENDING
PRAI US 1998-160067P 19980622 (60)
US 1998-150704P 19980930 (60)
DT Utility
FS APPLICATION
LN.CNT 7927
INCL INCLM: 514/211.040
INCLS: 514/212.040; 514/220.000; 514/212.050; 514/221.000
NCL NCLM: 514/211.040
NCLS: 514/212.040; 514/220.000; 514/212.050; 514/221.000
IC [7]
ICM: A61K031-55
ICS: A61K031-553; A61K031-554; A61K031-5513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 82 OF 374 USPATFULL on STN
AN 2003:213754 USPATFULL
TI Screening compounds for the ability to alter the production of amyloid-beta peptide (x-41)
IN Citron, Martin, Thousand Oaks, CA, UNITED STATES
Selkoe, Dennis J., Jamaica Plain, MA, UNITED STATES
Seubert, Peter A., San Francisco, CA, UNITED STATES
Schenk, Dale B., Burlingame, CA, UNITED STATES
PA Athena Neurosciences, Inc. a Delaware corporation, South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 2003148392 A1 20030807
AI US 2002-335035 A1 20021230 (10)
RLI Continuation of Ser. No. US 1996-665649, filed on 18 Jun 1996, PENDING Continuation-in-part of Ser. No. US 1993-79511, filed on 17 Jun 1993, GRANTED, Pat. No. US 5766846 Division of Ser. No. US 1992-965972, filed on 26 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-911647, filed on 10 Jul 1992, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1904
INCL INCLM: 435/007.200
INCLS: 435/007.930
NCL NCLM: 435/007.200
NCLS: 435/007.930
IC [7]
ICM: G01N033-53
ICS: G01N033-567; G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 83 OF 374 USPATFULL on STN

TI Novel APP mutation associated with an unusual Alzheimer's disease pathology
IN Cruts, Mare, Antwerpen, BELGIUM
Jonghe, Chris De, Edegem, BELGIUM
Singh, Samir Kumar, Edegem, BELGIUM
Broeckhoven, Christine van, Edegem, BELGIUM
PI US 2003148356 A1 20030807
AI US 2003-337970 A1 20030106 (10)
RLI Continuation of Ser. No. WO 2001-EP7830, filed on 6 Jul 2001, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 1415
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/252.300; 435/320.100; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/252.300; 435/320.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12N001-21; C12P021-02; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 84 OF 374 USPATFULL on STN
AN 2003:200445 USPATFULL
TI Modified ***antibodies*** with human milk fat globule specificity & uses
IN do Couto, Fernando J.R., Pleasanton, CA, UNITED STATES
Ceriani, Roberto L., Lafayette, CA, UNITED STATES
Peterson, Jerry A., Lafayette, CA, UNITED STATES
Padlan, Eduardo A., Kensington, CA, UNITED STATES
PI US 2003138428 A1 20030724
AI US 2001-947839 A1 20010906 (9)
RLI Division of Ser. No. US 1997-976288, filed on 21 Nov 1997, GRANTED, Pat. No. US 6315997 Division of Ser. No. US 1993-129930, filed on 30 Sep 1993, GRANTED, Pat. No. US 5804187 Continuation-in-part of Ser. No. US 1992-977696, filed on 16 Nov 1992, GRANTED, Pat. No. US 5792852
DT Utility
FS APPLICATION
LN.CNT 5365
INCL INCLM: 424/155.100
INCLS: 530/388.800; 435/344.000
NCL NCLM: 424/155.100
NCLS: 530/388.800; 435/344.000
IC [7]
ICM: A61K039-395
ICS: C12N005-06; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 85 OF 374 USPATFULL on STN
AN 2003:188395 USPATFULL
TI Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Droste, James, Indianapolis, IN, UNITED STATES
PI US 2003130188 A1 20030710
AI US 2002-246558 A1 20020919 (10)
RLI Division of Ser. No. US 1998-32019, filed on 27 Feb 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 11320
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 514/019.000; 514/400.000; 514/419.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 514/019.000; 514/400.000; 514/419.000
IC [7]
ICM: A61K038-10
ICS: A61K038-08; A61K038-06; A61K038-05; A61K031-4172; A61K031-405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:181505 USPATFULL
TI Compounds, compositions and methods for modulating beta-amyloid production
IN Connop, Bruce P., Vancouver, CANADA
Grant, Amelia, Vancouver, CANADA
Nathwani, Parimal S., Burnaby, CANADA
PA Active Pass Pharmaceuticals, Inc., Vancouver, CANADA, V5Z 4H5 (non-U.S. corporation)
PI US 2003125338 A1 20030703
AI US 2002-170224 A1 20020612 (10)
PRAI US 2001-309257P 20010731 (60)
US 2001-297845P 20010612 (60)
DT Utility
FS APPLICATION
LN.CNT 2198
INCL INCLM: 514/255.060
INCLS: 514/255.050; 544/405.000; 544/408.000
NCL NCLM: 514/255.060
NCLS: 514/255.050; 544/405.000; 544/408.000
IC [7]
ICM: A61K031-4965
ICS: C07D043-02; C07D241-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 87 OF 374 USPATFULL on STN
AN 2003:159820 USPATFULL
TI Methods of inhibiting amyloid toxicity
IN Prenner, Irene Griswald, Brisbane, CA, UNITED STATES
Wright, Sarah, San Francisco, CA, UNITED STATES
Yednock, Theodore, Forest knolls, CA, UNITED STATES
Rydel, Russell, Belmont, CA, UNITED STATES
PI US 2003109435 A1 20030612
AI US 2002-190548 A1 20020709 (10)
PRAI US 2001-304315P 20010709 (60)
US 2001-341772P 20011217 (60)
DT Utility
FS APPLICATION
LN.CNT 2361
INCL INCLM: 514/012.000
INCLS: 424/146.100
NCL NCLM: 514/012.000
NCLS: 424/146.100
IC [7]
ICM: A61K038-17
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 88 OF 374 USPATFULL on STN
AN 2003:152328 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2003103994 A1 20030605
AI US 2002-114666 A1 20020401 (10)
RLI Continuation-in-part of Ser. No. US 2001-895828, filed on 28 Jun 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 10295
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 89 OF 374 USPATFULL on STN
AN 2003:126723 USPATFULL
TI Basal cell markers in breast cancer and uses thereof
IN Botstein, David, Belmont, CA, UNITED STATES
Brown, Patrick O., Stanford, CA, UNITED STATES
Perou, Charles M., Carrboro, NC, UNITED STATES
Ring, Brian, Foster City, CA, UNITED STATES
Ross, Douglas, Burlingame, CA, UNITED STATES

van de Rijn, Jan Matthijs, LaHanda, CA, UNITED STATES
PI US 2003086934 A1 20030508
AI US 2001-916849 A1 20010726 (9)
PRAI US 2000-220967P 20000726 (60)
DT Utility
FS APPLICATION
LN.CNT 6518
INCL INCLM: 424/185.100
INCLS: 435/006.000; 435/007.230
NCL NCLM: 424/185.100
NCLS: 435/006.000; 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 90 OF 374 USPATFULL on STN
AN 2003:120996 USPATFULL
TI Novel glyphosate N-acetyl transferase (GAT) genes
IN Castle, Linda A., Mountain View, CA, UNITED STATES
Siehl, Dan, Menlow Park, CA, UNITED STATES
Giver, Lorraine J., Santa Clara, CA, UNITED STATES
Minshull, Jeremy, Menlo Park, CA, UNITED STATES
Ivy, Cristina, Los Altos, CA, UNITED STATES
Chen, Yong Hong, Foster City, CA, UNITED STATES
Duck, Nicholas B., Apex, NC, UNITED STATES
PA Maxygen, Inc., Redwood City, CA, UNITED STATES, 94063 (U.S. corporation)
PI US 2003083480 A1 20030501
AI US 2001-4357 A1 20011029 (10)
PRAI US 2000-244385P 20001030 (60)
DT Utility
FS APPLICATION
LN.CNT 11334
INCL INCLM: 536/023.100
NCL NCLM: 536/023.100
IC [7]
ICM: C07H021-02
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 91 OF 374 USPATFULL on STN
AN 2003:120174 USPATFULL
TI Monoclonal ***antibodies*** which identify the glycoprotein carrying the CA125 epitope
IN O'Brien, Timothy J., Little Rock, AR, UNITED STATES
PI US 2003082655 A1 20030501
AI US 2002-237920 A1 20020909 (10)
RLI Continuation of Ser. No. US 1998-69471, filed on 29 Apr 1998, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 611
INCL INCLM: 435/007.230
INCLS: 530/388.800
NCL NCLM: 435/007.230
NCLS: 530/388.800
IC [7]
ICM: G01N033-574
ICS: C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 92 OF 374 USPATFULL on STN
AN 2003:99221 USPATFULL
TI Immunogenic peptide composition for the prevention and treatment of Altzheimers Disease
IN Wang, Chang Yi, Cold Spring Harbor, NY, UNITED STATES
PI US 2003068325 A1 20030410
AI US 2001-865294 A1 20010525 (9)
DT Utility
FS APPLICATION
LN.CNT 2076
INCL INCLM: 424/185.100
INCLS: 435/226.000
NCL NCLM: 424/185.100
NCLS: 435/226.000
IC [7]

ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 93 OF 374 USPATFULL on STN
AN 2003:23331 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003017167 A1 20030123
AI US 2001-904456 A1 20010711 (9)
RLI Continuation-in-part of Ser. No. US 2001-878722, filed on 8 Jun 2001, PENDING
PRAI US 2001-290240P 20010510 (60)
US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)
DT Utility
FS APPLICATION
LN.CNT 8237
INCL INCLM: 424/185.100
INCLS: 514/044.000; 435/007.230; 435/006.000; 435/325.000; 435/320.100; 435/069.100; 536/023.200
NCL NCLM: 424/185.100
NCLS: 514/044.000; 435/007.230; 435/006.000; 435/325.000; 435/320.100; 435/069.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 94 OF 374 USPATFULL on STN
AN 2003:332380 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6667305 B1 20031223
AI US 2003-336745 20030106 (10)
RLI Division of Ser. No. US 2002-915379, filed on 27 Jul 2002, now patented, Pat. No. US 6579867 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS GRANTED
LN.CNT 19309
INCL INCLM: 514/220.000
INCLS: 514/221.000
NCL NCLM: 514/220.000
NCLS: 514/221.000
IC [7]
ICM: A61P025-28
EXF 514/220; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 95 OF 374 USPATFULL on STN
AN 2003:321588 USPATFULL
TI Mice comprising engrafted functional human hepatocytes
IN Kay, Mark A., Los Altos, CA, United States
Ohashi, Kazuo, Palo Alto, CA, United States
PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
PI US 6660905 B1 20031209
AI US 2000-614658 20000712 (9)
PRAI US 1999-143897P 19990714 (60)
DT Utility
FS GRANTED
LN.CNT 1586
INCL INCLM: 800/008.000
INCLS: 424/093.100; 530/388.100; 530/388.150; 530/388.200
NCL NCLM: 800/008.000
NCLS: 424/093.100; 530/388.100; 530/388.150; 530/388.200
IC [7]
ICM: A01K067-00
ICS: A01K067-033; A01K063-00; C07K016-00; C12P021-08
EXF 800/18; 800/21; 800/22; 800/26; 800/3; 800/8; 424/93.1; 530/388.1; 530/388.15; 530/388.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 96 OF 374 USPATFULL on STN
AN 2003:309076 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6653303 B1 20031125
AI US 2003-336824 20030106 (10)
RLI Division of Ser. No. US 2001-915480, filed on 27 Jul 2001, now patented, Pat. No. US 6544978 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS GRANTED
LN.CNT 19893
INCL INCLM: 514/220.000
INCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/513.000; 540/518.000
NCL NCLM: 514/220.000
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/513.000; 540/518.000
IC [7]
ICM: A61K031-55
ICS: C07D487-00; C07D491-00; C07D487-04; C07D243-12
EXF 514/220; 514/221; 540/496; 540/497; 540/498; 540/499; 540/504; 540/513; 540/518
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:302865 USPATFULL
TI Modified VEGF Oligonucleotides for Inhibition of tumor growth
IN Smyth, Adrienne P., Charlton, MA, United States
Robinson, Gregory S., Acton, MA, United States
PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6649596 B1 20031118
AI US 1998-124304 19980729 (9)
RLI Continuation-in-part of Ser. No. US 1996-629730, filed on 9 Apr 1996, now abandoned Continuation-in-part of Ser. No. US 1995-569926, filed on 8 Dec 1995, now patented, Pat. No. US 5641756
DT Utility
FS GRANTED
LN.CNT 1377
INCL INCLM: 514/044.000
INCLS: 536/024.500; 435/006.000; 435/325.000; 435/375.000
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/325.000; 435/375.000; 536/024.500
IC [7]
ICM: C07H021-04
ICS: C21N015-85; C21N015-86; C12Q001-68; A61K048-00
EXF 514/44; 435/6; 435/91.1; 435/91.3; 435/325; 435/375; 536/23.1; 536/24.5; 536/23.2; 536/24.3; 536/24.31; 536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 98 OF 374 USPATFULL on STN
AN 2003:279186 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6635632 B1 20031021
AI US 1997-996422 19971222 (8)
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS GRANTED
LN.CNT 22179
INCL INCLM: 514/212.030
INCLS: 514/212.040; 514/212.070; 514/212.080
NCL NCLM: 514/212.030
NCLS: 514/212.040; 514/212.070; 514/212.080
IC [7]
ICM: A61K031-55
ICS: A61P025-28
EXF 514/212.03; 514/212.04; 514/212.07; 514/212.08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 99 OF 374 USPATFULL on STN
AN 2003:260805 USPATFULL
TI .beta.-secretase enzyme compositions and methods
IN Anderson, John P., San Francisco, CA, United States
Basi, Guriqbal, Palo Alto, CA, United States
Doan, Minh Tam, Hayward, CA, United States

John, Varghese, San Francisco, CA, United States
Power, Michael, Fremont, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
Tatsuno, Gwen, Oakland, CA, United States
Tung, Jay, Belmont, CA, United States
Wang, Shuwen, Hersey, PA, United States
McConlogue, Lisa, Burlingame, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6627739 B1 20030930
AI US 2000-724566 20001128 (9)
RLI Continuation of Ser. No. US 2000-501708, filed on 10 Feb 2000
PRAI US 1999-119571P 19990210 (60)
US 1999-139172P 19990615 (60)
DT Utility
FS GRANTED
LN.CNT 4793
INCL INCLM: 530/387.900
INCLS: 530/388.100; 530/388.260; 530/389.100; 530/389.200
NCL NCLM: 530/387.900
NCLS: 530/388.100; 530/388.260; 530/389.100; 530/389.200
IC [7]
ICM: C07K016-40
EXF 530/387.9; 530/388.1; 530/388.26; 530/389.1; 530/389.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 100 OF 374 USPATFULL on STN
AN 2003:228237 USPATFULL
TI Screening compounds for the ability to alter the production of amyloid-.beta. peptide
IN Citron, Martin, Thousands Oaks, CA, United States
Selkoe, Dennis J., Jamaica Plain, MA, United States
Seubert, Peter A., San Francisco, CA, United States
Schenk, Dale, Burlingame, CA, United States
PA Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6610493 B1 20030826
AI US 1996-665649 19960618 (8)
RLI Continuation-in-part of Ser. No. US 1993-79511, filed on 17 Jun 1993, now patented, Pat. No. US 5766846
DT Utility
FS GRANTED
LN.CNT 2054
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/007.210; 435/007.230; 435/007.800; 435/007.920
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/007.210; 435/007.230; 435/007.800; 435/007.920
IC [7]
ICM: G01N033-53
EXF 435/7.1; 435/7.2; 435/7.21; 435/7.23; 435/7.8; 435/7.92; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 101 OF 374 USPATFULL on STN
AN 2003:143058 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen, Indianapolis, IN, United States
Stack, Douglas R., Fishers, IN, United States
VanMeter, Eldon E., Greenwood, IN, United States
Shi, Qing, Carmel, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Martinsville, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Elan Pharmaceutials, Inc., South San Francisco, CA, United States (U.S.

Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6569851 B1 20030527
AI US 1999-338191 19990622 (9)
PRAI US 1998-160067P 19980622 (60)
DT Utility
FS GRANTED
LN.CNT 12808
INCL INCLM: 514/219.000
INCLS: 514/220.000; 514/221.000; 540/509.000; 540/517.000; 540/518.000; 540/558.000; 540/559.000; 540/560.000; 540/561.000
NCL NCLM: 514/219.000
NCLS: 514/220.000; 514/221.000; 540/509.000; 540/517.000; 540/518.000; 540/558.000; 540/559.000; 540/560.000; 540/561.000
IC [7]
ICM: C07D243-24
ICS: C07D223-18; C07D223-16; C07D243-14; A61K031-55
EXF 540/509; 540/558; 540/559; 540/560; 540/561; 540/517; 540/518; 514/221; 514/219; 514/220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 102 OF 374 USPATFULL on STN
AN 2003:109100 USPATFULL
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen C., Indianapolis, IN, United States
Stack, Douglas R., Fishers, IN, United States
Shi, Qing, Carmel, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6552013 B1 20030422
AI US 1999-338121 19990622 (9)
PRAI US 1998-160067P 19980622 (60)
US 1998-150704P 19980930 (60)
DT Utility
FS GRANTED
LN.CNT 7962
INCL INCLM: 514/212.040
INCLS: 514/212.070; 540/522.000; 540/523.000
NCL NCLM: 514/212.040
NCLS: 514/212.070; 540/522.000; 540/523.000
IC [7]
ICM: C07D243-24
ICS: C07D223-18; C07D223-16; C07D409-12; A61K031-55
EXF 514/212.04; 514/212.07; 540/522; 540/523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 103 OF 374 USPATFULL on STN
AN 2003:60218 USPATFULL
TI Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Shi, Qing, Carmel, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6528505 B1 20030304
AI US 1999-338180 19990622 (9)
PRAI US 1998-160067P 19980622 (60)
US 1998-155238P 19980930 (60)
DT Utility
FS GRANTED
LN.CNT 7113
INCL INCLM: 514/212.040
INCLS: 514/212.070; 540/522.000; 540/523.000
NCL NCLM: 514/212.040
NCLS: 514/212.070; 540/522.000; 540/523.000
IC [7]

ICS: C07D243-06; C07D243-10; C07D243-12; A61K031-55
EXF 540/522; 540/523; 514/212.04; 514/212.07
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 104 OF 374 USPATFULL on STN
AN 2003:20224 USPATFULL
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen C., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Huffman, George W., Carmel, IN, United States
Latimer, Lee H., Oakland, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6509331 B1 20030121
AI US 1999-337484 19990621 (9)
PRAI US 1998-155265P 19980622 (60)
DT Utility
FS GRANTED
LN.CNT 6167
INCL INCLM: 514/212.040
INCLS: 514/212.070; 540/522.000; 540/523.000
NCL NCLM: 514/212.040
NCLS: 514/212.070; 540/522.000; 540/523.000
IC [7]
ICM: C07D487-00
ICS: C07D491-00; C07D498-00; C07D513-00; A61K031-55
EXF 540/522; 540/523; 514/212.04; 514/212.07
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 105 OF 374 USPATFULL on STN
AN 2003:13325 USPATFULL
TI Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Thorsett, Eugene D., Moss Beach, CA, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
Audia, James E., Indianapolis, IN, United States
Droste, James, Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6506782 B1 20030114
AI US 1998-32019 19980227 (9)
DT Utility
FS GRANTED
LN.CNT 9870
INCL INCLM: 514/364.000
NCL NCLM: 514/364.000
IC [7]
ICM: A61K031-4245
EXF 514/364
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 106 OF 374 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2003-14919 DRUGU M
TI Epitope and isotype specificities of ***antibodies*** to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology.
AU Bard F; Barbour R; Cannon C; Fox M; Games D; Guido T; Hoenow K; Hu K; Johnson Wood K
CS Elan
LO San Francisco, Cal., USA
SO Proc.Natl.Acad.Sci.U.S.A. (100, No. 4, 2023-28, 2003) 4 Fig. 2 Tab. 24 Ref.
CODEN: PNASA6 ISSN: 0027-8424
AV Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080, U.S.A. (22 authors). (e-mail: frederique.bard@elan.com).
LA English

FA AB; LA; CT
FS Literature

L4 ANSWER 107 OF 374 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004037115 EMBASE
TI Society for Neuroscience - 33rd Annual Meeting: Alzheimer's and Parkinson's diseases 8-12 November 2003, New Orleans, LA, USA.
AU Garvey R.; De La Rue S.
CS R. Garvey, Thomson Current Drugs, Middlesex House, 34-42 Cleveland Street, London W1T 4JE, United Kingdom. redmond.garvey@thomson.com
SO IDrugs, (2003) 6/12 (1111-1113).
ISSN: 1369-7056 CODEN: IDRUFN
CY United Kingdom
DT Journal; Conference Article
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
030 Pharmacology
038 Adverse Reactions Titles
LA English

L4 ANSWER 108 OF 374 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2003:36798162 BIOTECHNO
TI Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway
AU Roche Y.; Pasquier D.; Rambeaud J.-J.; Seigneurin D.; Duperray A.
CS Dr. A. Duperray, Unite INSERM 578, Institut Albert Bonniot, Domaine de la Merci, 38706 La Tronche Cedex, Grenoble, France.
E-mail: Alain.Duperray@ujf-grenoble.fr
SO Thrombosis and Haemostasis, (01 JUN 2003), 89/6 (1089-1097), 32 reference(s)
CODEN: THHADQ ISSN: 0340-6245
DT Journal; Article
CY Germany, Federal Republic of
LA English
SL English

L4 ANSWER 109 OF 374 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2004-37410 DRUGU P
TI Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.
AU Frenkel D; Dewachter I; Van Leuven F; Solomon B
CS Univ.Tel-Aviv; Univ.Leuven-Katholieke
LO Tel Aviv, Isr.; Louvain, Belg.
SO Vaccine (21, No. 11-12, 1060-65, 2003) 5 Fig. 18 Ref.
CODEN: VACCDE ISSN: 0264-410X
AV Department of Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel. (B.S.). (e-mail: beka@post.tau.ac.il).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 110 OF 374 BIOENG COPYRIGHT 2004 CSA on STN DUPLICATE
AN 2004466903 BIOENG
DN 5820013
TI Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment ***antibody*** against c-Met
AU Nguyen, TH; Loux, N; Dagher, I; Vons, C; Carey, K; Briand, P; Hadchouel, M; Franco, D; Jouanneau, J; Schwall, R; Weber, A
CS EMI 00-20 Hopital A. Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart, France, [mailto:anne.weber@abc.ap-hop-paris.fr]
SO Cancer Gene Therapy [Cancer Gene Ther.]. Vol. 10, no. 11, pp. 840-849. Nov 2003.
ISSN: 0929-1903
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts

L4 ANSWER 111 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

DN PREV200300492874
TI Evaluation of monoclonal ***antibody*** ***3D6*** in BALB/c nude mice with human lung cancer.
AU Jia, B. [Reprint Author]; Dai, Y.; Du, J. [Reprint Author]; Wang, F. [Reprint Author]
CS Medical Isotopes Research Center, School of Basic Medical Science, Peking University, 38 Xueyuan Road, Beijing, 100083, China
Wangfan@bjmu.edu.cn
SO Journal of Labelled Compounds and Radiopharmaceuticals, (August 2003) Vol. 46, No. Supplement 1, pp. S392. print.
Meeting Info.: 15th International Symposium on Radiopharmaceutical Chemistry. Sydney, Australia. August 10-14, 2003.
ISSN: 0362-4803 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 22 Oct 2003
Last Updated on STN: 22 Oct 2003

L4 ANSWER 112 OF 374 CABA COPYRIGHT 2004 CABI on STN DUPLICATE 38
AN 2003:116703 CABA
DN 20033091492
TI Cloning and nucleotide sequencing of ScFv gene against Cryptosporidium parvum sporozoite
AU Yin JiGang; Zhang XiChen; Zhu Ping; Zhang GuoLi; Li JianHua; He HongXuan; Tian ZongCheng; Yang Ju; Yin, J. G.; Zhang, X. C.; Zhu, P.; Zhang, G. L.; Li, J. H.; He, H. X.; Tian, Z. C.; Yang, J.
CS Faculty of Military Veterinary, Quartermaster University of PLA, Changchun 130062, China.
SO Chinese Journal of Veterinary Science, (2003) Vol. 23, No. 2, pp. 166-169. 10 ref.
Publisher: Editorial Board Chinese Journal of Veterinary Science. Changchun
ISSN: 1005-4545
CY China
DT Journal
LA Chinese
SL English
ED Entered STN: 20030707
Last Updated on STN: 20030707

L4 ANSWER 113 OF 374 CABA COPYRIGHT 2004 CABI on STN DUPLICATE 39
AN 2003:108107 CABA
DN 20033077660
TI Preparation and characterization of monoclonal ***antibodies*** against surface antigens of Cryptosporidium parvum sporozoites
AU Yin JiangAng; Zhang XiChen; Li JianHua; Wang YanZhao; He HongXuan; Yin, J. A.; Zhang, X. C.; Li, J. H.; Wang, Y. Z.; He, H. X.
CS The Quartermaster University of PLA, Changchun 130062, China.
SO Acta Parasitologica et Medica Entomologica Sinica, (2003) Vol. 10, No. 1, pp. 11-15. 10 ref.
Publisher: Editorial Board of Acta Parasitologica et Medica Entomologica Sinica. Beijing
ISSN: 1005-0507
CY China
DT Journal
LA Chinese
SL English
ED Entered STN: 20030707
Last Updated on STN: 20030707

L4 ANSWER 114 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:197007 BIOSIS
DN PREV200400197566
TI gamma - Secretase involvement in hypoxia - induced increase of K!+ channel currents in rat cerebellar granule neurones.
AU Freir, D. B. [Reprint Author]; Webster, N. J.; Plant, L. D.; Boyle, J. P.; Peers, C.; Pearson, H. A.
CS Sch. of Biomed. Sci., Univ. of Leeds, Leeds, UK
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 295.4. http://sfn.scholarone.com. e-file.
Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DT Conference; (Meeting)

LA English
ED Entered STN: 14 Apr 2004
Last Updated on STN: 14 Apr 2004

L4 ANSWER 115 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:195531 BIOSIS
DN PREV200400196090
TI Passive immunization of APPV717F transgenic mice with mid - domain - or amino - terminal - reactive anti - Abetaantibodies produce differential effects on immunoreactive Abeta burden and fibrillar (thioflavin - S positive) plaque deposits.
AU Gitter, B. D. [Reprint Author]; Hepburn, D. L. [Reprint Author]; Cummins, D. J.; Brown-Augsburger, P. L.; Bales, K. R. [Reprint Author]; Bailey, D. L.; Ballard, D. W.; Brazelton, A. D.; Czilli, D. L. [Reprint Author]; Schirtzinger, L. M.; Yue, X. M.; Farmen, M. W.; Devanarayan, V.; Paul, S. M. [Reprint Author]; Galbreath, E. J.
CS Neurosci. Res, Lilly Res. Labs, Indianapolis, IN, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 201.9. http://sfn.scholarone.com. e-file. Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Apr 2004
Last Updated on STN: 14 Apr 2004

L4 ANSWER 116 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:194330 BIOSIS
DN PREV200400194890
TI Comparative efficacy of different immunotherapeutic approaches in reducing AD - like neuropathology.
AU Seubert, P. [Reprint Author]; Games, D. [Reprint Author]; Khan, K. [Reprint Author]; Buttini, M. [Reprint Author]; Bard, F. [Reprint Author]; Guido, T. [Reprint Author]; Grajeda, H. [Reprint Author]; Barbour, R. [Reprint Author]; Nguyen, M. [Reprint Author]; Kling, K. [Reprint Author]; Vasquez, N. [Reprint Author]; Schenk, D. [Reprint Author]; Hagen, M.; Eldridge, J.
CS So. San Francisco, CA, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 133.3. http://sfn.scholarone.com. e-file. Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Apr 2004
Last Updated on STN: 14 Apr 2004

L4 ANSWER 117 OF 374 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2004-16593 DRUGU C P
TI Evaluation of monoclonal ***antibody*** ***3D6*** in Balb/c nude mice with human lung cancer.
AU Jia B; Dai Y; Du J; Wang F
CS Univ.Peking; Peking-Union-Med.Coll.
LO Beijing, China
SO J.Labelled Compd.Radiopharm. (46, Suppl. 1, S392, 2003) 1 Fig. 3 Ref.
CODEN: JLCRD4 ISSN: 0022-2135
AV Medical Isotopes Research Center, Peking University School of Basic Medical Science, 38 Xueyuan Road, Beijing 100083, P.R. China. (e-mail: Wangfan@bjrnu.edu.cn).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 118 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
DUPLICATE 40
AN 2003-09778 BIOTECHDS
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain;

expression in host cell for recombinant protein production and disease therapy
AU TSURUSHITA N; VASQUEZ M
PA LILLY and CO ELI
PI WO 2002088306 7 Nov 2002
AI WO 2002-US11853 26 Apr 2002
PRAI US 2001-287539 30 Apr 2001; US 2001-287539 30 Apr 2001
DT Patent
LA English
OS WPI: 2003-183835 [18]

L4 ANSWER 119 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN DUPLICATE 41
AN 2002-19245 BIOTECHDS
TI Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has ***3D6*** /10D5 variable region complementarity determining regions and variable framework region from human acceptor immunoglobulin;
humanized ***antibody*** production by ***antibody*** engineering for use in Alzheimer disease prevention, diagnosis, imaging, and therapy
AU BASI G; SALDANHA J; YEDNOCK T
PA NEURALAB LTD; WYETH
PI WO 2002046237 13 Jun 2002
AI WO 2000-US46587 6 Dec 2000
PRAI US 2000-251892 6 Dec 2000
DT Patent
LA English
OS WPI: 2002-519658 [55]

L4 ANSWER 120 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 42
AN 10193017 IFIPAT;IFIUDB;IFICDB
TI HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF; SPECIFICALLY BINDS TO HEPATOCYTE GROWTH FACTOR RECEPTOR; FOR TREATING CANCER
IN Schwall Ralph H; Tabor Kelly H
PA Unassigned Or Assigned To Individual (68000)
PI US 2002136721 A1 20020926
AI US 2001-995693 20011129
RLI WO 1996-US8094 19960531 Section 371 PCT Filing UNKNOWN
US 1998-952235 19980217 CONTINUATION 6207152
US 2000-669971 20000926 CONTINUATION PENDING
FI US 2002136721 20020926
US 6207152
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 40
GI 14 Figure(s).
FIGS. 1A and 1B show the amino acid sequences (and encoding nucleotides) for the light chain (FIG. 1A) and heavy chain (FIG. 1B), respectively, of monoclonal ***antibody*** 5D5 Fab.
FIG. 2 is a graph showing the inhibition of HGF binding to c-MetIgG fusion protein by monoclonal ***antibody*** 1A33.13.
FIG. 3 is a bar diagram showing the stimulatory effect of monoclonal ***antibodies*** ***3D6*** , 6G1, and 1A3.3.13 on human mammary epithelial cells in a proliferation assay.
FIG. 4 is a bar diagram showing the stimulatory effect of monoclonal ***antibodies*** ***3D6*** , 05-237 and 05-238 on mink lung cells : a proliferation assay.
FIG. 5 is a bar diagram showing the inhibitory effect of monoclonal ***antibody*** 1A3.3.13 Fab fragments on BaF3-hmet.8 cells in a proliferation assay.
FIG. 6A and 6B are FACS analysis graphs showing binding specificity of monoclonal ***antibody*** 5D5 to BaF3-hmet.8 cells expressing c-Met.
FIG. 7 is a graph showing the inhibition of HGF binding to c-MetIgG fusion protein by monoclonal ***antibody*** 5D5 and by 5D5 Fab.
FIGS. 8A and 8B are graphs showing the inhibitory effect of 5D5 Fab on BaF3-hmet.8 cells in a proliferation assay.
FIG. 9 is a graph showing the inhibitory effect of 5D5 Fab on a human breast carcinoma cell line (MDA-MB-435) which expresses cMet.
FIGS. 10A and 10B are bar diagrams showing the inhibitory effect of 5D5 Fab on c-Met tyrosine phosphorylation.
FIGS. 11A-11C are graphs comparing inhibitory effects of NK1 (FIG. 11A), 5D5 Fab (FIG. 11B). and 5D5 Fab and rhuHGF (FIG. 11C) on BaF3-hmet.8

heparin.
FIG. 12 is a restriction map of plasmid p5D5 containing the discistronic operon for expression of the chimer 5D5 Fab.
FIG. 13 is a graph showing the inhibition of HGF binding to cMet-IgG fusion protein by recombinant 5D5 Fab.
FIGS. 14A-14D graphs comparing the inhibitory effect of recombinant 5D5 Fab and recombinant anti-VEGF Fab (control Fab) on BaF3-hmet8 cells in a proliferation assay conducted in the presence or absence of heparin.

L4 ANSWER 121 OF 374 USPATFULL on STN DUPLICATE 43
AN 2002:287132 USPATFULL
TI Modulation of Abeta levels by beta-secretase BACE2
IN Cordell, Barbara, Palo Alto, CA, UNITED STATES
Schimmoller, Frauke, Menlo Park, CA, UNITED STATES
Liu, Yu-Wang, Santa Clara, CA, UNITED STATES
Quon, Diana Hom, Redwood City, CA, UNITED STATES
PI US 2002159991 A1 20021031
US 6713276 B2 20040330
AI US 2001-886143 A1 20010620 (9)
PRAI US 2000-215729P 20000628 (60)
DT Utility
FS APPLICATION
LN.CNT 1421
INCL INCLM: 424/094.630
NCL NCLM: 435/023.000
NCLS: 435/024.000; 435/069.200
IC [7]
ICM: A61K038-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 122 OF 374 USPATFULL on STN DUPLICATE 44
AN 2002:273410 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002151538 A1 20021017
US 6579867 B2 20030617
AI US 2001-915379 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26543
INCL INCLM: 514/212.040
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 123 OF 374 USPATFULL on STN DUPLICATE 45
AN 2002:251790 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release

IN Wu, Jing, San Mateo, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
PI US 2002137743 A1 20020926
US 6642261 B2 20031104
AI US 2001-984834 A1 20011031 (9)
RLI Continuation of Ser. No. US 1999-303655, filed on 3 May 1999, PATENTED
Continuation of Ser. No. US 1997-976179, filed on 21 Nov 1997, PATENTED
DT Utility
FS APPLICATION
LN.CNT 3784
INCL INCLM: 514/227.500
INCLS: 514/237.800; 514/252.120; 514/357.000; 514/534.000; 514/561.000; 544/059.000; 544/159.000; 544/400.000; 546/336.000; 560/041.000; 560/155.000
NCL NCLM: 514/357.000
NCLS: 546/336.000
IC [7]
ICM: A61K031-54
ICS: A61K031-535; A61K031-495; A61K031-44; A61K031-198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 124 OF 374 USPATFULL on STN DUPLICATE 46
AN 2002:251785 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002137738 A1 20020926
US 6559141 B2 20030506
AI US 2001-915564 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26049
INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080; 540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000; 540/527.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 125 OF 374 USPATFULL on STN DUPLICATE 47
AN 2002:228326 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical

peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002123486 A1 20020905
US 6632811 B2 20031014
AI US 2001-915342 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26177
INCL INCLM: 514/212.020
INCLS: 514/659.000
NCL NCLM: 514/220.000
NCLS: 514/221.000
IC [7]
ICM: A61K031-55
ICS: A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 126 OF 374 USPATFULL on STN DUPLICATE 48
AN 2002:214264 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002115652 A1 20020822
US 6541466 B2 20030401
AI US 2001-915362 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25618
INCL INCLM: 514/212.010
INCLS: 514/248.000; 514/258.000; 514/279.000; 514/410.000; 514/659.000

NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080; 540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000; 540/527.000
IC [7]
ICM: A61K031-55
ICS: A61K031-519; A61K031-5025; A61K031-4745; A61K031-407; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 127 OF 374 USPATFULL on STN DUPLICATE 49
AN 2002:193026 USPATFULL
TI METHOD FOR IDENTIFYING ALZHEIMER'S DISEASE THERAPEUTICS USING TRANSGENIC ANIMAL MODELS
IN GAMES, KATE DORA, BELMONT, CA, UNITED STATES
SCHENK, DALE BERNARD, BURLINGAME, CA, UNITED STATES
MCCONLOGUE, LISA CLAIRE, SAN FRANCISCO, CA, UNITED STATES
SEUBERT, PETER ANDREW, SAN FRANCISCO, CA, UNITED STATES
RYDEL, RUSSELL E., BELMONT, CA, UNITED STATES
PI US 2002104104 A1 20020801
US 6717031 B2 20040406
AI US 1998-149718 A1 19980908 (9)
RLI Continuation-in-part of Ser. No. US 1996-660487, filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-480653, filed on 7 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1996-659797, filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-486538, filed on 7 Jun 1995, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4514
INCL INCLM: 800/003.000
INCLS: 435/354.000; 435/029.000; 800/012.000; 800/018.000
NCL NCLM: 800/012.000
NCLS: 435/006.000; 435/007.100; 800/003.000; 800/018.000
IC [7]
ICM: A01K067-027
ICS: C12Q001-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 128 OF 374 USPATFULL on STN DUPLICATE 50
AN 2002:172330 USPATFULL
TI Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
IN Zhang, Yuesheng, Tucson, AZ, UNITED STATES
Ho, Tony W., Malvern, PA, UNITED STATES
Li, Yun, Tucson, AZ, UNITED STATES
PI US 2002091087 A1 20020711
US 6812248 B2 20041102
AI US 2001-897934 A1 20010705 (9)
PRAI US 2000-215812P 20000705 (60)
DT Utility
FS APPLICATION
LN.CNT 1287
INCL INCLM: 514/018.000
INCLS: 514/023.000; 514/506.000; 514/717.000; 514/733.000; 514/731.000
NCL NCLM: 514/514.000
NCLS: 514/474.000
IC [7]
ICM: A61K038-06
ICS: A61K031-7024; A61K031-26; A61K031-075; A61K031-05
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 129 OF 374 USPATFULL on STN DUPLICATE 51
AN 2002:99458 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES

Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002052359 A1 20020502
US 6544978 B2 20030408
AI US 2001-915480 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25908
INCL INCLM: 514/212.010
INCLS: 514/327.000; 514/424.000; 514/519.000; 514/529.000; 514/683.000; 514/676.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080; 540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000; 540/527.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-40; A61K031-215; A61K031-275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 130 OF 374 USPATFULL on STN
AN 2002:308378 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002173504 A1 20021121
AI US 2001-915519 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25650
INCL INCLM: 514/212.040
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/212.040
NCLS: 514/327.000; 514/424.000; 514/659.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 131 OF 374 USPATFULL on STN
AN 2002:265874 USPATFULL
TI Mucin-1 specific binding members and methods of use thereof

Henderikx, Maria P.G., Wijngaardstraat, BELGIUM
PI US 2002146750 A1 20021010
AI US 2001-822698 A1 20010330 (9)
RLI Continuation-in-part of Ser. No. US 2000-538913, filed on 30 Mar 2000, PENDING
DT Utility
FS APPLICATION
LN.CNT 4442
INCL INCLM: 435/007.230
INCLS: 424/155.100; 435/069.500; 530/351.000; 424/085.100
NCL NCLM: 435/007.230
NCLS: 424/155.100; 435/069.500; 530/351.000; 424/085.100
IC [7]
ICM: G01N033-574
ICS: C12P021-02; A61K039-395; C07K014-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 132 OF 374 USPATFULL on STN
AN 2002:206646 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-Amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Varghese, John, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002111343 A1 20020815
AI US 2001-915547 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25803
INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/212.030
NCLS: 514/327.000; 514/424.000; 514/659.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 133 OF 374 USPATFULL on STN
AN 2002:191195 USPATFULL
TI Human tumor necrosis factor receptor-like 2 (TR2) ***antibodies***
IN Harrop, Jeremy A., Malvern, PA, UNITED STATES
Holmes, Stephen D., Epsom, UNITED KINGDOM
Reddy, Manjula P., Phoenixville, PA, UNITED STATES
Truneh, Alemseged, West Chester, PA, UNITED STATES
PA SmithKline Beecham Corporation (U.S. corporation)
PI US 2002102258 A1 20020801
AI US 2001-20787 A1 20011214 (10)
RLI Continuation of Ser. No. US 1999-403815, filed on 26 Oct 1999, ABANDONED A 371 of International Ser. No. WO 1998-US9744, filed on 12 May 1998, UNKNOWN
PRAI US 1997-46249P 19970512 (60)
DT Utility
FS APPLICATION

INCL INCLM: 424/143.100
NCL NCLM: 424/143.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 134 OF 374 USPATFULL on STN
AN 2002:186091 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Wang, Tongtong, Medina, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
PI US 2002099012 A1 20020725
AI US 2001-895828 A1 20010628 (9)
PRAI US 2000-215696P 20000629 (60)
US 2000-227142P 20000822 (60)
US 2000-230481P 20000906 (60)
US 2000-257729P 20001221 (60)
DT Utility
FS APPLICATION
LN.CNT 10022
INCL INCLM: 514/012.000
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/183.000; 530/350.000; 536/023.100
NCL NCLM: 514/012.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/183.000; 530/350.000; 536/023.100
IC [7]
ICM: A61K038-17
ICS: C12Q001-68; C07H021-04; C12N009-00; C12N005-06; C12P021-02; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 135 OF 374 USPATFULL on STN
AN 2002:133883 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002068741 A1 20020606
AI US 2001-915263 A1 20010726 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25726
INCL INCLM: 514/248.000
INCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000; 514/410.000; 514/411.000
NCL NCLM: 514/248.000
NCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000; 514/410.000; 514/411.000

ICM: A61K031-517
ICS: A61K031-502; A61K031-498; A61K031-473; A61K031-403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 136 OF 374 USPATFULL on STN
AN 2002:106291 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002055500 A1 20020509
AI US 2001-916440 A1 20010730 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25439
INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/212.030
NCLS: 514/327.000; 514/424.000; 514/659.000
IC [7]
ICM: A61K031-55
ICS: A61K031-45; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 137 OF 374 USPATFULL on STN
AN 2002:99421 USPATFULL
TI Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
IN Audia, James E., Indianapolis, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Folmer, Beverly K., Newark, DE, UNITED STATES
Huffman, George W., Carmel, IN, UNITED STATES
Varghese, John, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Wu, Jing, San Mateo, CA, UNITED STATES
Eid, Clark Norman, Cheshire, CT, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
PI US 2002052322 A1 20020502
AI US 2001-789487 A1 20010220 (9)
RLI Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED, Pat. No. US 6191166
PRAI US 1996-108166P 19961122 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
US 1997-64859P 19970228 (60)
DT Utility

LN.CNT 14911
INCL INCLM: 514/018.000
INCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000
NCL NCLM: 514/018.000
NCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000
IC [7]
ICM: A61K038-06
ICS: A61K031-05; A61K031-4172; A61K031-405; A61K031-198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 138 OF 374 USPATFULL on STN
AN 2002:85701 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Indianapolis, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002045747 A1 20020418
AI US 2001-916282 A1 20010730 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26053
INCL INCLM: 540/450.000
INCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000
NCL NCLM: 540/450.000
NCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000
IC [7]
ICM: A61K031-551
ICS: C07D243-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 139 OF 374 USPATFULL on STN
AN 2002:72987 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Clapper, Jonathan D., Seattle, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PI US 2002040127 A1 20020404
AI US 2001-878722 A1 20010608 (9)
PRAI US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)
US 2001-290240P 20010510 (60)
DT Utility
FS APPLICATION
LN.CNT 8110
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/320.100; 435/325.000; 435/069.100
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/320.100; 435/325.000; 435/069.100
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06

L4 ANSWER 140 OF 374 USPATFULL on STN
AN 2002:16575 USPATFULL
TI NEW MONOCLONAL ***ANTIBODIES*** WHICH IDENTIFY THE GLYCOPROTEIN CARRYING THE CA125 EPITOPE
IN O'BRIEN, TIMOTHY J., LITTLE ROCK, AR, UNITED STATES
PI US 2002009451 A1 20020124
AI US 1998-69471 A1 19980429 (9)
RLI Continuation of Ser. No. US 1996-626675, filed on 2 Apr 1996, GRANTED, Pat. No. US 5976818 Continuation of Ser. No. US 1994-343357, filed on 22 Nov 1994, ABANDONED Continuation of Ser. No. US 1991-808219, filed on 16 Dec 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 611
INCL INCLM: 424/156.100
  INCLS: 435/007.100; 424/178.100
NCL NCLM: 424/156.100
  NCLS: 435/007.100; 424/178.100
IC [7]
  ICM: G01N033-53
  ICS: A61K039-395; G01N033-574; A61K039-40; A61K039-42; A61K039-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 141 OF 374 USPATFULL on STN
AN 2002:291111 USPATFULL
TI Compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis
IN Wu, Jing, San Mateo, CA, United States
  Tung, Jay S., Belmont, CA, United States
  Thorsett, Eugene D., Moss Beach, CA, United States
  Reel, Jon K., Carmel, IN, United States
  Porter, Warren J., Indianapolis, IN, United States
  Nissen, Jeffrey S., Indianapolis, IN, United States
  Mabry, Thomas E., Indianapolis, IN, United States
  Latimer, Lee H., Oakland, CA, United States
  John, Varghese, San Francisco, CA, United States
  Folmer, Beverly K., Newark, DE, United States
  Droste, James J., Indianapolis, IN, United States
  Britton, Thomas C., Carmel, IN, United States
  Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
  Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6476263 B1 20021105
AI US 2001-826412 20010403 (9)
RLI Continuation of Ser. No. US 1998-164448, filed on 30 Sep 1998, now patented, Pat. No. US 6211235 Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997, now patented, Pat. No. US 6191166
PRAI US 1996-108166P 19961122 (60)
  US 1997-64859P 19970228 (60)
  US 1997-108161P 19970228 (60)
  US 1997-98558P 19970228 (60)
DT Utility
FS GRANTED
LN.CNT 12409
INCL INCLM: 564/152.000
  INCLS: 564/153.000; 564/159.000; 564/160.000; 564/161.000; 564/041.000; 560/041.000; 562/450.000
NCL NCLM: 564/152.000
  NCLS: 560/041.000; 562/450.000; 564/041.000; 564/153.000; 564/159.000; 564/160.000; 564/161.000
IC [7]
  ICM: C07C233-00
EXF 564/152; 564/153; 564/159; 564/160; 564/161; 560/41; 562/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 142 OF 374 USPATFULL on STN
AN 2002:275738 USPATFULL
TI Hepatocyte growth factor receptor antagonists and uses thereof
IN Schwall, Ralph H., Pacifica, CA, United States
  Tabor, Kelly H., Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6468529 B1 20021022

RLI Continuation of Ser. No. US 952235, now patented, Pat. No. US 6207152 Continuation-in-part of Ser. No. US 1995-460368, filed on 2 Jun 1995, now patented, Pat. No. US 5686292
DT Utility
FS GRANTED
LN.CNT 2994
INCL INCLM: 424/130.100
INCLS: 424/130.100; 424/133.100; 424/134.100; 424/135.100; 424/138.100; 424/141.100
NCL NCLM: 424/130.100
NCLS: 424/133.100; 424/134.100; 424/135.100; 424/138.100; 424/141.100
IC [7]
ICM: A61K039-395
EXF 424/133.1; 424/134.1; 424/135.1; 424/138.1; 424/141.1; 536/23.53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 143 OF 374 USPATFULL on STN
AN 2002:246898 USPATFULL
TI Transgenic mice expressing human APP and TGF-.beta. demonstrate cerebrovascular amyloid deposits
IN Mucke, Lennart, Foster City, CA, United States
Wyss-Coray, Tony, Berkeley, CA, United States
Masliah, Eliezer, Chula Vista, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6455757 B1 20020924
AI US 1999-262519 19990304 (9)
RLI Continuation-in-part of Ser. No. US 1997-947295, filed on 8 Oct 1997
DT Utility
FS GRANTED
LN.CNT 1966
INCL INCLM: 800/012.000
INCLS: 800/003.000; 800/018.000
NCL NCLM: 800/012.000
NCLS: 800/003.000; 800/018.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027; A01K067-033; G01N033-00
EXF 800/3; 800/12; 800/14; 800/18; 514/44; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 144 OF 374 USPATFULL on STN
AN 2002:188237 USPATFULL
TI Method for detecting candida infection
IN Miyada, Charles Garrett, Mountain View, CA, United States
Switchenko, Arthur C., Palo Alto, CA, United States
Quong, Melanie W, La Jolla, CA, United States
Wong, Man-Ying Laurie, Fremont, CA, United States
PA Dade Behring Marburg GmbH, Marburg, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6426204 B1 20020730
AI US 1995-476394 19950607 (8)
RLI Division of Ser. No. US 1995-400417, filed on 3 Mar 1995, now patented, Pat. No. US 5451517 Continuation of Ser. No. US 1994-184764, filed on 21 Jan 1994, now abandoned Continuation of Ser. No. US 1991-731218, filed on 12 Jul 1991, now abandoned
DT Utility
FS GRANTED
LN.CNT 1052
INCL INCLM: 435/190.000
INCLS: 435/026.000; 435/034.000; 435/255.400; 435/921.000; 435/924.000
NCL NCLM: 435/190.000
NCLS: 435/026.000; 435/034.000; 435/255.400; 435/921.000; 435/924.000
IC [7]
ICM: C12N009-04
EXF 435/26; 435/34; 435/190; 435/255.4; 435/921; 435/924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 145 OF 374 USPATFULL on STN
AN 2002:129982 USPATFULL
TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting alpha- amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States

Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Whitesitt, Celia A., Greenwood, IN, United States
PA Athena Neurosciences, Inc., San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6399628 B1 20020604
AI US 1999-266908 19990312 (9)
RLI Continuation of Ser. No. US 1997-975977, filed on 21 Nov 1997, now patented, Pat. No. US 5965614
PRAI US 1996-104593P 19961122 (60)
DT Utility
FS GRANTED
LN.CNT 2944
INCL INCLM: 514/311.000
INCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000; 514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000; 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000; 548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000; 560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
NCL NCLM: 514/311.000
NCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000; 514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000; 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000; 548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000; 560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
IC [7]
ICM: C07D215-38
ICS: C07D277-82; C07D209-20; C07D319-14; C07D317-44; C07D307-02; C07C229-28
EXF 514/311; 514/367; 514/413; 514/423; 514/452; 514/465; 514/467; 514/471; 514/529; 514/533; 514/538; 514/550; 514/567; 546/171; 548/161; 548/496; 548/540; 549/366; 549/439; 549/451; 549/496; 560/43; 560/45; 560/161; 562/433; 562/457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 146 OF 374 USPATFULL on STN
AN 2002:129948 USPATFULL
TI Modified VEGF oligonucleotides
IN Robinson, Gregory S., Acton, MA, United States
PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6399586 B1 20020604
AI US 1999-320911 19990527 (9)
RLI Continuation of Ser. No. US 1998-124304, filed on 29 Jul 1998, now abandoned Continuation of Ser. No. US 1996-761708, filed on 6 Dec 1996 Continuation-in-part of Ser. No. US 1996-629730, filed on 9 Apr 1996, now abandoned Continuation-in-part of Ser. No. US 1995-569926, filed on 8 Dec 1995, now patented, Pat. No. US 5641756 Continuation-in-part of Ser. No. US 1995-398945, filed on 2 Mar 1995, now patented, Pat. No. US 5639872 Continuation-in-part of Ser. No. US 1995-378860, filed on 26 Jan 1995, now patented, Pat. No. US 5731294 Continuation-in-part of Ser. No. US 1993-98942, filed on 27 Jul 1993
DT Utility
FS GRANTED
LN.CNT 1274
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/091.100; 435/091.310; 435/375.000; 435/325.000; 536/023.100; 536/023.200; 536/024.500; 536/024.300; 536/024.310; 536/024.330
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/091.100; 435/091.310; 435/325.000; 435/375.000; 536/023.100; 536/023.200; 536/024.300; 536/024.310; 536/024.330; 536/024.500
IC [7]
ICM: A61K048-00
ICS: C07H021-04
EXF 435/6; 435/91.1; 435/91.3; 435/375; 435/325; 536/23.1; 536/23.2; 536/24.5; 536/24.3; 536/24.31; 536/24.33; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 147 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 52
AN 2002:517566 BIOSIS

TI Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.
AU Bacskai, Brian J.; Kajdasz, Stephen T.; McLellan, Megan E.; Games, Dora; Seubert, Peter; Schenk, Dale; Hyman, Bradley T. [Reprint author]
CS Alzheimer's Disease Research Unit, Massachusetts General Hospital, 114 16th Street, Charlestown Navy Yard 2450, Charlestown, MA, 02129, USA bhyman@partners.org
SO Journal of Neuroscience, (September 15, 2002) Vol. 22, No. 18, pp. 7873-7878. print.
CODEN: JNRSDS. ISSN: 0270-6474.
DT Article
LA English
ED Entered STN: 9 Oct 2002
Last Updated on STN: 9 Oct 2002

L4 ANSWER 148 OF 374 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2002-13564 DRUGU M
TI Passive intranasal monoclonal ***antibody*** prophylaxis against murine Pneumocystis carinii pneumonia.
AU Gigliotti F; Haidaris C G; Wright T W; Harmsen A G
CS Univ.Rochester; Trudeau-Inst.
LO Rochester; Saranac Lake, N.Y., USA
SO Infect.Immun. (70, No. 3, 1069-74, 2002) 4 Fig. 1 Tab. 19 Ref.
CODEN: INFIBR ISSN: 0019-9567
AV Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester NY 14642, U.S.A. (e-mail: Francis_Gigliotti@urmc.rochester.edu).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 149 OF 374 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
AN 2002:36033256 BIOTECHNO
TI Immunological approaches as therapy for Alzheimer's disease
AU Solomon B.
CS B. Solomon, Department of Molecular Microbiology, George S. Wise Fac. of Life Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel. E-mail: beka@post.tau.ac.il
SO Expert Opinion on Biological Therapy, (2002), 2/8 (907-917), 85 reference(s)
CODEN: EOBTA2 ISSN: 1471-2598
DT Journal; General Review
CY United Kingdom
LA English
SL English

L4 ANSWER 150 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 54
AN 2003:14498 BIOSIS
DN PREV200300014498
TI Antitumor effects of the conjugates of pingyangmycin linked to monoclonal ***antibody*** ***3D6*** and its Fab' fragment on hepatoma in mice
AU Liu Xiu-jun [Reprint Author]; Jiang Min [Reprint Author]; Liu Xiao-yun [Reprint Author]; Zhen Yong-Su [Reprint Author]
CS Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China
SO Zhongguo Kangshengsu Zazhi, (2002) Vol. 27, No. 8, pp. 496-501. print.
CODEN: ZKZAEY. ISSN: 1001-8689.
DT Article
LA Chinese
ED Entered STN: 25 Dec 2002
Last Updated on STN: 25 Dec 2002

L4 ANSWER 151 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 55
AN 2002:572097 BIOSIS
DN PREV200200572097
TI Antibiotics acting on matrix metalloproteinases.
AU Wang Feng-qiang [Reprint author]; Jiang Min [Reprint author]; Zhen Yong-Su [Reprint author]
CS Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China
SO Zhongguo Kangshengsu Zazhi, (2002) Vol. 27, No. 7, pp. 434-438, 448.

CODEN: ZKZAEY. ISSN: 1001-8689.
DT Article
LA Chinese
ED Entered STN: 7 Nov 2002
Last Updated on STN: 7 Nov 2002

L4 ANSWER 152 OF 374 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2002-42727 DRUGU P
TI Immunological concept in the treatment of Alzheimer's disease.
AU Solomon B
CS Univ.Tel-Aviv
LO Tel Aviv, Isr.
SO Drug Dev.Res. (56, No. 2, 163-67, 2002) 39 Ref.
CODEN: DDREDK ISSN: 0272-4391
AV Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel. (e-mail: beka@post.tau.ac.il).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 153 OF 374 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2002-42726 DRUGU T P
TI Beta-amyloid immunization approaches for Alzheimer's disease.
AU Imbimbo B P
CS Chiesi
LO Parma, It.
SO Drug Dev.Res. (56, No. 2, 150-62, 2002) 4 Fig. 75 Ref.
CODEN: DDREDK ISSN: 0272-4391
AV Research and Development Department, Chiesi Farmaceutici, Via Palermo 26/A, 43100 Parma, Italy. (e-mail: b.imbimbo@chiesigroup.com).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 154 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 56
AN 2002:372789 BIOSIS
DN PREV200200372789
TI Antitumor effects of monoclonal ***antibody*** Fab' fragment-containing immunoconjugates.
AU Liu Xiaoyun; Zhen Yongsu [Reprint author]
CS Institute of Medicinal Biotechnology, CAMS and PUMC, Beijing, 100050, China
SO Chinese Medical Sciences Journal, (March, 2002) Vol. 17, No. 1, pp. 1-6. print.
ISSN: 1001-9294.
DT Article
LA English
ED Entered STN: 3 Jul 2002
Last Updated on STN: 3 Jul 2002

L4 ANSWER 155 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 57
AN 2002:179103 CAPLUS
DN 136:198924
TI conjugate of lidamycin with active fragment of monoclonal ***antibody***
IN Zhen, Yongsu; Liu, Xiaoyun; Shao, Rongguang; Shang, Boyang
PA Inst. of Medical Bio-Technology, Chinese Academy of Medical Sciences, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 17 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1306008	A	20010801	CN 2001-101937	20010118
	CN 1128157	B	20031119		
PRAI	CN 2001-101937		20010118		

L4 ANSWER 156 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 58
AN 2002:453253 CAPLUS
DN 136:406839

cyclodextrin as coupling agent
IN Zhen, Yongsu; Liu, Xiaoyun; Liu, Xiujun; Li, Yi
PA Institute of Medical and Biological Technology, Chinese Academy of Medical Sciences, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 10 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1305847	A	20010801	CN 2001-101936	20010118
PRAI	CN 2001-101936		20010118		

L4 ANSWER 157 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 59
AN 03572420 IFIPAT;IFIUDB;IFICDB
TI METHOD FOR DETECTING CANDIDA INFECTION; ARABINITOL OXIDOREDUCTASE; FOR USE IN THE DIAGNOSIS OF MICROORGANISMAL INFECTION
IN Miyada Charles Garrett; Quong Melanie W; Switchenko Arthur C; Wong Man-Ying Laurie
PA Dade Behring Marburg GmbH DE (46971)

PI	US 6287833	B1	20010911		
AI	US 1995-472599		19950607		
RLI	US 1991-731218		19910712	CONTINUATION	ABANDONED
	US 1994-184764		19940121	CONTINUATION	ABANDONED
	US 1995-400417		19950303	DIVISION	5451517
FI	US 6287833		20010911		
	US 5451517				

DT Utility
FS CHEMICAL
GRANTED
MRN 009168 MFN: 0310
009178 0174
009472 0001
009507 0015
010121 0426
010121 0451
CLMN 7

L4 ANSWER 158 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 60
AN 03565000 IFIPAT;IFIUDB;IFICDB
TI METHOD FOR DETECTING CANDIDA INFECTION; DETERMINATION OF D-ARABINITOL USING D-ARABINITOL DEHYDROGENASE
IN Miyada Charles Garrett; Quong Melanie W; Switchenko Arthur C; Wong Man-Ying Laurie
PA Dade Behring Marburg GmbH DE (46971)

PI	US 6280988	B1	20010828		
AI	US 1995-487946		19950607		
RLI	US 1991-731218		19910712	CONTINUATION	ABANDONED
	US 1994-184764		19940121	CONTINUATION	ABANDONED
	US 1995-400417		19950303	DIVISION	5451517
FI	US 6280988		20010828		
	US 5451517				

DT Utility
FS CHEMICAL
GRANTED
MRN 009168 MFN: 0310
009178 0174
009472 0001
009507 0015
010121 0426
010121 0451
CLMN 6

L4 ANSWER 159 OF 374 USPATFULL on STN DUPLICATE 61
AN 2001:176227 USPATFULL
TI Anti-cryptosporidium parvum preparations
IN Riggs, Michael W., Tucson, AZ, United States
Perryman, Lance E., Cary, NC, United States
PA North Carolina State University, Raleigh, NC, 27695 (U.S. corporation)

PI	US 2001028882	A1	20011011
	US 6730307	B2	20040504
AI	US 2001-832888	A1	20010412 (9)

RLI Continuation of Ser. No. US 2000-557324, filed on 25 Apr 2000, PENDING
Continuation of Ser. No. US 1997-828943, filed on 27 Mar 1997, GRANTED,

PRAI US 1996-14410P 19960329 (60)
US 1996-21465P 19960710 (60)
DT Utility
FS APPLICATION
LN.CNT 1401
INCL INCLM: 424/151.100
NCL NCLM: 424/266.100
NCLS: 424/151.100; 424/184.100; 424/265.100; 424/269.100; 424/535.000; 424/807.000; 435/007.220; 435/329.000; 435/342.000; 435/947.000; 530/350.000; 530/388.600; 530/389.100; 530/395.000; 530/822.000; 530/832.000
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 160 OF 374 USPATFULL on STN DUPLICATE 62
AN 2001:150648 USPATFULL
TI N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
IN AUDIA, JAMES E., INDIANAPOLIS, IN, United States
FOLMER, BEVERLY K., NEWARK, DE, United States
JOHN, VARGHESE, SAN FRANCISCO, CA, United States
LATIMER, LEE H., OAKLAND, CA, United States
NISSEN, JEFFREY S., INDIANAPOLIS, IN, United States
PORTER, WARREN J., INDIANAPOLIS, IN, United States
THORSETT, EUGENE D., MOSS BEACH, CA, United States
WU, JING, SAN MATEO, CA, United States
PI US 2001020097 A1 20010906
US 6495693 B2 20021217
AI US 1999-280966 A1 19990330 (9)
RLI Continuation of Ser. No. US 1997-976191, filed on 21 Nov 1997, GRANTED, Pat. No. US 6096782
DT Utility
FS APPLICATION
LN.CNT 3729
INCL INCLM: 546/162.000
INCLS: 514/313.000; 514/367.000; 514/400.000; 514/419.000; 514/616.000; 514/620.000; 514/506.000; 514/399.000; 560/039.000; 560/043.000; 560/041.000; 564/156.000; 564/157.000; 564/163.000; 564/168.000; 548/161.000; 548/178.000; 548/338.100; 548/495.000; 546/163.000
NCL NCLM: 546/162.000
NCLS: 546/163.000; 548/161.000; 548/178.000; 548/338.100; 548/495.000; 560/039.000; 560/041.000; 560/043.000; 564/156.000; 564/157.000; 564/163.000; 564/168.000
IC [7]
ICM: C07D277-82
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 161 OF 374 USPATFULL on STN
AN 2001:235274 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Fang, Lawrence Y., Foster City, CA, United States
Audia, James E., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6333351 B1 20011225
AI US 1999-303655 19990503 (9)
RLI Continuation of Ser. No. US 1997-976179, filed on 21 Nov 1997, now patented, Pat. No. US 6117901
PRAI US 1996-98551P 19961122 (60)
US 1996-19790P 19960614 (60)
DT Utility
FS GRANTED
LN.CNT 3252
INCL INCLM: 514/538.000

NCL NCLM: 514/538.000
NCLS: 514/432.000; 514/452.000; 549/023.000; 549/362.000; 560/037.000
IC [7]
ICM: C07C229-06
ICS: A61K031-24; A61K031-38; A61K031-335
EXF 560/37; 514/538; 514/432; 514/452; 549/23; 549/362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 162 OF 374 USPATFULL on STN
AN 2001:226429 USPATFULL
TI Assays for detecting .beta.-secretase inhibition
IN Anderson, John P., San Francisco, CA, United States
Jacobson-Croak, Kirsten L., San Bruno, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6329163 B1 20011211
AI US 1998-54334 19980402 (9)
RLI Continuation of Ser. No. US 1995-485152, filed on 7 Jun 1995, now abandoned
DT Utility
FS GRANTED
LN.CNT 735
INCL INCLM: 435/023.000
INCLS: 435/004.000; 435/024.000; 435/007.100; 435/007.950; 436/518.000
NCL NCLM: 435/023.000
NCLS: 435/004.000; 435/007.100; 435/007.950; 435/024.000; 436/518.000
IC [7]
ICM: C12Q001-37
ICS: G01N033-53
EXF 435/7.1; 435/7.2; 435/23; 435/70.21; 435/240.27; 435/961; 435/4; 435/24; 435/7.95; 436/516; 436/518; 436/529; 436/530; 436/547; 436/548; 436/155; 436/161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 163 OF 374 USPATFULL on STN
AN 2001:202194 USPATFULL
TI Use of modified ***antibodies*** with human milk fat globule specificity
IN do Couto, Fernando J.R., Pleasanton, CA, United States
Ceriani, Roberto L., Lafayette, CA, United States
Peterson, Jerry A., Lafayette, CA, United States
Padlan, Eduardo A., Kensinton, CA, United States
PA Cancer Research Fund, San Francisco, CA, United States (U.S. corporation)
PI US 6315997 B1 20011113
AI US 1997-976288 19971121 (8)
RLI Division of Ser. No. US 1993-129930, filed on 30 Sep 1993, now patented, Pat. No. US 5804187 Continuation-in-part of Ser. No. US 1992-977696, filed on 16 Nov 1992, now patented, Pat. No. US 5792852
DT Utility
FS GRANTED
LN.CNT 4677
INCL INCLM: 424/134.100
INCLS: 424/133.100; 424/135.100; 424/138.100; 424/178.100; 424/182.100
NCL NCLM: 424/134.100
NCLS: 424/133.100; 424/135.100; 424/138.100; 424/178.100; 424/182.100
IC [7]
ICM: A61K039-395
EXF 424/133.1; 424/134.1; 424/135.1; 424/138.1; 424/178.1; 424/182.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 164 OF 374 USPATFULL on STN
AN 2001:197049 USPATFULL
TI N(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Fang, Lawrence Y., Foster City, CA, United States
Audia, James E., Indianapolis, IN, United States

corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6313152 B1 20011106
AI US 1999-390692 19990907 (9)
RLI Division of Ser. No. US 1997-976179, filed on 21 Nov 1997, now patented, Pat. No. US 6117901
PRAI US 1996-98551P 19961122 (60)
US 1996-19790P 19960614 (60)
DT Utility
FS GRANTED
LN.CNT 3130
INCL INCLM: 514/357.000
INCLS: 514/375.000; 514/379.000; 514/438.000; 514/439.000; 514/461.000; 514/469.000
NCL NCLM: 514/357.000
NCLS: 514/375.000; 514/379.000; 514/438.000; 514/439.000; 514/461.000; 514/469.000
IC [7]
ICM: A61K031-44
ICS: A61K031-425
EXF 514/357; 514/375; 514/379; 514/438; 514/439; 514/461; 514/469
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 165 OF 374 USPATFULL on STN
AN 2001:185264 USPATFULL
TI Modified VEGF oligonucleotides for treatment of skin disorders
IN Smyth, Adrienne P., Charlton, MA, United States
Robinson, Gregory S., Acton, MA, United States
PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6306829 B1 20011023
AI US 1996-761708 19961206 (8)
RLI Continuation-in-part of Ser. No. US 1996-629730, filed on 9 Apr 1996, now abandoned Continuation-in-part of Ser. No. US 1995-569926, filed on 8 Dec 1995, now patented, Pat. No. US 5641756
DT Utility
FS GRANTED
LN.CNT 1365
INCL INCLM: 514/044.000
INCLS: 536/024.500; 536/023.100; 536/023.500; 435/375.000; 435/455.000; 435/006.000
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/375.000; 435/455.000; 536/023.100; 536/023.500; 536/024.500
IC [7]
ICM: A61K031-70
ICS: C07H021-04; C12N005-00
EXF 514/44; 435/375; 435/61; 435/377; 435/455; 536/24.5; 536/23.1; 536/23.5; 536/24.31; 536/24.3; 536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 166 OF 374 USPATFULL on STN
AN 2001:173325 USPATFULL
TI Protein/(poly)peptide libraries
IN Knappik, Achim, Grafelfing, Germany, Federal Republic of
Pack, Peter, Munchen, Germany, Federal Republic of
Ge, Liming, Munchen, Germany, Federal Republic of
Moroney, Simon, Munchen, Germany, Federal Republic of
Pluckthun, Andreas, Zurich, Switzerland
PA Morphosys AG, Munich, Germany, Federal Republic of (non-U.S. corporation)
PI US 6300064 B1 20011009
AI US 1998-25769 19980218 (9)
RLI Continuation of Ser. No. WO 1996-EP3647, filed on 19 Aug 1996
PRAI EP 1995-113021 19950818
DT Utility
FS GRANTED
LN.CNT 7901
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/320.100; 435/440.000; 435/455.000; 435/471.000; 435/328.000; 435/069.100; 435/069.300; 435/DIG.002; 435/DIG.003; 435/DIG.015; 435/DIG.017; 435/DIG.051; 536/023.100; 536/024.100; 514/044.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/069.300; 435/320.100; 435/328.000;

435/DIG.015; 435/DIG.017; 435/DIG.051; 514/044.000; 536/023.100;
536/024.100
IC [7]
ICM: G01N033-53
ICS: A61K039-29
EXF 435/6; 435/71.1; 435/69.7; 435/69.1; 435/7.1; 435/320.1; 435/440;
435/455; 435/471; 435/328; 435/69.3; 435/DIG.2; 435/DIG.3; 435/DIG.15;
435/DIG.17; 435/DIG.51; 536/23.1; 536/24.1; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 167 OF 374 USPATFULL on STN
AN 2001:142468 USPATFULL
TI Hybridoma and anti-KC-4 humanized monoclonal ***antibody***
IN do Couto, F. J. R., Pleasanton, CA, United States
Ceriani, R. L., Lafayette, CA, United States
Peterson, J. A., Lafayette, CA, United States
PA Coulter Corporation, Miami, FL, United States (U.S. corporation)
PI US 6281335 B1 20010828
AI US 1993-134346 19931008 (8)
DT Utility
FS GRANTED
LN.CNT 2039
INCL INCLM: 530/388.850
INCLS: 530/388.800; 424/009.100; 424/133.100; 436/518.000; 435/007.950;
435/328.000
NCL NCLM: 530/388.850
NCLS: 424/009.100; 424/133.100; 435/007.950; 435/328.000; 436/518.000;
530/388.800
IC [7]
ICM: C07K016-30
ICS: A61K049-00; C12N005-16; G01N033-53
EXF 530/388.8; 530/388.85; 424/9.1; 424/133.1; 436/518; 435/7.95; 435/328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 168 OF 374 USPATFULL on STN
AN 2001:121591 USPATFULL
TI HIV-vaccines
IN Katinger, Hermann, Vienna, Austria
Buchacher, Andrea, Vienna, Austria
Ernst, Wolfgang, Vienna, Austria
Ballaun, Claudia, Vienna, Austria
Purtscher, Martin, Vienna, Austria
Trkola, Alexandra, Vienna, Austria
Predl, Renate, Deutsch-Wagram, Austria
Schmatz, Christine, Vienna, Austria
Klima, Annelies, Vienna, Austria
Steindl, Franz, Vienna, Austria
Muster, Thomas, Vienna, Austria
PA Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria
(non-U.S. corporation)
PI US 6268484 B1 20010731
AI US 1998-124900 19980730 (9)
RLI Division of Ser. No. US 1995-478536, filed on 7 Jun 1995, now patented,
Pat. No. US 5911989 Continuation-in-part of Ser. No. WO 1995-EP1481,
filed on 19 Apr 1995
DT Utility
FS GRANTED
LN.CNT 804
INCL INCLM: 530/388.350
INCLS: 424/192.100; 424/208.100; 435/005.000; 435/007.100; 435/339.100
NCL NCLM: 530/388.350
NCLS: 424/192.100; 424/208.100; 435/005.000; 435/007.100; 435/339.100
IC [7]
ICM: C07K016-00
ICS: A61K039-00; A61K039-21; C12Q001-70; G01N033-53
EXF 424/192.1; 424/208.1; 530/388.35; 435/5; 435/7.1; 435/339.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 169 OF 374 USPATFULL on STN
AN 2001:116835 USPATFULL
TI Method and device for detection of specific target cells in specialized
or mixed cell populations and solutions containing mixed cell
populations
IN Fodstad, .O slashed.ystein, Oslo, Norway
H.o slashed.if.o slashed.dt, Hanne Kleppe, Hvalstad, Norway

PA Oystein Fodstad, Oslo, Norway (non-U.S. corporation)
PI US 6265229 B1 20010724
WO 9524648 19950914
AI US 1996-704619 19961104 (8)
WO 1995-NO52 19950310
19961104 PCT 371 date
19961104 PCT 102(e) date
PRAI NO 1994-866 19940310
DT Utility
FS GRANTED
LN.CNT 1694
INCL INCLM: 436/526.000
INCLS: 422/101.000; 435/007.200; 435/007.210; 435/007.230; 435/007.240; 435/033.000; 435/395.000; 436/518.000; 436/525.000; 436/526.000; 436/809.000
NCL NCLM: 436/526.000
NCLS: 422/101.000; 435/007.200; 435/007.210; 435/007.230; 435/007.240; 435/033.000; 435/395.000; 436/518.000; 436/525.000; 436/809.000
IC [7]
ICM: G01N033-553
ICS: B01L011-00
EXF 422/101; 435/7.1; 435/7.2-7.32; 435/29; 435/30; 435/33; 435/383; 435/395; 435/401; 435/975; 436/518; 436/525; 436/526; 436/808; 436/809
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 170 OF 374 USPATFULL on STN
AN 2001:116789 USPATFULL
TI Direct molecular cloning of foreign genes into poxviruses and methods for the preparation of recombinant proteins
IN Dorner, Friedrich, Vienna, Austria
Scheiflinger, Friedrich, Orth/Donau, Austria
Falkner, Falko Gunter, Mannsdorf, Austria
Pfleiderer, Michael, Breitstetten, Austria
PA Baxter Aktiengesellschaft, Vienna, Australia (non-U.S. corporation)
PI US 6265183 B1 20010724
AI US 1994-358928 19941219 (8)
RLI Continuation-in-part of Ser. No. US 1992-914738, filed on 20 Jul 1992, now abandoned Continuation-in-part of Ser. No. US 1991-750080, filed on 26 Aug 1991, now patented, Pat. No. US 5445953
DT Utility
FS GRANTED
LN.CNT 5471
INCL INCLM: 435/069.100
INCLS: 435/320.100; 424/232.100; 424/199.100; 424/208.100
NCL NCLM: 435/069.100
NCLS: 424/199.100; 424/208.100; 424/232.100; 435/320.100
IC [7]
ICM: C12P021-06
ICS: C12N015-00; A61K039-275
EXF 435/67.1; 435/70.1; 435/71.1; 435/172.3; 424/188.1; 424/208.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 171 OF 374 USPATFULL on STN
AN 2001:112566 USPATFULL
TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
Eid, Clark N., Cheshire, CT, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., S. San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6262302 B1 20010717
AI US 1999-398211 19990917 (9)
RLI Continuation of Ser. No. US 1997-976295, filed on 21 Nov 1997, now patented, Pat. No. US 6153652
PRAI US 1996-98551P 19961122 (60)
US 1997-113671P 19970228 (60)
DT Utility
FS GRANTED

INCL INCLM: 564/152.000
INCLS: 564/155.000; 564/158.000; 564/168.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 549/303.000; 549/304.000; 548/471.000; 548/475.000; 546/309.000; 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000; 514/535.000; 514/539.000; 514/619.000
NCL NCLM: 564/152.000
NCLS: 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/155.000; 564/158.000; 564/168.000
IC [7]
ICM: C07C229-38
ICS: C07C233-64; C07D307-00; C07D211-00; C07D213-00
EXF 560/43; 560/45; 560/47; 560/39; 560/41; 560/42; 514/349; 514/352; 514/357; 514/417; 514/470; 514/535; 514/539; 514/619; 564/152; 564/168; 564/155; 564/158; 549/303; 549/304; 548/471; 548/475; 546/309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 172 OF 374 USPATFULL on STN
AN 2001:59667 USPATFULL
TI .beta.-secretase ***antibody***
IN Chrysler, Susanna M. S., San Bruno, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
Keim, Pamela S., San Mateo, CA, United States
Anderson, John P., San Francisco, CA, United States
Tan, Hua, Daly City, CA, United States
McConlogue, Lisa Clair, San Francisco, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6221645 B1 20010424
AI US 1996-660531 19960607 (8)
RLI Continuation-in-part of Ser. No. US 1995-480498, filed on 7 Jun 1995, now patented, Pat. No. US 5744346
DT Utility
FS Granted
LN.CNT 1908
INCL INCLM: 435/226.000
INCLS: 435/212.000; 435/219.000; 530/387.100; 530/388.100; 530/388.150; 530/388.260
NCL NCLM: 435/226.000
NCLS: 435/212.000; 435/219.000; 530/387.100; 530/388.100; 530/388.150; 530/388.260
IC [7]
ICM: C07K016-00
EXF 435/226; 435/219; 435/212; 530/387.1; 530/388.26; 530/388.1; 530/388.15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 173 OF 374 USPATFULL on STN
AN 2001:51568 USPATFULL
TI Hepatocyte growth factor receptor antagonists and uses thereof
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly Helen, Hillsborough, CA, United States
PA Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6214344 B1 20010410
AI US 1998-6776 19980114 (9)
RLI Continuation of Ser. No. US 1995-459849, filed on 2 Jun 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1428
INCL INCLM: 424/174.100
INCLS: 424/130.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100; 424/155.100; 424/172.100; 530/387.700; 530/388.220; 530/388.800; 530/388.850; 530/389.700
NCL NCLM: 424/174.100
NCLS: 424/130.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100; 424/155.100; 424/172.100; 530/387.700; 530/388.220; 530/388.800; 530/388.850; 530/389.700
IC [7]
ICM: C07K016-28
ICS: C07K016-30; A61K039-395
EXF 424/138.1; 424/143.1; 424/152.1; 424/130.1; 424/141.1; 424/155.1; 424/172.1; 424/174.1; 530/388.8; 530/388.88; 530/389.7; 530/387.7; 530/388.22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 174 OF 374 USPATFULL on STN
AN 2001:48108 USPATFULL
TI Compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Reel, Jon K., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Folmer, Beverly K., Newark, DE, United States
Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IL, United States (U.S. corporation)
PI US 6211235 B1 20010403
AI US 1998-164448 19980930 (9)
RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-98558P 19970228 (60)
DT Utility
FS Granted
LN.CNT 14056
INCL INCLM: 514/534.000
INCLS: 574/619.000; 560/041.000; 560/040.000; 564/163.000
NCL NCLM: 514/534.000
NCLS: 514/019.000; 514/619.000; 544/162.000; 546/233.000; 546/336.000; 548/479.000; 548/496.000; 560/040.000; 560/041.000; 564/163.000
IC [7]
ICM: A01N037-12
ICS: C07C229-00; C07C233-00
EXF 514/534; 514/619; 564/163; 560/40; 560/41
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 175 OF 374 USPATFULL on STN
AN 2001:44268 USPATFULL
TI Compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis
IN Audia, James E., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Droste, James J., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
Huffman, George W., Carmel, IN, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Tung, Jay S., Belmont, CA, United States
Wu, Jing, San Mateo, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6207710 B1 20010327
AI US 1998-164385 19980930 (9)
RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
DT Utility
FS Granted
LN.CNT 12026
INCL INCLM: 514/551.000
INCLS: 514/534.000; 514/563.000; 560/037.000; 560/038.000; 560/040.000; 560/041.000; 654/123.000; 654/155.000
NCL NCLM: 514/551.000

560/040.000; 560/041.000; 564/123.000; 564/155.000
IC [7]
ICM: A01N037-12
ICS: C07C229-00; C07C233-00
EXF 514/551; 514/534; 514/563; 560/37; 560/38; 560/40; 560/41; 564/123; 564/155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 176 OF 374 USPATFULL on STN
AN 2001:43710 USPATFULL
TI Hepatocyte growth factor receptor antagonists and uses thereof
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly H., Hillsborough, CA, United States
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)
PI US 6207152 B1 20010327
WO 9638557 19961205
AI US 1998-952235 19980217 (8)
WO 1996-US8094 19960531
19980217 PCT 371 date
19980217 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-460368, filed on 2 Jun 1995, now patented, Pat. No. US 5686292
DT Utility
FS Granted
LN.CNT 2855
INCL INCLM: 424/130.100
INCLS: 424/133.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100; 424/155.100; 424/156.100; 424/174.100; 530/387.100; 530/387.300; 530/388.220; 530/388.880; 530/388.850; 530/389.100; 530/389.700; 435/007.100; 435/007.200; 435/007.210; 435/007.230
NCL NCLM: 424/130.100
NCLS: 424/133.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100; 424/155.100; 424/156.100; 424/174.100; 435/007.100; 435/007.200; 435/007.210; 435/007.230; 530/387.100; 530/387.300; 530/388.220; 530/388.800; 530/388.850; 530/389.100; 530/389.700
IC [7]
ICM: C07K016-18
ICS: C07K016-28; A61K039-395
EXF 530/388.22; 530/387.1; 530/387.3; 530/388.88; 530/388.85; 530/389.1; 530/389.7; 424/130.1; 424/133.1; 424/138.1; 424/141.1; 424/143.1; 424/152.1; 424/155.1; 424/156.1; 424/174.1; 435/7.1; 435/7.2; 435/7.21; 435/7.23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 177 OF 374 USPATFULL on STN
AN 2001:25931 USPATFULL
TI Methods and compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis
IN Audia, James E., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Droste, James J., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
Huffman, George W., Carmel, IN, United States
Varghese, John, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Tung, Jay S., Belmont, CA, United States
Wu, Jing, San Mateo, CA, United States
Eid, Clark Norman, Cheshire, CT, United States
Scott, William Leonard, Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6191166 B1 20010220
AI US 1997-976289 19971121 (8)
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-698556P 19970228 (60)
DT Utility
FS Granted

INCL INCLM: 514/534.000
INCLS: 514/535.000; 514/616.000; 514/619.000
NCL NCLM: 514/534.000
NCLS: 514/535.000; 514/616.000; 514/619.000
IC [7]
ICM: A01N037-12
EXF 574/534; 574/535; 574/616; 574/619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 178 OF 374 USPATFULL on STN
AN 2001:18290 USPATFULL
TI Method for detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
IN Fodstad, .O slashed.ystein, Frits Kiers v. 28, N-0383 Oslo, Norway
Kvalheim, Gunnar, .ang.sstubben 13, N-0381 Oslo, Norway
PI US 6184043 B1 20010206
AI US 1997-881393 19970624 (8)
RLI Division of Ser. No. US 403844
PRAI WO 1992-NO151 19920914
DT Utility
FS Granted
LN.CNT 1107
INCL INCLM: 436/526.000
INCLS: 435/002.000; 435/007.100; 435/007.200; 435/007.230; 435/007.240; 435/007.250; 435/007.500; 435/007.800; 435/007.940; 435/040.000; 435/052.000; 435/174.000; 435/181.000; 435/961.000; 436/513.000; 436/518.000; 436/523.000; 436/532.000; 436/534.000; 436/538.000; 436/540.000; 436/824.000; 436/828.000
NCL NCLM: 436/526.000
NCLS: 435/002.000; 435/007.100; 435/007.200; 435/007.230; 435/007.240; 435/007.250; 435/007.500; 435/007.800; 435/007.940; 435/040.000; 435/052.000; 435/174.000; 435/181.000; 435/961.000; 436/513.000; 436/518.000; 436/523.000; 436/532.000; 436/534.000; 436/538.000; 436/540.000; 436/824.000; 436/828.000
IC [7]
ICM: G01N033-553
EXF 435/2; 435/7.1; 435/7.2; 435/7.23; 435/7.24; 435/7.25; 435/7.5; 435/7.8; 435/7.94; 435/40.52; 435/174; 435/181; 435/961; 436/513; 436/518; 436/523; 436/526; 436/532; 436/534; 436/538; 436/540; 436/824; 436/828
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 179 OF 374 USPATFULL on STN
AN 2001:8223 USPATFULL
TI Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
IN Mucke, Lennart, Foster City, CA, United States
Wyss-Coray, Tony, Berkeley, CA, United States
Masliah, Eliezer, Chula Vista, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6175057 B1 20010116
AI US 1997-947295 19971008 (8)
DT Utility
FS Granted
LN.CNT 1697
INCL INCLM: 800/012.000
INCLS: 800/003.000; 800/018.000; 424/009.200
NCL NCLM: 800/012.000
NCLS: 424/009.200; 800/003.000; 800/018.000
IC [7]
ICM: A01K067-00
ICS: A01K067-033; G01N033-00
EXF 800/3; 800/8; 800/9; 800/12; 800/13; 800/18; 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 180 OF 374 USPATFULL on STN
AN 2001:4473 USPATFULL
TI Monoclonal ***antibodies*** reactive with defined regions of the T cell antigen receptor
IN Skibbens, Robert V., Brookline, MA, United States
Henry, Larry D., Brookline, MA, United States
Rittershaus, Charles W., Malden, MA, United States
Tian, Wei-Tao, Allston, MA, United States
Ip, Stephen H., Sudbury, MA, United States
Kung, Patrick C., Lexington, MA, United States

Ko, Jone-Long, Cambridge, MA, United States
Wood, Nancy L., Cambridge, MA, United States
PA Astra AB, Sodertalje, Sweden (non-U.S. corporation)
PI US 6171799 B1 20010109
AI US 1995-450275 19950525 (8)
RLI Division of Ser. No. US 1993-83408, filed on 25 Jun 1993, now patented, Pat. No. US 6048526 Division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented, Pat. No. US 5223426 Continuation-in-part of Ser. No. US 1989-343189, filed on 25 Apr 1989, now abandoned Continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988, now abandoned
DT Patent
FS Granted
LN.CNT 3046
INCL INCLM: 435/007.100
INCLS: 436/503.000; 436/548.000; 436/063.000; 436/804.000; 436/811.000
NCL NCLM: 435/007.100
NCLS: 436/063.000; 436/503.000; 436/548.000; 436/804.000; 436/811.000
IC [7]
ICM: G01N033-53
EXF 424/144.1; 530/388.22; 530/388.75; 435/240.27; 435/172.3; 435/70.21; 435/7.1; 436/503; 436/548; 436/63; 436/804; 436/811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 181 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:562501 BIOSIS
DN PREV200100562501
TI Multiple mechanisms are involved in clearance of amyloid-beta by immunotherapy.
AU Bacskai, B. J. [Reprint author]; Kajdasz, S. T. [Reprint author]; McLellan, M. E. [Reprint author]; Games, D.; Seubert, P.; Schenk, D.; Hyman, B. T. [Reprint author]
CS Dept Neurology, Mass General Hospital, Charlestown, MA, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 1807. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 5 Dec 2001
Last Updated on STN: 25 Feb 2002

L4 ANSWER 182 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 63
AN 2001:468726 BIOSIS
DN PREV200100468726
TI An immunoconjugate targeting matrix metalloproteinase shows highly potent cytotoxicity and anti-angiogenic activity.
AU Zhen, Yong-Su [Reprint author]; Liu, Xiao-Yun [Reprint author]; Wang, Xin-Hua [Reprint author]; Liu, Xiu-jun [Reprint author]
CS Chinese Acad. Med. Sci., Beijing, China
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2001) Vol. 42, pp. 290. print.
Meeting Info.: 92nd Annual Meeting of the American Association for Cancer Research. New Orleans, LA, USA. March 24-28, 2001.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 3 Oct 2001
Last Updated on STN: 23 Feb 2002

L4 ANSWER 183 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 64
AN 2001:223921 BIOSIS
DN PREV200100223921
TI Expression of c-Kit (CD117) in benign and malignant human endometrial epithelium.
AU Elmore, Lynne W. [Reprint author]; Domson, Kelly; Moore, Jonathan R.; Kornstein, Michael; Burks, R. Tucker
CS Department of Pathology, Medical College of Virginia at Virginia Commonwealth University, Richmond, VA, 23298, USA
SO Archives of Pathology and Laboratory Medicine, (January, 2001) Vol. 125,

CODEN: ĀRPAAQ. ISSN: 0363-0153.
DT Article
LA English
ED Entered STN: 9 May 2001
Last Updated on STN: 18 Feb 2002

L4 ANSWER 184 OF 374 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2001:32679499 BIOTECHNO
TI Characterization of a monoclonal ***antibody*** against neopterin using an enzyme-linked immunosorbent assay with penicillinase as label
AU Malakaneh M.; Rasaee M.J.; Rahbarizadeh F.; Madani R.; Forozandeh M.M.; Khabiri K.; Alimohammadian M.H.
CS Dr. M.J. Rasaee, Department of Biochemistry, School of Medical Sciences, Tarbiat Modarres University, P.O. Box 14155-4838, Tehran, Iran. E-mail: rasaee_mj@yahoo.com
SO Hybridoma, (2001), 20/2 (117-121), 32 reference(s)
CODEN: HYBRDY ISSN: 0272-457X
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 185 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 66
AN 2001:231762 CAPLUS
DN 134:227345
TI Anti-matrix metalloprotease monoclonal ***antibody*** Fab'-medicine conjugate and its antitumor action
IN Zhen, Yongsu; Liu, Xiaoyun; Xu, Linna; Shang, Boyang
PA Inst. of Medicinal Biological Technology, Chinese Academy of Medical Sciences, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 14 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1268377	A	20001004	CN 2000-103497	20000315
PRAI CN 2000-103497		20000315		

L4 ANSWER 186 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 67
AN 2001:65029 CAPLUS
DN 134:91120
TI Monoclonal ***antibody*** Fab'-pingyangmycin conjugate and its anticancer action
IN Zhen, Yongsu; Liu, Xiaoyun; Wang, Weigang; Liu, Xiujun
PA Chinese Academy of Medical Sciences, Institute of Biomedical Technology, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 9 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1255378	A	20000607	CN 1999-110806	19990721
CN 1110322	B	20030604		
PRAI CN 1999-110806		19990721		

L4 ANSWER 187 OF 374 USPATFULL on STN
AN 2000:161048 USPATFULL
TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
Eid, Clark N., Cheshire, CT, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

AI US 1997-976295 19971121 (8)
PRAI US 1996-1551P 19961122 (60)
US 1997-113671P 19970228 (60)
DT Utility
FS Granted
LN.CNT 3652
INCL INCLM: 514/619.000
INCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000; 514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000
NCL NCLM: 514/619.000
NCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000; 514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000
IC [7]
ICM: A01N037-18
ICS: A01N037-12; A01N037-44; A61K031-165
EXF 564/155; 564/158; 564/152; 564/168; 546/309; 548/471; 548/475; 549/303; 549/304; 560/39; 560/41; 560/42; 560/43; 514/349; 514/352; 514/357; 514/417; 514/470; 514/535; 514/539; 514/619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 188 OF 374 USPATFULL on STN
AN 2000:121544 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
IN Wu, Jing, San Mateo, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Fang, Lawrence Y., Foster City, CA, United States
Audia, James E., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6117901 20000912
AI US 1997-976179 19971121 (8)
PRAI US 1996-98551P 19961122 (60)
US 1996-19790P 19960614 (60)
DT Utility
FS Granted
LN.CNT 3321
INCL INCLM: 514/513.000
NCL NCLM: 514/513.000
IC [7]
ICM: A61K031-16
EXF 514/513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 189 OF 374 USPATFULL on STN
AN 2000:113492 USPATFULL
TI Anti-Cryptosporidium parvum preparations
IN Riggs, Michael W., Tucson, AZ, United States
Perryman, Lance E., Cary, NC, United States
PA North Carolina State University, Raleigh, NC, United States (U.S. corporation)
The Arizona Board of Regents, Tucson, AZ, United States (U.S. corporation)
PI US 6110463 20000829
AI US 1997-828943 19970327 (8)
PRAI US 1996-14410P 19960329 (60)
US 1996-21465P 19960710 (60)
DT Utility
FS Granted
LN.CNT 1611
INCL INCLM: 424/151.100
INCLS: 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/172.200; 435/342.000; 530/388.600; 530/822.000; 530/832.000
NCL NCLM: 424/151.100
NCLS: 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/342.000; 530/388.600; 530/822.000; 530/832.000

ICM: A61K039-395
ICS: A61K035-20; C07K016-20; C12N005-20
EXF 424/130.1; 424/151.1; 424/265.1; 424/266.1; 424/269.1; 424/535; 424/807; 435/7.22; 435/70.21; 435/172.2; 435/947; 435/342; 530/388.6; 530/389.1; 530/822; 530/832; 935/104; 935/107; 935/108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 190 OF 374 USPATFULL on STN
AN 2000:105429 USPATFULL
TI Methods for generating immune responses employing modified vaccinia of fowlpox viruses
IN Dorner, Friedrich, Vienna, Austria
Scheiflinger, Friedrich, Orth/Donau, Austria
Falkner, Falko Gunter, Mannsdorf, Austria
Pfleiderer, Michael, Breitstetten, Austria
PA Immuno AG., Vienna, Austria (non-U.S. corporation)
PI US 6103244 20000815
AI US 1996-651472 19960522 (8)
RLI Division of Ser. No. US 1994-358928, filed on 19 Dec 1994 which is a continuation-in-part of Ser. No. US 1992-914738, filed on 20 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-750080, filed on 26 Aug 1991, now patented, Pat. No. US 5445953
DT Utility
FS Granted
LN.CNT 7208
INCL INCLM: 424/199.100
INCLS: 424/188.100; 424/232.100
NCL NCLM: 424/199.100
NCLS: 424/188.100; 424/232.100
IC [7]
ICM: A61K039-12
ICS: A61K039-21; A61K039-275
EXF 435/320.1; 424/184.1; 424/199.1; 424/204.1; 424/207.1; 424/208.1; 424/232.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 191 OF 374 USPATFULL on STN
AN 2000:101874 USPATFULL
TI Hepatocyte growth factor receptor agonists and uses thereof
IN Hillan, Kenneth J., San Francisco, CA, United States
Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly H., Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6099841 20000808
AI US 1997-884669 19970627 (8)
PRAI US 1996-21215P 19960703 (60)
DT Utility
FS Granted
LN.CNT 1908
INCL INCLM: 424/143.100
INCLS: 424/134.100; 424/135.100; 424/136.100; 424/138.100; 435/334.000; 530/387.700; 530/387.300; 530/388.220; 530/389.100; 530/389.200; 530/389.700; 530/350.000
NCL NCLM: 424/143.100
NCLS: 424/134.100; 424/135.100; 424/136.100; 424/138.100; 435/334.000; 530/350.000; 530/387.300; 530/387.700; 530/388.220; 530/389.100; 530/389.200; 530/389.700
IC [7]
ICM: C07K016-28
ICS: C12N015-06; A61K039-395
EXF 530/388.22; 530/389.1; 530/387.3; 530/350; 530/387.7; 530/389.7; 530/389.2; 435/334; 435/7.1; 514/2; 424/143.1; 424/134.1; 424/135.1; 424/136.1; 424/138.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 192 OF 374 USPATFULL on STN
AN 2000:98466 USPATFULL
TI N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States

Porter, Warren J., Indianapolis, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Wu, Jing, San Mateo, CA, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6096782 20000801
AI US 1997-976191 19971121 (8)
PRAI US 1996-77175P 19961122 (60)
DT Utility
FS Granted
LN.CNT 3343
INCL INCLM: 514/506.000
INCLS: 514/399.000; 548/335.500; 560/041.000
NCL NCLM: 514/506.000
NCLS: 514/399.000; 548/335.500; 560/041.000
IC [7]
ICM: A01N037-20
ICS: A01N043-50; C07C229-24; C07D233-61
EXF 560/41; 514/506; 514/399; 548/335.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 193 OF 374 USPATFULL on STN
AN 2000:43767 USPATFULL
TI Monoclonal ***antibodies*** reactive with defined regions of the T cell antigen receptor
IN Skibbens, Robert V., Chapel Hill, NC, United States
Henry, Larry D., Brookline, MA, United States
Rittershaus, Charles W., Malden, MA, United States
Tian, Wei-Tao, Allston, MA, United States
Ip, Stephen H., Sudbury, MA, United States
Kung, Patrick C., Lexington, MA, United States
Snider, Mary Ellen, Ledyard, CT, United States
Ko, Jone-Long, Cambridge, MA, United States
Wood, Nancy L., Cambridge, MA, United States
PA Astra AB, United States (non-U.S. corporation)
PI US 6048526 20000411
AI US 1993-83408 19930625 (8)
RLI Division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented, Pat. No. US 5223426 which is a continuation-in-part of Ser. No. US 1989-343189, filed on 25 Apr 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 3237
INCL INCLM: 424/144.100
INCLS: 530/388.750
NCL NCLM: 424/144.100
NCLS: 530/388.750
IC [7]
ICM: A61K039-395
ICS: C12P021-08
EXF 424/144.1; 424/144.4; 530/388.22; 530/388.75; 435/240.27; 435/172.3; 435/70.21; 435/7.1; 435/7.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 194 OF 374 USPATFULL on STN
AN 2000:34194 USPATFULL
TI Peptides derived from immunodominant epitopes of myelin basic protein
IN Weiner, Howard L., Brookline, MA, United States
Hafler, David A., West Newton, MA, United States
PA Autoimmune, Inc., Lexington, MA, United States (U.S. corporation)
PI US 6039947 20000321
AI US 1994-297395 19940811 (8)
RLI Continuation of Ser. No. US 1993-59189, filed on 6 May 1993, now abandoned which is a continuation of Ser. No. US 1990-502559, filed on 30 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. WO 1988-US2139, filed on 24 Jun 1988, now abandoned And a continuation-in-part of Ser. No. US 1987-65734, filed on 24 Jun 1987, now abandoned
DT Utility
FS Granted
LN.CNT 1507
INCL INCLM: 424/184.100

530/326.000
NCL NCLM: 424/184.100
NCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000
IC [7]
ICM: A61K039-00
ICS: A61K038-17; C07K007-08; C07K014-47
EXF 424/184.1; 530/300; 530/350; 530/324; 530/325; 530/326; 514/12; 514/13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 195 OF 374 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2000-36596 DRUGU P
TI Peripherally administered ***antibodies*** against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.
AU Bard F; Cannon C; Barbour R; Burke R L; Games D; Grajeda H; Guido T; Hu K; Huang J; Johnson Wood K
LO San Francisco, Cal., USA
SO Nat.Med. (6, No. 8, 916-19, 2000) 3 Fig. 1 Tab. 10 Ref.
CODEN: MAMEF ISSN: 1078-8956
AV Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080, U.S.A. (23 authors). (e-mail: fbard@elanpharma.com).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 196 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:245001 BIOSIS
DN PREV200000245001
TI Antitumor effects of novel immunoconjugates with downsized-molecule prepared by linking lidamycin to Fab' and scFv ***antibody*** .
AU Liu, Xiao Yun [Reprint author]; Li, S. Q.; Jiang, M.; Zhen, Y. S.
CS Inst for Med Bio, Chinese Acad of Med Sci, Beijing, China
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2000) No. 41, pp. 290-291. print.
Meeting Info.: 91st Annual Meeting of the American Association for Cancer Research. San Francisco, California, USA. April 01-05, 2000.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Jun 2000
Last Updated on STN: 5 Jan 2002

L4 ANSWER 197 OF 374 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2000-31155 DRUGU P
TI Antitumor effects of novel immunoconjugates with downsized-molecule prepared by linking lidamycin to Fab' and scFv ***antibody*** .
AU Liu X Y; Li S Q; Jiang M; Zhen Y S
CS Chinese-Acad.Med.Sci.
LO Beijing, China
SO Proc.Am.Assoc.Cancer Res. (41, 91 Meet., 290-91, 2000) ISSN: 0197-016X
AV Inst. for Med Bio, Chinese Acad of Med Sci, China.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 198 OF 374 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2000:31001699 BIOTECHNO
TI Standardization of measurement of .beta.-amyloid((1-42)) in cerebrospinal fluid and plasma
AU Vanderstichele H.; Van Kerschaver E.; Hesse C.; Davidsson P.; Buyse M.-A.; Andreasen N.; Minthon L.; Wallin A.; Blennow K.; Vanmechelen E.
CS Dr. H. Vanderstichele, Innogenetics NV, Box 4, Industriepark Zwijnaarde 7, B-9052 Ghent, Belgium.
E-mail: hugovdr@innogenetics.be
SO Amyloid, (2000), 7/4 (245-258), 51 reference(s)
CODEN: AIJIET ISSN: 1350-6129
DT Journal; Article
CY United Kingdom

SL English

L4 ANSWER 199 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 69
AN 2000:368395 BIOSIS
DN PREV200000368395
TI Antineoplastic effect of intracellular expression of a single-chain ***antibody*** directed against type IV collagenase.
AU Wang, Weigang; Zhou, Jinghua; Xu, Linna; Zhen, Yongsu [Reprint author]
CS Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China
SO Journal of Environmental Pathology Toxicology and Oncology, (2000) Vol. 19, No. 1-2, pp. 61-68. print.
CODEN: JEPOEC. ISSN: 0731-8898.
DT Article
LA English
ED Entered STN: 23 Aug 2000
Last Updated on STN: 8 Jan 2002

L4 ANSWER 200 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:80301 BIOSIS
DN PREV200100080301
TI Dissociation between age-related and age-independent memory deficits in the PDAPP mouse.
AU Morris, R. G.; Chen, G.; Chen, K. S.; Knox, J.; Inglis, J.; Martin, S. J.; Justice, A.; Games, D.; Freedman, S. B.
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-275.4. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L4 ANSWER 201 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:121222 BIOSIS
DN PREV200100121222
TI Intraneuronal Abeta42 immunoreactivity in Down syndrome brain.
AU Mori, C. [Reprint author]; Spooner, E. T.; Lu, M.; Wisniewski, K.; Wisniewski, T.; Yamaguchi, H.; Saido, T. C.; Selkoe, D. J.; Lemere, C. A.
CS Brigham " Women's Hospital, Harvard Medical School, Boston, MA, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-764.7. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 7 Mar 2001
Last Updated on STN: 15 Feb 2002

L4 ANSWER 202 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 70
AN 1999:249109 CAPLUS
DN 130:293622
TI Process for detecting, extracting or removing human or mammalian cells with a disturbed cellular cycle regulation or unlimited proliferation or tumor-forming ability
IN Abken, Hinrich
PA Germany
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9918235	A1	19990415	WO 1998-EP6384	19981007
	W: JP, US				

PT, SE

	DE 19821506	A1	19990415	DE 1998-19821506	19980513
	EP 1021564	A1	20000726	EP 1998-954373	19981007
	R: AT, CH, DE, DK, ES, FR, GB, IT, LI				
	JP 2001519169	T2	20011023	JP 2000-515027	19981007
PRAI	DE 1997-19744335	A	19971007		
	DE 1997-19749118	A	19971106		
	DE 1998-19821506	A	19980513		
	WO 1998-EP6384	W	19981007		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 203 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:184272 CAPLUS
DN 130:223588
TI Preparation and properties of biomolecules containing an elastomeric peptide
IN Reiersen, Herald; Rees, Anthony; Korsnes, Lars
PA Dynal As, Norway
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911661	A1	19990311	WO 1998-GB2602	19980828
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2301981	AA	19990311	CA 1998-2301981	19980828
	AU 9888755	A1	19990322	AU 1998-88755	19980828
	AU 759080	B2	20030403		
	EP 1009761	A1	20000621	EP 1998-940427	19980828
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, PT, IE, FI				
	BR 9811421	A	20000822	BR 1998-11421	19980828
	JP 2001514263	T2	20010911	JP 2000-508699	19980828
	NZ 503097	A	20020328	NZ 1998-503097	19980828
PRAI	GB 1997-18463	A	19970829		
	WO 1998-GB2602	W	19980828		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 204 OF 374 USPATFULL on STN
AN 1999:166965 USPATFULL
TI Protein sequences of serrate gene products
IN Ish-Horowicz, David, Oxford, United Kingdom
Henrique, Domingos Manuel Pinto, Oxford, United Kingdom
Lewis, Julian Hart, Oxford, United Kingdom
Myat, Anna Mary, Oxford, United Kingdom
Fleming, Robert J., Rochester, NY, United States
Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
Mann, Robert S., Hamden, CT, United States
Gray, Grace E., New Haven, CT, United States
PA Imperial Cancer Research Technology, Ltd., London, United Kingdom (non-U.S. corporation)
Yale University, New Haven, CT, United States (U.S. corporation)
PI US 6004924 19991221
AI US 1996-611729 19960306 (8)
RLI Continuation-in-part of Ser. No. US 1995-400159, filed on 7 Mar 1995 which is a continuation-in-part of Ser. No. US 1994-255102, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 1993-121979, filed on 14 Sep 1993, now abandoned which is a continuation of Ser. No. US 1991-808458, filed on 11 Dec 1991, now abandoned
DT Utility
FS Granted
LN.CNT 6539
INCL INCLM: 514/002.000
INCLS: 514/013.000; 514/015.000; 530/300.000; 530/326.000; 530/328.000; 530/350.000

NCLS: 514/013.000; 514/015.000; 530/300.000; 530/326.000; 530/328.000; 530/350.000
IC [6]
ICM: A01N037-18
ICS: A61K037-00; C07K014-00
EXF 530/300; 530/326; 530/328; 530/350; 514/15; 514/13; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 205 OF 374 USPATFULL on STN
AN 1999:141299 USPATFULL
TI Monoclonal ***antibodies*** reactive with defined regions of the T cell antigen receptor
IN Skibbens, Robert V., Chapel Hill, NC, United States
Henry, Larry D., Brookline, MA, United States
Rittershaus, Charles W., Malden, MA, United States
Tian, Wei-Tao, Allston, MA, United States
Ip, Stephen H., Sudbury, MA, United States
Kung, Patrick C., Lexington, MA, United States
Snider, Mary Ellen, Ledyard, CT, United States
Ko, Jone-Long, Cambridge, MA, United States
Wood, Nancy L., Cambridge, MA, United States
PA Astra AB, Sodertalje, Sweden (non-U.S. corporation)
PI US 5980892 19991109
AI US 1995-450425 19950525 (8)
RLI Division of Ser. No. US 1993-83408, filed on 25 Jun 1993 which is a division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented, Pat. No. US 5223426 which is a continuation-in-part of Ser. No. US 1989-343189, filed on 25 Apr 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 3139
INCL INCLM: 424/144.100
INCLS: 424/154.100; 435/007.100; 435/007.240
NCL NCLM: 424/144.100
NCLS: 424/154.100; 435/007.100; 435/007.240
IC [6]
ICM: A61K039-395
EXF 435/7.1; 435/7.24; 424/144.1; 424/154.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 206 OF 374 USPATFULL on STN
AN 1999:136967 USPATFULL
TI Monoclonal ***antibodies*** which identify the glycoprotein carrying the CA 125 epitope
IN O'Brien, Timothy J., Little Rock, AR, United States
PA The Board of Trustees of The University of Arkansas, Little Rock, AR, United States (U.S. corporation)
PI US 5976818 19991102
AI US 1996-626675 19960402 (8)
RLI Continuation of Ser. No. US 1994-343357, filed on 22 Nov 1994, now abandoned which is a continuation of Ser. No. US 1991-808219, filed on 16 Dec 1991
DT Utility
FS Granted
LN.CNT 595
INCL INCLM: 435/007.230
INCLS: 435/007.900; 435/007.920; 436/063.000; 436/064.000; 530/388.800
NCL NCLM: 435/007.230
NCLS: 435/007.900; 435/007.920; 436/063.000; 436/064.000; 530/388.800
IC [6]
ICM: G01N033-574
ICS: G01N033-53; G01N033-542; G01N033-48
EXF 530/387.7; 530/388.8; 436/63; 436/64; 435/7.23; 435/7.9; 435/7.92; 435/7.94
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 207 OF 374 USPATFULL on STN
AN 1999:136683 USPATFULL
TI Monoclonal ***antibodies*** reactive with defined regions of the T cell antigen receptor
IN Skibbens, Robert V., Chapel Hill, NC, United States
Henry, Larry D., Brookline, MA, United States
Rittershaus, Charles W., Malden, MA, United States

Ip, Stephen H., Sudbury, MA, United States
Kung, Patrick C., Lexington, MA, United States
Snider, Mary Ellen, Ledyard, CT, United States
Ko, Jone-Long, Cambridge, MA, United States
Wood, Nancy L., Cambridge, MA, United States
PA Astra AB, Sodertalje, Sweden (non-U.S. corporation)
PI US 5976533 19991102
AI US 1995-449890 19950525 (8)
RLI Division of Ser. No. US 1993-83408, filed on 25 Jun 1993 which is a division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented, Pat. No. US 5223426 which is a continuation-in-part of Ser. No. US 1989-343189, filed on 25 Apr 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 3019
INCL INCLM: 424/144.100
INCLS: 435/070.210; 530/388.220; 530/388.750
NCL NCLM: 424/144.100
NCLS: 435/070.210; 530/388.220; 530/388.750
IC [6]
ICM: A61K039-395
ICS: C12N005-16
EXF 424/144.1; 530/388.22; 530/388.75; 435/240.27; 435/172.3; 435/70.21; 435/325; 435/372.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 208 OF 374 USPATFULL on STN
AN 1999:124950 USPATFULL
TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Whitesitt, Celia A., Greenwood, IN, United States
PA Athena Neurosciences, Inc., United States (U.S. corporation)
PI US 5965614 19991012
AI US 1997-975977 19971121 (8)
PRAI US 1996-104593P 19961122 (60)
DT Utility
FS Granted
LN.CNT 2939
INCL INCLM: 514/538.000
INCLS: 514/508.000; 560/043.000; 560/035.000
NCL NCLM: 514/538.000
NCLS: 514/508.000; 560/035.000; 560/043.000
IC [6]
ICM: A01N037-12
ICS: A01N037-52; C07C229-28
EXF 514/538; 514/508; 560/43; 560/35
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 209 OF 374 USPATFULL on STN
AN 1999:99548 USPATFULL
TI Assays for detecting .beta.-secretase
IN Anderson, John P., San Francisco, CA, United States
Jacobson-Croak, Kirsten L., San Bruno, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5942400 19990824
AI US 1996-659984 19960607 (8)
RLI Continuation-in-part of Ser. No. US 1995-485152, filed on 7 Jun 1995 And a continuation-in-part of Ser. No. US 1995-480498, filed on 7 Jun 1995, now patented, Pat. No. US 5744346
DT Utility
FS Granted
LN.CNT 2312
INCL INCLM: 435/007.100

NCL NCLM: 435/007.100
NCLS: 435/023.000; 435/961.000; 436/063.000; 436/161.000
IC [6]
ICM: G01N033-53
EXF 435/7.1; 435/7.2; 435/23; 435/325; 435/961; 436/515; 436/516; 436/161; 436/63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 210 OF 374 USPATFULL on STN
AN 1999:67010 USPATFULL
TI HIV-vaccines
IN Katinger, Hermann, Vienna, Austria
Buchacher, Andrea, Vienna, Austria
Ernst, Wolfgang, Vienna, Austria
Ballaun, Claudia, Vienna, Austria
Purtscher, Martin, Vienna, Austria
Trkola, Alexandra, Vienna, Austria
Predl, Renate, Deutsch-Wagram, Austria
Schmatz, Christine, Vienna, Austria
Klima, Annelies, Vienna, Austria
Steindl, Franz, Vienna, Austria
Muster, Thomas, Vienna, Austria
PA Polynum Scientific Immunbiologische Forschung GmbH, Vienna, Austria (non-U.S. corporation)
PI US 5911989 19990615
AI US 1995-478536 19950607 (8)
RLI Continuation-in-part of Ser. No. WO 1995-EP1481, filed on 19 Apr 1995
DT Utility
FS Granted
LN.CNT 857
INCL INCLM: 424/160.100
INCLS: 530/388.350; 424/208.100; 435/005.000
NCL NCLM: 424/160.100
NCLS: 424/208.100; 435/005.000; 530/388.350
IC [6]
ICM: A61K039-42
ICS: A61K039-21; C12Q001-70; C07K016-00
EXF 424/160.1; 424/208.1; 530/388.35; 435/5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 211 OF 374 USPATFULL on STN
AN 1999:18950 USPATFULL
TI Nucleotide and protein sequences of the serrate gene and methods based thereon
IN Ish-Horowicz, David, Oxford, England
Henrique, Domingos Manuel Pinto, Oxford, England
Lewis, Julian Hart, Oxford, England
Myat, Anna Mary, Oxford, England
Fleming, Robert J., Rochester, NY, United States
Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
Mann, Robert S., Hamden, CT, United States
Gray, Grace E., New Haven, CT, United States
PA Imperial Cancer Research Technology, Ltd., London, England (non-U.S. corporation)
Yale University, Haven, CT, United States (U.S. corporation)
PI US 5869282 19990209
AI US 1995-400159 19950307 (8)
RLI Continuation-in-part of Ser. No. US 1994-255102, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 1993-121979, filed on 14 Sep 1993, now abandoned which is a continuation of Ser. No. US 1991-808458, filed on 11 Dec 1991, now abandoned
DT Utility
FS Granted
LN.CNT 5411
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/252.300; 435/320.100; 536/023.100; 536/024.300; 530/300.000; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 435/325.000; 530/300.000; 530/350.000; 536/023.100; 536/024.300
IC [6]
ICM: C12P021-00
ICS: C12N015-00; C07H017-00; C07K014-00
EXF 536/23.1; 536/24.3; 435/69.1; 435/320.1; 435/240.1; 435/252.3; 435/325; 530/300; 530/350

L4 ANSWER 212 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 71
AN 2000:76243 BIOSIS
DN PREV200000076243
TI A human anti-HIV autoantibody enhances EBV transformation and HIV infection.
AU Cavacini, Lisa A. [Reprint author]; Wisnewski, Adam [Reprint author]; Peterson, Jennifer E. [Reprint author]; Montefiori, David; Emes, Charlotte [Reprint author]; Duval, Mark [Reprint author]; Kingsbury, Gillian [Reprint author]; Wang, Anlai [Reprint author]; Scadden, David [Reprint author]; Posner, Marshall R. [Reprint author]
CS Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, USA
SO Clinical Immunology (Orlando), (Dec., 1999) Vol. 93, No. 3, pp. 263-273. print.
ISSN: 1521-6616.
DT Article
LA English
ED Entered STN: 23 Feb 2000
Last Updated on STN: 3 Jan 2002

L4 ANSWER 213 OF 374 AGRICOLA Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted materials. All rights reserved. (2004) on STN DUPLICATE 72
AN 2000:4580 AGRICOLA
DN IND22009396
TI Monoclonal ***antibody*** production in murine ascites. II. Production characteristics.
AU Jackson, L.R.; Trudel, L.J.; Fox, J.G.; Lipman, N.S.
CS Biogen, Inc., Cambridge, MA.
SO Laboratory animal science, Feb 1999. Vol. 49, No. 1. p. 81-86
Publisher: Cordova, Tenn. : American Association for Laboratory Animal Science.
CODEN: LBASAE; ISSN: 0023-6764
NTE Includes references
CY Tennessee; United States
DT Article
FS U.S. Imprints not USDA, Experiment or Extension
LA English

L4 ANSWER 214 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:209028 BIOSIS
DN PREV199900209028
TI Monoclonal ***antibody*** production in murine ascites: I. Clinical and pathologic features.
AU Jackson, Lynn R. [Reprint author]; Trudel, Laura J.; Fox, James G.; Lipman, Neil S.
CS Biogen, Inc., 14 Cambridge Center, Cambridge, MA, 02142, USA
SO Laboratory Animal Science, (Feb., 1999) Vol. 49, No. 1. print.
CODEN: LBASAE. ISSN: 0023-6764.
DT Article
LA English
ED Entered STN: 26 May 1999
Last Updated on STN: 26 May 1999

L4 ANSWER 215 OF 374 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 73
AN 02981273 IFIPAT;IFIUDB;IFICDB
TI HUMAN MONOCLONAL ANTI-HIV-I- ***ANTIBODIES*** ; CAPABLE OF SELECTIVELY BINDING TO GP41 OF ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
IN von Baehr Ruediger (DE); Grunow Roland (DE); Jungbauer Alois A (AT); Katinger Hermann W D (AT); Porstmann Tomas (DE); Steindl Franz J (AT)
PA Unassigned Or Assigned To Individual (68000)
PI US 5753503 A 19980519
AI US 1994-347966 19941201
RLI US 1990-583505 19900917 CONTINUATION ABANDONED
US 1993-97170 19930723 CONTINUATION ABANDONED
US 1993-105360 19930810 CONTINUATION ABANDONED
US 1987-120489 19871113 DIVISION ABANDONED
FI US 5753503 19980519
DT Utility
FS CHEMICAL

CLMN 7
GI 5 Drawing Sheet(s), 8 Figure(s).

L4 ANSWER 216 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:59054 CAPLUS
DN 128:124544
TI Hepatocyte growth factor receptor agonists and uses thereof
IN Hillan, Kenneth J.; Schwall, Ralph H.; Tabor, Kelly H.
PA Genentech, Inc., USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9800543	A1	19980108	WO 1997-US10688	19970620
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2258153	AA	19980108	CA 1997-2258153	19970620
	AU 9734949	A1	19980121	AU 1997-34949	19970620
	AU 729029	B2	20010125		
	EP 922102	A1	19990616	EP 1997-931275	19970620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000515735	T2	20001128	JP 1998-504193	19970620
	US 6099841	A	20000808	US 1997-884669	19970627
	ZA 9705851	A	19990104	ZA 1997-5851	19970701
PRAI	US 1996-21215P	P	19960703		
	WO 1997-US10688	W	19970620		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 217 OF 374 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 1998:106834 TOXCENTER
CP Copyright 2004 ACS
DN CA12811124544M
TI Hepatocyte growth factor receptor agonists and uses thereof
AU Hillan, Kenneth J.; Schwall, Ralph H.; Tabor, Kelly H.
CS ASSIGNEE: Genentech, Inc.
PI WO 98543 A1 8 Jan 1998
SO (1998) PCT Int. Appl., 48 pp.
CODEN: PIXXD2.
CY UNITED STATES
DT Patent
FS CAPLUS
OS CAPLUS 1998:59054
LA English
ED Entered STN: 20011116
Last Updated on STN: 20020605

L4 ANSWER 218 OF 374 USPATFULL on STN
AN 1998:135175 USPATFULL
TI Human monoclonal anti-HIV-I- ***antibodies***
IN Katinger, Hermann, Heiligenstadterstrasse 131-139, A-1190 Vienna, Austria
Jungbauer, Alois, Vienna, Austria
Steindl, Franz, Vienna, Austria
Buchacher, Andrea, Vienna, Austria
PA Katinger, Hermann, Austria (non-U.S. individual)
PI US 5831034 19981103
AI US 1994-293842 19940822 (8)
RLI Continuation of Ser. No. US 1991-693730, filed on 30 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1987-120489, filed on 13 Nov 1987, now abandoned
DT Utility
FS Granted
LN.CNT 506
INCL INCLM: 530/388.350

NCL NCLM: 530/388.350
NCLS: 435/005.000; 435/069.100; 530/413.000; 536/023.530; 536/024.200
IC [6]
ICM: C07K016-00
ICS: C12Q001-70; C12P021-06; A23J001-00
EXF 435/5; 435/69.1; 536/23.53; 536/24.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 219 OF 374 USPATFULL on STN
AN 1998:108026 USPATFULL
TI Modified ***antibodies*** with human milk fat globule specificity
IN do Couto, Fernando J. R., Pleasanton, CA, United States
Ceriani, Roberto L., Lafayette, CA, United States
Peterson, Jerry A., Lafayette, CA, United States
PA Cancer Research Fund of Contra Costa, Walnut Creek, CA, United States (U.S. corporation)
PI US 5804187 19980908
AI US 1993-129930 19930930 (8)
RLI Continuation-in-part of Ser. No. US 1992-977696, filed on 16 Nov 1992
DT Utility
FS Granted
LN.CNT 5440
INCL INCLM: 424/134.100
INCLS: 424/133.100; 424/138.100; 435/007.230; 435/328.000; 435/330.000; 530/387.300; 530/387.700
NCL NCLM: 424/134.100
NCLS: 424/133.100; 424/138.100; 435/007.230; 435/328.000; 435/330.000; 530/387.300; 530/387.700
IC [6]
ICM: A61K039-395
ICS: A61K039-40; A61K039-42; G01N033-574
EXF 530/387.3; 530/388.85; 424/133.1; 424/134.1; 424/156.1; 424/1.11; 435/240.27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 220 OF 374 USPATFULL on STN
AN 1998:95622 USPATFULL
TI Polynucleotides encoding modified ***antibodies*** with human milk fat globule specificity
IN do Couto, Fernando J. R., Pleasanton, CA, United States
Ceriani, Roberto L., Lafayette, CA, United States
Peterson, Jerry A., Lafayette, CA, United States
Padlan, Eduardo A., Kensington, MD, United States
PA Cancer Research Fund of Contra Costa, Walnut Creek, CA, United States (U.S. corporation)
PI US 5792852 19980811
AI US 1992-977696 19921116 (7)
DT Utility
FS Granted
LN.CNT 5011
INCL INCLM: 536/023.530
INCLS: 536/023.500; 530/387.300; 424/133.100; 424/134.100; 424/135.100
NCL NCLM: 536/023.530
NCLS: 424/133.100; 424/134.100; 424/135.100; 530/387.300; 536/023.500
IC [6]
ICM: C07H021-04
ICS: C12P021-08; A61K039-695; A61K039-40
EXF 530/387.3; 530/387.7; 530/388.15; 530/388.8; 424/133.1; 424/134.1; 424/135.1; 424/136.1; 424/138.1; 424/155.1; 536/23.5; 536/23.53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 221 OF 374 USPATFULL on STN
AN 1998:68799 USPATFULL
TI Kit containing d-arabinitol dehydrogenase and NAD+ for determining d-arabinitol
IN Miyada, Charles Garrett, Mountainview, CA, United States
Switchenko, Arthur C., Palo Alto, CA, United States
Quong, Melanie W., La Jolla, CA, United States
Wong, Man-Ying Laurie, Fremont, CA, United States
PA Syntex (USA) Inc., San Jose, CA, United States (U.S. corporation)
PI US 5766874 19980616
AI US 1995-479069 19950607 (8)
RLI Division of Ser. No. US 1995-400417, filed on 3 Mar 1995, now patented, Pat. No. US 5451517 which is a continuation of Ser. No. US 1994-184764, filed on 21 Jan 1994, now abandoned which is a continuation of Ser. No.

DT Utility
FS Granted
LN.CNT 1094
INCL INCLM: 435/026.000
INCLS: 435/190.000; 435/255.400; 435/810.000; 435/921.000; 435/924.000
NCL NCLM: 435/026.000
NCLS: 435/190.000; 435/255.400; 435/810.000; 435/921.000; 435/924.000
IC [6]
ICM: C12Q001-32
ICS: C12N009-04; C12N001-16
EXF 435/190; 435/255.4; 435/921; 435/924; 435/810; 435/26
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 222 OF 374 USPATFULL on STN
AN 1998:45086 USPATFULL
TI .beta.-secretase
IN Chrysler, Susanna M. S., San Bruno, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
Keim, Pamela S., San Mateo, CA, United States
Anderson, John P., San Francisco, CA, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5744346 19980428
AI US 1995-480498 19950607 (8)
DT Utility
FS Granted
LN.CNT 689
INCL INCLM: 435/226.000
INCLS: 435/219.000; 435/212.000
NCL NCLM: 435/226.000
NCLS: 435/212.000; 435/219.000
IC [6]
ICM: C12N009-64
ICS: C12N009-50; C12N006-48
EXF 435/226; 435/219; 435/212
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 223 OF 374 USPATFULL on STN
AN 1998:33788 USPATFULL
TI Complexes of nucleic acid and polymer, their process of preparation and their use for the transfection of cells
IN Midoux, Patrick, Orleans, France
Erbacher, Patrick, Orleans, France
Roche-Degremont, Annie-Claude, Sandillon, France
Monsigny, Michel, Saint-Cyr-En-Val, France
PA I.D.M. Immuno-Designed Molecules, France (non-U.S. corporation)
PI US 5733762 19980331
AI US 1996-741678 19961031 (8)
RLI Continuation-in-part of Ser. No. US 1995-505068, filed on 21 Jul 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-288681, filed on 10 Aug 1994, now patented, Pat. No. US 5595897, issued on 21 Jan 1997
PRAI FR 1994-5174 19940428
DT Utility
FS Granted
LN.CNT 2545
INCL INCLM: 435/172.300
INCLS: 435/325.000; 514/044.000; 530/300.000; 530/345.000; 530/350.000; 530/395.000; 530/402.000; 536/023.200; 536/023.500; 536/024.500; 536/023.700
NCL NCLM: 435/458.000
NCLS: 435/325.000; 514/044.000; 530/300.000; 530/345.000; 530/350.000; 530/395.000; 530/402.000; 536/023.200; 536/023.500; 536/023.700; 536/024.500
IC [6]
ICM: C07K001-00
ICS: C07K001-107; C12N015-00; C12N015-88
EXF 435/6; 435/69.1; 435/91.1; 435/172.3; 435/172.1; 435/240.2; 435/183; 435/189; 435/193; 435/194; 435/207; 435/325; 435/375; 435/91.3; 435/91.31; 435/320.1; 530/345; 530/395; 530/402; 530/300; 530/350; 536/23.1; 536/23.2; 536/23.5; 536/23.7; 536/23.72; 536/23.74; 536/24.5; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 224 OF 374 BIOENG COPYRIGHT 2004 CSA on STN DUPLICATE

DN 4537352
TI Functional and molecular characterization of human monoclonal ***antibody*** reactive with the immunodominant region of HIV type 1 glycoprotein 41
AU Cavacini, LA; Emes, CL; Wisnewski, AV; Power, J; Lewis, G; Montefiori, D; Posner, MR
CS Beth Israel Deaconess Medical Center, 21-27 Burlington Avenue, P.O. Box 15709, Boston, Massachusetts 02215, USA, [mailto:lcavacin@bidmc.harvard.edu]
SO AIDS Research and Human Retroviruses [AIDS Res. Hum. Retroviruses]. Vol. 14, no. 14, pp. 1271-1280. 20 Sep 1998.
ISSN: 0889-2229
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts; Virology & AIDS Abstracts

L4 ANSWER 225 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 75
AN 1998:443408 BIOSIS
DN PREV199800443408
TI Molecular characterization of five neutralizing anti-HIV type 1 ***antibodies*** : Identification of nonconventional D segments in the human monoclonal ***antibodies*** 2G12 and 2F5.
AU Kunert, Renate [Reprint author]; Ruker, Florian; Katinger, Hermann
CS Inst. Applied Microbiol., Univ. Agricultural Sciences, Muthgasse 18, Haus B, A-1190 Vienna, Austria
SO AIDS Research and Human Retroviruses, (Sept. 1, 1998) Vol. 14, No. 13, pp. 1115-1128. print.
CODEN: ARHRE7. ISSN: 0889-2229.
DT Article
LA English
ED Entered STN: 21 Oct 1998
Last Updated on STN: 21 Oct 1998

L4 ANSWER 226 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:13917 BIOSIS
DN PREV199900013917
TI Capture of human monoclonal ***antibodies*** from cell culture supernatant by ion exchange media exhibiting high charge density.
AU Necina, Roman; Amatschek, Karin; Jungbauer, A. [Reprint author]
CS Inst. Appl. Microbiol., Univ. Agric. For. Biotechnol., Nussdorferlaende 11, A-1190 Vienna, Austria
SO Biotechnology and Bioengineering, (Dec. 20, 1998) Vol. 60, No. 6, pp. 689-698. print.
CODEN: BIBIAU. ISSN: 0006-3592.
DT Article
LA English
ED Entered STN: 11 Jan 1999
Last Updated on STN: 11 Jan 1999

L4 ANSWER 227 OF 374 USPATFULL on STN
AN 97:120717 USPATFULL
TI Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
IN Arnot, David E., New York, NY, United States
Enea, Vincenzo, New York, NY, United States
Nussenzweig, Ruth S., New York, NY, United States
Nussenzweig, Victor, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 5700906 19971223
WO 8700533 19870129
AI US 1987-43550 19870409 (7)
WO 1986-US1373 19860624
19870409 PCT 371 date
19870409 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1985-754645, filed on 12 Jul 1985, now abandoned
DT Utility
FS Granted
LN.CNT 1827
INCL INCLM: 530/324.000
INCLS: 530/326.000; 530/300.000; 530/350.000

NCLS: 530/300.000; 530/326.000; 530/350.000
IC [6]
ICM: C07K007-08
ICS: C07K014-445
EXF 530/328; 530/403; 530/324; 530/326; 530/300; 530/350; 435/172.3; 435/69.1; 435/71.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 228 OF 374 USPATFULL on STN
AN 97:104323 USPATFULL
TI Hepatocyte growth factor receptor antagonist ***antibodies*** and uses thereof
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly Helen, Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5686292 19971111
AI US 1995-460368 19950602 (8)
DT Utility
FS Granted
LN.CNT 1406
INCL INCLM: 435/240.270
INCLS: 424/133.100; 424/143.100; 530/387.300; 530/387.700; 530/388.100; 530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100; 530/389.700
NCL NCLM: 424/143.100
NCLS: 424/133.100; 435/334.000; 530/387.300; 530/387.700; 530/388.100; 530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100; 530/389.700
IC [6]
ICM: C12N005-12
ICS: A61K039-395; C07K016-28
EXF 530/387.7; 530/388.1; 530/388.2; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 530/387.3; 424/133.1; 424/143.1; 435/240.27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 229 OF 374 USPATFULL on STN
AN 97:75973 USPATFULL
TI Immortalized human cell lines containing exogenous cytochrome P450 genes
IN Harris, Curtis C., 8402 Thornden Terr., Bethesda, MD, United States 20817
Gelboin, Harry V., 2806 Abilene Dr., Chevy Chase, MD, United States 20815
Gonzalez, Frank J., 5000 Battery La., Apt. #101, Bethesda, MD, United States 20814
Mace, Katharine C., Rue Haldimand 10, 1003 Lausanne, Switzerland
Pfeifer, Andrea M. A., Chemin de Chaponeyres 6, 1800 Vevey, Switzerland
PI US 5660986 19970826
AI US 1995-462998 19950605 (8)
RLI Division of Ser. No. US 1993-65201, filed on 19 May 1993, now patented, Pat. No. US 5506131 which is a continuation-in-part of Ser. No. US 1992-869818, filed on 13 Apr 1992, now patented, Pat. No. US 5356806 which is a continuation-in-part of Ser. No. US 1991-787777, filed on 6 Nov 1991, now patented, Pat. No. US 5164313 which is a continuation-in-part of Ser. No. US 1987-58387, filed on 5 Jun 1987, now abandoned , said Ser. No. US -869818 which is a continuation-in-part of Ser. No. US 1991-636712, filed on 2 Jan 1991, now patented, Pat. No. US 5443954 which is a continuation-in-part of Ser. No. US 1988-265883, filed on 1 Nov 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-114508, filed on 30 Oct 1987, now patented, Pat. No. US 4885238
DT Utility
FS Granted
LN.CNT 1057
INCL INCLM: 435/006.000
INCLS: 435/172.100; 435/029.000; 435/032.000
NCL NCLM: 435/006.000
NCLS: 435/029.000; 435/032.000; 435/441.000
IC [6]
ICM: C12Q001-68
EXF 435/6; 435/172.1; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 230 OF 374 USPATFULL on STN
AN 97:59098 USPATFULL

antibodies
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly Helen, Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5646036 19970708
AI US 1995-459388 19950602 (8)
DT Utility
FS Granted
LN.CNT 1402
INCL INCLM: 435/252.300
INCLS: 435/240.200; 435/320.100; 536/023.530; 530/387.700; 530/388.220; 530/388.800; 530/388.850; 530/389.100; 530/389.700
NCL NCLM: 435/252.300
NCLS: 435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800; 530/388.850; 530/389.100; 530/389.700; 536/023.530
IC [6]
ICM: C12N015-13
ICS: C12N015-85; C12N001-21; C07K016-28
EXF 536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 231 OF 374 USPATFULL on STN
AN 97:54206 USPATFULL
TI Modified VEGF oligonucleotides
IN Robinson, Gregory S., Acton, MA, United States
PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5641756 19970624
AI US 1995-569926 19951208 (8)
RLI Continuation-in-part of Ser. No. US 1995-398945, filed on 2 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-378860, filed on 26 Jan 1995 which is a continuation-in-part of Ser. No. US 1993-98942, filed on 27 Jul 1993
DT Utility
FS Granted
LN.CNT 1264
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/375.000; 536/024.500; 536/023.500; 536/024.300; 536/024.310; 536/024.330
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/375.000; 536/023.500; 536/024.300; 536/024.310; 536/024.330; 536/024.500
IC [6]
ICM: A61K031-70
ICS: C07H021-00; C12N005-10; C12Q001-68
EXF 536/24.5; 536/23.5; 536/24.3; 536/24.31; 536/24.33; 514/44; 435/6; 435/240.2; 435/172.3; 935/33; 935/34; 935/36; 935/8; 935/9; 935/11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 232 OF 374 USPATFULL on STN
AN 97:51892 USPATFULL
TI Resurfacing of rodent ***antibodies***
IN Pedersen, Jan T., Bath, United Kingdom
Searle, Stephen M. J., Bath, United Kingdom
Rees, Anthony R., Bath, United Kingdom
Roguska, Michael A., Ashland, MA, United States
Guild, Braydon C., Concord, MA, United States
PA Immunogen Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5639641 19970617
AI US 1992-942245 19920909 (7)
DT Utility
FS Granted
LN.CNT 2777
INCL INCLM: 435/069.600
INCLS: 435/172.100; 530/387.300; 530/387.700; 530/388.300
NCL NCLM: 435/069.600
NCLS: 530/387.300; 530/387.700; 530/388.300
IC [6]
ICM: C12N015-00
ICS: C07K016-00; A61K039-395
EXF 530/387.3; 530/387.7; 530/388.8; 435/69.6; 435/172.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 233 OF 374 USPATFULL on STN

TI Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
IN Van Aken, Morgan, Bainbridge Island, WA, United States
Paskell, Stefan L., Bainbridge Island, WA, United States
PA Bainbridge Sciences, Inc., Redmond, WA, United States (U.S. corporation)
PI US 5591830 19970107
AI US 1995-456855 19950601 (8)
RLI Continuation of Ser. No. US 1994-178219, filed on 6 Jan 1994, now patented, Pat. No. US 5512657 which is a continuation of Ser. No. US 1993-96490, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-721756, filed on 26 Jun 1991, now patented, Pat. No. US 5264370, issued on 23 Nov 1993 which is a continuation-in-part of Ser. No. US 1988-283397, filed on 12 Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 1908
INCL INCLM: 530/388.850
INCLS: 530/387.100; 530/388.100; 530/388.200; 435/007.230
NCL NCLM: 530/388.850
NCLS: 435/007.230; 530/387.100; 530/388.100; 530/388.200
IC [6]
ICM: C07K016-00
ICS: C07K016-18
EXF 530/387.1; 530/388.1; 530/388.2; 530/388.85; 435/7.23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 234 OF 374 USPATFULL on STN
AN 97:1325 USPATFULL
TI Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
IN Van Aken, Morgan, Bainbridge Island, WA, United States
Paskell, Stefan L., Bainbridge Island, WA, United States
PA Bainbridge Sciences, Inc., Redmond, WA, United States (U.S. corporation)
PI US 5591595 19970107
AI US 1995-457285 19950601 (8)
RLI Continuation of Ser. No. US 1994-178219, filed on 6 Jan 1994, now patented, Pat. No. US 5512657 which is a continuation of Ser. No. US 1993-96490, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-721756, filed on 26 Jun 1991, now patented, Pat. No. US 5264370, issued on 23 Nov 1993 which is a continuation-in-part of Ser. No. US 1988-283397, filed on 12 Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 2087
INCL INCLM: 435/007.230
INCLS: 435/007.100; 435/007.200; 435/007.900; 435/007.920; 436/501.000; 436/064.000; 436/813.000
NCL NCLM: 435/007.230
NCLS: 435/007.100; 435/007.200; 435/007.900; 435/007.920; 436/064.000; 436/501.000; 436/813.000
IC [6]
ICM: G01N033-574
ICS: G01N033-53
EXF 435/7.23; 435/7.1; 435/7.2; 435/7.9; 435/7.92; 436/501; 436/64; 436/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 235 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:291603 CAPLUS
DN 129:94197
TI Production of monoclonal ***antibodies*** against bovine parvovirus
AU Mahmoud, Mervat M.; Karim, Ikram A.; Shalaby, M. A.
CS Animal Health Research Institute, Giza, Egypt
SO Veterinary Medical Journal Giza (1997), 45(4), 449-455
CODEN: VMJGEA; ISSN: 1110-1423
PB Cairo University, Faculty of Veterinary Medicine
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 236 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 76
AN 1997:61863 BIOSIS

TI Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging.
AU Duperray, Alain; Languino, Lucia R.; Plescia, Janet; McDowall, Alison; Hogg, Nancy; Craig, Alister G.; Berendt, Anthony R.; Altieri, Dario C. [Reprint author]
CS Yale Univ. Sch. Med., BCMM 436B, 295 Congress Ave., New Haven, CT 06536, USA
SO Journal of Biological Chemistry, (1997) Vol. 272, No. 1, pp. 435-441. CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 11 Feb 1997
Last Updated on STN: 11 Feb 1997

L4 ANSWER 237 OF 374 USPATFULL on STN
AN 96:113802 USPATFULL
TI Agglutination assay
IN Hillyard, Carmel J., Queensland, Australia
Rylatt, Dennis B., Queensland, Australia
PA Agen Limited, Queensland, Australia (non-U.S. corporation)
PI US 5583003 19961210
AI US 1994-351105 19941130 (8)
RLI Continuation of Ser. No. US 1992-842343, filed on 25 Mar 1992, now abandoned
PRAI AU 1989-6558 19890925
DT Utility
FS Granted
LN.CNT 1912
INCL INCLM: 435/007.250
INCLS: 435/007.400; 435/972.000; 435/973.000
NCL NCLM: 435/007.250
NCLS: 435/007.400; 435/972.000; 435/973.000
IC [6]
ICM: G01N033-53
ICS: G01N033-555; G01N033-567
EXF 435/972; 435/973; 435/7.4; 435/7.25
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 238 OF 374 USPATFULL on STN
AN 96:101449 USPATFULL
TI Chemical event selection by suicide substrate conjugates
IN Janda, Kim D., San Diego, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5571681 19961105
AI US 1994-209525 19940310 (8)
DT Utility
FS Granted
LN.CNT 3030
INCL INCLM: 435/007.600
INCLS: 435/188.500; 435/041.000
NCL NCLM: 435/007.600
NCLS: 435/041.000; 435/188.500; 435/DIG.004; 435/DIG.021; 435/DIG.035
IC [6]
ICM: C12Q001-25
ICS: C12N009-00
EXF 435/188.5; 435/7.6; 435/7.71; 435/7.72; 435/41
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 239 OF 374 USPATFULL on STN
AN 96:67898 USPATFULL
TI Methods for determining the invasiveness of a bladder tumor
IN Houghton, Raymond L., Bothell, WA, United States
Van Aken, Morgan, Bainbridge Island, WA, United States
Jones, Tobin K., Bainbridge Island, WA, United States
PA Bard Diagnostic Sciences, Inc., Redmond, WA, United States (U.S. corporation)
PI US 5541076 19960730
AI US 1995-460496 19950602 (8)
RLI Continuation-in-part of Ser. No. US 1994-178219, filed on 6 Jan 1994 which is a continuation of Ser. No. US 1993-96490, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-721756, filed on 26 Jun 1991, now patented, Pat. No. US 5264370 which is a continuation-in-part of Ser. No. US 1988-283397, filed on 12 Dec 1988, now abandoned

FS Granted
LN.CNT 1489
INCL INCLM: 435/007.230
INCLS: 435/007.900; 436/064.000; 436/813.000
NCL NCLM: 435/007.230
NCLS: 435/007.900; 436/064.000; 436/813.000
IC [6]
ICM: G01N033-574
ICS: G01N033-53
EXF 435/7.23; 435/7.9; 436/64; 436/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 240 OF 374 USPATFULL on STN
AN 96:36652 USPATFULL
TI Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
IN Van Aken, Morgan, Bainbridge Island, WA, United States
Paskell, Stefan L., Bainbridge Island, WA, United States
PA Bainbridge Sciences, Inc., Redmond, WA, United States (U.S. corporation)
PI US 5512657 19960430
AI US 1994-178219 19940106 (8)
RLI Continuation of Ser. No. US 1993-96490, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-721756, filed on 26 Jun 1991, now patented, Pat. No. US 5264370, issued on 23 Nov 1993 which is a continuation-in-part of Ser. No. US 1988-283397, filed on 12 Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 1885
INCL INCLM: 530/350.000
INCLS: 530/412.000; 530/413.000; 530/416.000; 436/064.000; 436/811.000; 436/813.000; 436/820.000; 435/004.000; 435/029.000
NCL NCLM: 530/350.000
NCLS: 435/004.000; 435/029.000; 436/064.000; 436/811.000; 436/813.000; 436/820.000; 530/412.000; 530/413.000; 530/416.000
IC [6]
ICM: C07K014-435
ICS: C07K001-22; G01N033-483; G01N033-493
EXF 530/350; 530/412; 530/413; 530/416; 435/4; 435/29; 436/63; 436/64; 436/811; 436/813; 436/820
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 241 OF 374 USPATFULL on STN
AN 96:29461 USPATFULL
TI Immortalized human cell lines containing exogenous cytochrome P450 genes
IN Harris, Curtis C., Bethesda, MD, United States
Gelboin, Harry V., Chevy Chase, MD, United States
Gonzalez, Frank J., Bethesda, MD, United States
Mace, Katharine C., Lousanne, Switzerland
Pfeifer, Andrea M. A., Vevey, Switzerland
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5506131 19960409
AI US 1993-65201 19930519 (8)
RLI Continuation-in-part of Ser. No. US 1992-869818, filed on 13 Apr 1992, now patented, Pat. No. US 5356806 which is a continuation-in-part of Ser. No. US 1991-787777, filed on 6 Nov 1991, now patented, Pat. No. US 5164313 which is a continuation-in-part of Ser. No. US 1987-58387, filed on 5 Jun 1987, now abandoned , said Ser. No. US -869818 which is a continuation-in-part of Ser. No. US 1991-636712, filed on 2 Jan 1991, now patented, Pat. No. US 5443954 which is a continuation-in-part of Ser. No. US 1988-265883, filed on 1 Nov 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-114508, filed on 30 Oct 1987, now patented, Pat. No. US 4885238
DT Utility
FS Granted
LN.CNT 1259
INCL INCLM: 435/240.200
INCLS: 435/006.000
NCL NCLM: 435/006.000
NCLS: 435/371.000
IC [6]
ICM: C12N005-10
EXF 435/6; 435/7.21; 435/69.1; 435/172.2; 435/172.3; 435/240.2; 935/70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 242 OF 374 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
AN 1996:26231373 BIOTECHNO
TI Specific inhibition of T lymphocyte coactivation by triggering integrin .beta..sub.1 reveals convergence of .beta..sub.1, .beta..sub.2, and .beta..sub.7 signaling pathways
AU Woodside D.G.; Teague T.K.; McIntyre B.W.
CS Department of Immunology, M. D. Andreson Cancer Center, University of Texas, 1515 Holcombe Boulevard,Houston, TX 77030, United States.
SO Journal of Immunology, (1996), 157/2 (700-706)
CODEN: JOIMA3 ISSN: 0022-1767
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 243 OF 374 CABA COPYRIGHT 2004 CABI on STN
AN 97:137303 CABA
DN 19972214088
TI Antigen analysis of egg drop syndrome 76 virus by using monoclonal ***antibodies***
AU Yang KeJun; Kong DeYing; Xin ChaoAn; Yang, K. J.; Kong, D. Y.; Xin, C. A.
CS Department of Animal Medicine, South China Agricultural University, Guangzhou, Guangdong 510642, China.
SO Chinese Journal of Veterinary Medicine, (1996) Vol. 22, No. 5, pp. 3-6. 12 ref.
DT Journal
LA Chinese
SL English
ED Entered STN: 19971112
Last Updated on STN: 19971112

L4 ANSWER 244 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1996-02092 BIOTECHDS
TI Isolated ligand for T cell surface molecule, especially CTLA4; antigen-specific apoptosis using a T-lymphocyte CTLA4 human monoclonal ***antibody*** , for application in graft rejection inhibition and autoimmune disease therapy
AU Gribben J G; Freeman G J; Nadler L M; Rennert P; Jellis C L; Greenfield E; Gray G
PA Repligen; Dana-Farber-Cancer-Inst.
LO Cambridge, MA, USA; Boston, MA, USA.
PI WO 9533770 14 Dec 1995
AI WO 1995-US6726 2 Jun 1995
PRAI US 1994-253783 3 Jun 1994
DT Patent
LA English
OS WPI: 1996-040187 [04]

L4 ANSWER 245 OF 374 USPATFULL on STN
AN 95:84315 USPATFULL
TI D-arabinitol dehydrogenase from Candida tropicalis ATCC 750 or Candida shehatae
IN Miyada, Charles G., Mountain View, CA, United States
Switchenko, Arthur C., Palo Alto, CA, United States
Quong, Melanie W., La Jolla, CA, United States
Wong, Man-Ying L., Fremont, CA, United States
PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5451517 19950919
AI US 1995-400417 19950303 (8)
RLI Continuation of Ser. No. US 1994-184764, filed on 21 Jan 1994, now abandoned which is a continuation of Ser. No. US 1991-731218, filed on 12 Jul 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1085
INCL INCLM: 435/190.000
INCLS: 435/255.400; 435/921.000; 435/924.000
NCL NCLM: 435/190.000
NCLS: 435/255.400; 435/921.000; 435/924.000
IC [6]
ICM: C12N009-04
ICS: C12N001-16; C12N001-00
EXF 435/190; 435/255.4; 435/921; 435/924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 246 OF 374 USPATFULL on STN
AN 95:40851 USPATFULL
TI Erythrocyte agglutination assay
IN Hillyard, Carmel J., Brisbane, Australia
Rylatt, Dennis B., Rosalie, Australia
Kemp, Bruce E., Kew, Australia
Bundesen, Peter G., Fig Tree Pocket, Australia
PA Agen Biomedical, Ltd., Acadia Ridge, Australia (non-U.S. corporation)
PI US 5413913 19950509
AI US 1994-191064 19940203 (8)
RLI Continuation of Ser. No. US 1991-770845, filed on 4 Oct 1991, now abandoned which is a continuation of Ser. No. US 1989-324500, filed on 16 Mar 1989, now patented, Pat. No. US 5086002 which is a continuation-in-part of Ser. No. US 1988-143343, filed on 13 Jan 1988, now patented, Pat. No. US 4894347 which is a continuation-in-part of Ser. No. US 1987-111313, filed on 22 Oct 1987, now abandoned
PRAI AU 1987-4400 19870907
AU 1987-5018 19871022
DT Utility
FS Granted
LN.CNT 1176
INCL INCLM: 435/007.250
INCLS: 435/002.000; 435/975.000; 436/519.000; 436/520.000; 436/819.000; 530/388.700; 530/391.100
NCL NCLM: 435/007.250
NCLS: 435/002.000; 435/975.000; 436/519.000; 436/520.000; 436/819.000; 530/388.700; 530/391.100
IC [6]
ICM: G01N033-555
EXF 435/2; 435/7.5; 435/70.21; 435/975; 436/501; 436/519; 436/520; 436/547; 436/548; 436/819; 530/388.1; 530/388.2; 530/388.7; 530/391.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 247 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:950241 CAPLUS
DN 124:6696
TI BiP binding sequences in ***antibodies***
AU Knarr, Gerhard; Gething, Mary-Jane; Modrow, Susanne; Buchner, Johannes
CS Inst. Biophys. Physikalische Biochemie, Univ. Regensburg, Regensburg, 93040, Germany
SO Journal of Biological Chemistry (1995), 270(46), 27589-94
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Bio logy
DT Journal
LA English

L4 ANSWER 248 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 78
AN 1995:438091 BIOSIS
DN PREV199598452391
TI Interaction between a Fab fragment against gp41 of human immunodeficiency virus 1 and its peptide epitope: Characterization using a peptide epitope library and molecular modeling.
AU Stigler, Rolf-Dietrich; Rueker, Florian; Katinger, Dietmar; Elliott, Graham; Hoehne, Wolfgang; Henklein, Peter; Ho, Joseph X.; Keeling, Kim; Carter, Dan C.; Nugel, Elsa; Kramer, Achim; Porstmann, Tomas; Schneider-Mergener, Jens [Reprint author]
CS Inst. Med. Immunologie, Universitaetsklin. Charite, Humboldt-Univ. zu Berlin, Schumannstrasse 20-21, 10098 Berlin, Germany
SO Protein Engineering, (1995) Vol. 8, No. 5, pp. 471-479.
CODEN: PRENE9. ISSN: 0269-2139.
DT Article
LA English
ED Entered STN: 10 Oct 1995
Last Updated on STN: 10 Oct 1995

L4 ANSWER 249 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 79
AN 1994:271698 BIOSIS
DN PREV199497284698
TI HIV-1 gp41 shares a common immunologic determinant with human T, B and monocyte cell lines.
AU Chen, Ying-Hua; Susanna, Alex; Boeck, Guenther; Steindl, Franz; Katinger, Hermann; Dierich, Manfred P. [Reprint author]
CS Inst. Hygiene, Fritz-Pregl-Strasse 3, A-6010 Innsbruck, Austria

CODEN: IMLED6. ISSN: 0165-2478.
DT Article
LA English
ED Entered STN: 24 Jun 1994
Last Updated on STN: 24 Jun 1994

L4 ANSWER 250 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 80
AN 1994:128940 BIOSIS
DN PREV199497141940
TI Stable, continuous large-scale production of human monoclonal HIV-1 ***antibody*** using a computer-controlled pilot plant.
AU Unterluggauer, F. [Reprint author]; Doblhoff-Dier, O.; Tauer, C.; Jungbauer, A.; Gaida, T.; Reiter, M.; Schmatz, C.; Zach, N.; Katinger, H.
CS Inst. Applied Microbiol., Univ. Agric. and Forestry, Nussdorfer Laende 11, A-1190 Vienna, Austria
SO Biotechniques, (1994) Vol. 16, No. 1, pp. 140-144, 146-147.
CODEN: BTNQDO. ISSN: 0736-6205.
DT Article
LA English
ED Entered STN: 24 Mar 1994
Last Updated on STN: 24 Mar 1994

L4 ANSWER 251 OF 374 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 94:100602 SCISEARCH
GA The Genuine Article (R) Number: MQ935
TI STABLE, CONTINUOUS LARGE-SCALE PRODUCTION OF HUMAN MONOCLONAL HIV-1 ***ANTIBODY*** USING A COMPUTER-CONTROLLED PILOT-PLANT
AU UNTERLUGGAUER F (Reprint); DOBLHOFFDIER O; TAUER C; JUNGBAUER A; GAIDA T; REITER M; SCHMATZ C; ZACH N; KATINGER H
CS UNIV AGR & FORESTRY, INST APPL MICROBIOL, NUSSDORFER LANDE 11, A-1190 VIENNA, AUSTRIA (Reprint)
CYA AUSTRIA
SO BIOTECHNIQUES, (JAN 1994) Vol. 16, No. 1, pp. 140.
ISSN: 0736-6205.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 25
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 252 OF 374 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 93:38865 DISSABS Order Number: AAR9320691
TI APPLICATION OF MONOCLONAL ***ANTIBODIES*** IN THE STUDY OF MYCOPLASMA GALLISEPTICUM SURFACE EPITOPES AND AS A DIAGNOSTIC TOOL
AU GARCIA, MARICARMEN [PH.D.]; KLEVEN, STANLEY H. [advisor]
CS UNIVERSITY OF GEORGIA (0077)
SO Dissertation Abstracts International, (1993) Vol. 54, No. 3B, p. 1314.
Order No.: AAR9320691. 118 pages.
DT Dissertation
FS DAI
LA English
ED Entered STN: 19930817
Last Updated on STN: 19930817

L4 ANSWER 253 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
DUPLICATE 81
AN 1993-04124 BIOTECHDS
TI New D-arabinitol-dehydrogenase enzyme; produced by Candida shehatae or Candida tropicalis, which is incapable of oxidizing D-mannitol, is useful for detecting Candida infections; monoclonal ***antibody***
PA Syntex
PI EP 522875 13 Jan 1993
AI EP 1992-306371 10 Jul 1992
PRAI US 1991-731218 12 Jul 1991
DT Patent
LA English
OS WPI: 1993-010684 [02]

L4 ANSWER 254 OF 374 USPATFULL on STN
AN 93:106926 USPATFULL
TI Assay by enzyme-catalyzed isotopic exchange

Ullman, Edwin F., Atherton, CA, United States
PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5272054 19931221
AI US 1992-857883 19920326 (7)
DT Utility
FS Granted
LN.CNT 1476
INCL INCLM: 435/004.000
INCLS: 435/007.720; 435/007.900; 435/015.000; 435/026.000; 435/189.000; 435/191.000; 435/810.000; 435/814.000; 435/968.000; 435/975.000; 436/504.000; 436/542.000; 436/545.000; 436/804.000; 424/001.100
NCL NCLM: 435/004.000
NCLS: 435/007.720; 435/007.900; 435/015.000; 435/026.000; 435/189.000; 435/191.000; 435/810.000; 435/814.000; 435/968.000; 435/975.000; 436/504.000; 436/542.000; 436/545.000; 436/804.000
IC [5]
ICM: C12Q001-00
ICS: G01N033-567
EXF 435/4; 435/7.72; 435/7.9; 435/15; 435/26; 435/189; 435/191; 435/810; 435/814; 435/968; 435/975; 436/504; 436/542; 436/545; 436/804; 424/1.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 255 OF 374 USPATFULL on STN
AN 93:52504 USPATFULL
TI Monoclonal ***antibodies*** reactive with defined regions of the T-cell antigen receptor
IN Skibbens, Robert V., Chapel Hill, NC, United States
Henry, Larry D., Brookline, MA, United States
Rittershaus, Charles W., Malden, MA, United States
Tian, Wei-Tao, Allston, MA, United States
Ip, Stephen H., Sudbury, MA, United States
Kung, Patrick C., Lexington, MA, United States
Snider, Mary Ellen, Ledyard, CT, United States
Ko, Jone-Long, Cambridge, MA, United States
Wood, Nancy L., Cambridge, MA, United States
PA T Cell Sciences, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5223426 19930629
AI US 1989-449692 19891211 (7)
RLI Continuation-in-part of Ser. No. US 1989-343189, filed on 25 Apr 1989 which is a continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 2972
INCL INCLM: 435/240.270
INCLS: 530/387.100; 530/387.900; 424/085.800
NCL NCLM: 435/331.000
NCLS: 424/144.100; 424/154.100; 530/387.100; 530/387.900; 530/388.220; 530/388.750
IC [5]
ICM: A61K039-00
ICS: A61K035-16
EXF 530/387; 530/381.1; 530/2; 530/395; 435/240.27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 256 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 82
AN 1993:410131 BIOSIS
DN PREV199396075856
TI HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells.
AU Marschang, Peter [Reprint author]; Guertler, Lutz; Toetsch, Martin; Thielens, Nicole M.; Arlaud, Gerard J.; Hittmair, Anton; Katinger, Hermann; Dierich, Manfred P.
CS Inst. Hygeine, Fritz-Pregl-Str. 3, 6020 Innsbruck, Austria
SO AIDS (Philadelphia), (1993) Vol. 7, No. 7, pp. 903-910.
CODEN: AIDSET. ISSN: 0269-9370.
DT Article
LA English
ED Entered STN: 8 Sep 1993
Last Updated on STN: 8 Sep 1993

L4 ANSWER 257 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 83
AN 1993:587931 BIOSIS

TI Expression of colorectal carcinoma-associated antigens in colonic polyps.
AU Salem, Ronald R. [Reprint author]; Wolf, Barbara C. [Reprint author]; Sears, Henry F. [Reprint author]; Lavin, Philip T. [Reprint author]; Ravikumar, Thanjavur S. [Reprint author]; Decoste, Deborah [Reprint author]; D'Emilia, John C. [Reprint author]; Herlyn, Meenhard; Schlom, Jeffrey
CS Dep. Surg., Lab. Cancer Biol., New England Deaconess Hosp., Harvard Med. Sch., Boston, MA 02138, USA
SO Journal of Surgical Research, (1993) Vol. 55, No. 3, pp. 249-255. CODEN: JSGRA2. ISSN: 0022-4804.
DT Article
LA English
ED Entered STN: 28 Dec 1993
Last Updated on STN: 28 Dec 1993

L4 ANSWER 258 OF 374 CANCERLIT on STN DUPLICATE 84
AN 93114405 CANCERLIT
DN 93114405 PubMed ID: 7678090
TI Characterization of hemopoietic cell populations from human cord blood expressing c-kit.
AU Reisbach G; Bartke I; Kempkes B; Kostka G; Ellwart J; Birner A; Thalmeier K; Mailhammer R; Bornkamm G W; Ullrich A; +
CS GSF-Institute of Experimental Hematology, Munich, Germany.
SO EXPERIMENTAL HEMATOLOGY, (1993 Jan) 21 (1) 74-9. Journal code: 0402313. ISSN: 0301-472X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 93114405
EM 199301
ED Entered STN: 19941107
Last Updated on STN: 19960517

L4 ANSWER 259 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1993-09567 BIOTECHDS
TI Isoprotein analysis by ionexchange chromatography using a linear pH gradient combined with a salt gradient;
monoclonal ***antibody*** purification (conference paper)
AU Kaltenbrunner O; Tauer C; Brunner J; *Jungbauer A
LO Institut fuer angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Nussdorfer Laende 11, A-1190 Vienna, Austria.
SO J.Chromatogr.; (1993) 639, 1, 41-49
CODEN: JOCRAM
DT Journal
LA English

L4 ANSWER 260 OF 374 USPATFULL on STN
AN 92:9052 USPATFULL
TI Erythrocyte agglutination assay
IN Hillyard, Carmel J., Brisbane, Australia
Rylatt, Dennis B., Rosalie, Australia
Kemp, Bruce E., Kew, Australia
Bundesen, Peter G., Fig Tree Pocket, Australia
PA Agen Biomedical, Ltd., Acacia Ridge, Australia (non-U.S. corporation)
PI US 5086002 19920204
AI US 1989-324500 19890316 (7)
RLI Continuation-in-part of Ser. No. US 1988-143343, filed on 13 Jan 1988, now patented, Pat. No. US 4894347 which is a continuation-in-part of Ser. No. US 1987-111313, filed on 22 Oct 1987, now abandoned
PRAI AU 1987-4400 19870907
AU 1987-5018 19871022
DT Utility
FS Granted
LN.CNT 1284
INCL INCLM: 436/540.000
INCLS: 436/501.000; 436/519.000; 422/061.000; 530/387.000
NCL NCLM: 436/540.000
NCLS: 422/061.000; 435/007.250; 436/501.000; 436/519.000; 530/387.300; 530/388.700; 530/389.100; 530/866.000
IC [5]
ICM: G01N033-541
EXF 530/387; 530/389; 422/61; 436/519; 436/520; 436/540; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1992-390692 [48] WPIDS
DNC C1992-173320
TI Prodn. of human immunodeficiency virus gp-41 derivs. - using plasmid contg. FR-coat proteins, 2N-terminal aminoacid(s) and HIV gene AA474-647, to produce immunologically active gp-41.
DC B04 D16
IN DREILINJA, D; KOZLOVSKAJA, T; OZOLS, J; PORSTMANN, T; PUMPEN, P; PUSHKO, P; ULRICH, R
PA (ALOR) AS LATV ORGANIC SYNTHESIS INST; (UYBE) UNIV BERLIN HUMBOLDT
CYC 1
PI DD 300690 A5 19920702 (199248)* 4 C12N015-48
ADT DD 300690 A5 DD 1990-338996 19900323
PRAI DD 1990-338996 19900323
IC ICM C12N015-48
ICS C07K015-04; C12N015-62; C12P021-02

L4 ANSWER 262 OF 374 AGRICOLA Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted materials. All rights reserved. (2004) on STN DUPLICATE 85
AN 92:115808 AGRICOLA
DN IND92071156
TI Demonstration of peptidoglycan-associated Brucella outer-membrane proteins by use of monoclonal ***antibodies*** .
AU Cloeckaert, A.; Zygmunt, M.S.; Wergifosse, P. de; Dubray, G.; Limet, J.N.
CS Catholic University of Louvain, Brussels, Belgium
AV DNAL (448.3 J823)
SO The Journal of general microbiology, July 1992. Vol. 138, No. pt.7. p. 1543-1550
Publisher: Reading : Society for General Microbiology.
CODEN: JGMIAN; ISSN: 0022-1287
NTE Includes references.
DT Article
FS Non-U.S. Imprint other than FAO
LA English

L4 ANSWER 263 OF 374 LIFESCI COPYRIGHT 2004 CSA on STN
AN 93:53806 LIFESCI
TI Demonstration of peptidoglycan-associated Brucella outer-membrane proteins by use of monoclonal ***antibodies*** .
AU Coeckaert, A.; Zygmunt, M.S.; de Wergifosse, P.; Dubray, G.; Limet, J.N.
CS Unit Exp. Med., Catholic Univ. Louvain, 75 Ave. Hippocrate, B-1200 Brussels, Belgium
SO J. GEN. MICROBIOL., (1992) vol. 138, no. 7, pp. 1543-1550.
DT Journal
FS J; M; F
LA English
SL English

L4 ANSWER 264 OF 374 PASCAL COPYRIGHT 2004 INIST-CNRS. ALL RIGHTS RESERVED. on STN
AN 1992-0540032 PASCAL
TIEN Demonstration of peptidoglycan-associated Brucella outer-membrane proteins by use of monoclonal ***antibodies***
AU CLOACKAERT A.; ZYGMUNT M. S.; DE WERGIFOSSE P.; DUBRAY G.; LIMET J. N.
CS Catholic univ. Louvain, unit exp. medicine, 1200 Brussels, Belgium
SO JGM. Journal of general microbiology, (1992), 138(p.7), 1543-1550, refs. 1 p.
DT Journal
BL Analytic
CY United Kingdom
LA English
AV INIST-4410, 354000020157910310

L4 ANSWER 265 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 86
AN 1992:391924 BIOSIS
DN PREV199294064099; BA94:64099
TI MONOCLONAL ***ANTIBODIES*** AND RABBIT ANTISERA RECOGNIZING 4 AMINOBIPHENYL-DNA ADDUCTS AND APPLICATION TO IMMUNOAFFINITY CHROMATOGRAPHY.
AU GROOPMAN J D [Reprint author]; SKIPPER P L; DONAHUE P R; TRUDEL L J; WILDSCHUTTE M; KADLUBAR F F; TANNENBAUM S R
CS DEP ENVIRONMENTAL HEALTH SCIENCES, JOHNS HOPKINS UNIV, SCH HYGIENE PUBLIC HEALTH, 615 NORTH WOLFE STREET, BALTIMORE, MD 21205, USA

CODEN: ČRNGDP. ISSN: 0143-3334.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 24 Aug 1992
Last Updated on STN: 24 Aug 1992

L4 ANSWER 266 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 87
AN 1992:504534 BIOSIS
DN PREV199294123059; BA94:123059
TI GLOBAL FOREBRAIN ISCHEMIA RESULTS IN DECREASED IMMUNOREACTIVITY OF CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II.
AU CHURN S B [Reprint author]; YAGHMAI A; POVLISHOCK J; RAFIQ A; DELORENZO R J
CS DEP NEUROLOGY, MED COLL VA, BOX 599 MCV STATION, RICHMOND, VA 23298, USA
SO Journal of Cerebral Blood Flow and Metabolism, (1992) Vol. 12, No. 5, pp. 784-793.
CODEN: JCBMDN. ISSN: 0271-678X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 9 Nov 1992
Last Updated on STN: 10 Nov 1992

L4 ANSWER 267 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN DUPLICATE 88
AN 1992-12664 BIOTECHDS
TI Growth and production kinetics of human x mouse and mouse hybridoma cells at reduced temperature and serum content;
and effect of substrate limitation on heterohybridoma cell culture
AU Borth N; Heider R; Assadian A; Katinger H
LO Institute of Applied Microbiology, University of Agriculture, Nussdorfer Laende 11, 1190 Vienna, Austria.
SO J.Biotechnol.; (1992) 25, 3, 319-31
CODEN: JBITD4
DT Journal
LA English

L4 ANSWER 268 OF 374 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 93:5268 SCISEARCH
GA The Genuine Article (R) Number: KD862
TI GROWTH AND PRODUCTION KINETICS OF HUMAN X MOUSE AND MOUSE HYBRIDOMA CELLS AT REDUCED TEMPERATURE AND SERUM CONTENT
AU BORTH N (Reprint); HEIDER R; ASSADIAN A; KATINGER H
CS UNIV AGR VIENNA, INST APPL MICROBIOL, NUSSDORFER LANDE 11, A-1190 VIENNA, AUSTRIA (Reprint)
CYA AUSTRIA
SO JOURNAL OF BIOTECHNOLOGY, (SEP 1992) Vol. 25, No. 3, pp. 319-331.
ISSN: 0168-1656.
DT Article; Journal
FS AGRI
LA ENGLISH
REC Reference Count: 36
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 269 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1992-08168 BIOTECHDS
TI Microencapsulation of hybridomas by cellulose sulfate-polydimethyldiallylammonium chloride procedure;
hybridoma encapsulation and cell culture for mouse and human monoclonal ***antibody*** preparation
AU Groot-Wassink T; Dautzenberg H; Grunow R; von Baehr R
LO Bereich Medizin (Charite) der Humboldt-Universitaet zu Berlin, Institut fuer Medizinische Immunologie, Schumannstrasse 20/21, PSF 150, O-1040 Berlin, Germany.
SO Acta Biotechnol.; (1992) 12, 3, 169-78
CODEN: ACBTDD
DT Journal
LA English

L4 ANSWER 270 OF 374 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 93:59597 DISSABS Order Number: AARC313016 (not available for sale by

TI CLONING AND EXPRESSION OF A SINGLE-CHAIN PROTEIN IN ESCHERICHIA COLI
KLONIERUNG UND EXPRESSION EINES ANTIGENBINDENDEN PROTEINS IN ESCHERICHIA COLI
AU KOHL, JOHANN [DR.NAT.]
CS UNIVERSITAET FUER BODENKULTUR WIEN (AUSTRIA) (5808)
SO Dissertation Abstracts International, (1991) Vol. 54, No. 4C, p. 1078. Order No.: AARC313016 (not available for sale by UMI). 58 pages.
DT Dissertation
FS DAI
LA English
ED Entered STN: 19931214
Last Updated on STN: 19931214

L4 ANSWER 271 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
DUPLICATE 89
AN 1992-03259 BIOTECHDS
TI Recombinant protein which binds to complex viral antigen of HIV virus-1; human recombinant ***antibody*** containing variable region of human monoclonal ***antibody*** ; DNA sequence; useful in detection, quantification, purification of HIV virus-1 antigen
PA Jungbauer A
PI WO 9118983 12 Dec 1991
AI WO 1991-AT67 28 May 1991
PRAI AT 1990-1178 29 May 1990
DT Patent
LA German
OS WPI: 1992-007468 [01]

L4 ANSWER 272 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 90
AN 1992:119275 BIOSIS
DN PREV199293065075; BA93:65075
TI ANALYSIS OF VARIOUS ANTIGENS IN GOLDEN HAMSTER TESTIS BY MONOCLONAL ***ANTIBODIES*** .
AU OHSAKO S [Reprint author]; KUROHMARU M; NISHIDA T; HAYASHI Y
CS DEP VETERINARY ANATOMY, FAC AGRIC, UNIVERSITY TOKYO, BUNKYO-KU, TOKYO 113, JAPAN
SO Journal of Veterinary Medical Science, (1991) Vol. 53, No. 6, pp. 969-974. CODEN: JVMSEQ. ISSN: 0916-7250.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 1 Mar 1992
Last Updated on STN: 1 Mar 1992

L4 ANSWER 273 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
DUPLICATE 91
AN 1992-07605 BIOTECHDS
TI Expression of a human monoclonal anti-HIV-1 ***antibody*** in CHO cells;
production of human recombinant monoclonal ***antibody*** specific for HIV virus-1 gp41 by expression of heavy chain and light chain from vector pair in CHO cell culture (conference paper)
AU Rueker F; Ebert V; Kohl J; Steindl F; Riegler H; Katinger H
LO Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Nussdorfer Laende 11, A-1190 Vienna, Austria.
SO Ann.N.Y.Acad.Sci.; (1991) 646, 212-19
CODEN: ANYAA9
DT Journal
LA English

L4 ANSWER 274 OF 374 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
AN 1991:22266099 BIOTECHNO
TI Expression of a human monoclonal anti-HIV-1 ***antibody*** in CHO cells
AU Ruker F.; Ebert V.; Kohl J.; Steindl F.; Riegler H.; Katinger H.
CS Inst. fur Angewandte Mikrobiologie, Universitat fur Bodenkultur, Nussdorfer Lande 11,A-1190 Vienna, Austria.
SO Annals of the New York Academy of Sciences, (1991), 646/- (212-219)
CODEN: ANYAA0 ISSN: 0077-8923
DT Journal; Conference Article
CY United States
LA English
SL English

L4 ANSWER 275 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:467394 CAPLUS
DN 115:67394
TI The effect of a monoclonal ***antibody*** on specific steps of the reaction sequence of the calcium-magnesium ATPase from sarcoplasmic reticulum
AU Mata, Ana M.; Colyer, John; Michelangeli, Francesco; Lee, Anthony G.; East, J. Malcolm
CS Dep. Biochem., Univ. Southampton, Southampton, SO9 3TU, UK
SO Biochemical Society Transactions (1991), 19(2), 205S
CODEN: BCSTB5; ISSN: 0300-5127
DT Journal
LA English

L4 ANSWER 276 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
DUPLICATE 93
AN 1992-07389 BIOTECHDS
TI Cloning and expression of an HIV-1 specific single-chain Fv region fused to Escherichia coli alkaline phosphatase;
anti-HIV virus-1 recombinant monoclonal ***antibody*** fragment production and purification following ***antibody*** engineering (conference paper)
AU Kohl J; *Rueker F; Himmler G; Razazzi E; Katinger H
LO Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Nussdorfer Laende 11, A-1190 Vienna, Austria.
SO Ann.N.Y.Acad.Sci.; (1991) 646, 106-14
CODEN: ANYAA9
DT Journal
LA English

L4 ANSWER 277 OF 374 USPATFULL on STN
AN 90:4355 USPATFULL
TI Erythrocyte agglutination assay
IN Hillyard, Carmel J., Brisbane, Australia
Rylatt, Dennis B., Rosalie, Australia
Kemp, Bruce E., Kew, Australia
Bundesen, Peter G., Fig Tree Pocket, Australia
PA Agen Limited, Australia (non-U.S. corporation)
PI US 4894347 19900116
AI US 1988-143343 19880113 (7)
RLI Continuation-in-part of Ser. No. US 1989-111313, filed on 22 Oct 1989
PRAI AU 1987-4400 19870917
DT Utility
FS Granted
LN.CNT 701
INCL INCLM: 436/540.000
INCLS: 436/501.000; 436/519.000; 422/061.000; 530/387.000
NCL NCLM: 436/540.000
NCLS: 422/061.000; 436/501.000; 436/519.000; 530/387.300; 530/388.700
IC [4]
ICM: G01N033-541
EXF 530/387; 530/389; 422/61; 436/519; 436/520; 436/540; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 278 OF 374 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
DUPLICATE 94
AN 1990-12830 BIOTECHDS
TI Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of a human monoclonal ***antibody*** specific to HIV-1 - gp41;
HIV virus-1 gp41; heavy and light chain DNA sequence
AU Flegenhauer M; Kohl J; *Rueker F
LO Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Peter Jordanstrasse 82, A-1190 Wien, Austria.
SO Nucleic Acids Res.; (1990) 18, 16, 4927
CODEN: NARHAD
DT Journal
LA English

L4 ANSWER 279 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:196651 CAPLUS
DN 112:196651
TI Pilot production of human monoclonal ***antibodies*** against HIV-1
AU Jungbauer, Alois; Steindl, Franz; Grunow, Roland; Porstmann, Tomas; Ernst, Wolfgang; Purtscher, Martin; Reiter, Manfred; Tauer, Christa; Wenisch,

CS Inst. Angew. Mikrobiol., Univ. Bodenkult., Vienna, A-1190, Austria
SO Zeitschrift fuer Klinische Medizin (1985) (1990), 45(4), 351-4
CODEN: ZKMEEF; ISSN: 0233-1608
DT Journal
LA German

L4 ANSWER 280 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 95
AN 1990:517848 BIOSIS
DN PREV199090135124; BA90:135124
TI CHARACTERIZATION OF MONOCLONAL ***ANTIBODIES*** TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 GP41 BY HIV-1 POLYPEPTIDES EXPRESSED IN ESCHERICHIA-COLI.
AU LARCHER C [Reprint author]; BROEKER M; HUEMER H P; SOELDER B; SCHULZ T F; HOFBAUER J M; WACHTER H; DIERICH M P
CS INST HYGIENE, UNIV INNSBRUCK, FRITZ-PREGL-STR 3, A-6020 INNSBRUCK, AUSTRIA
SO FEMS (Federation of European Microbiological Societies) Microbiology Immunology, (1990) Vol. 64, No. 2, pp. 103-110.
ISSN: 0920-8534.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 19 Nov 1990
Last Updated on STN: 19 Nov 1990

L4 ANSWER 281 OF 374 MEDLINE on STN
AN 91077155 MEDLINE
DN PubMed ID: 1701654
TI Characterization of monoclonal ***antibodies*** to human immunodeficiency virus type 1 gp41 by HIV-1 polypeptides expressed in Escherichia coli.
AU Larcher C; Broker M; Huemer H P; Solder B; Schulz T F; Hofbauer J M; Wachter H; Dierich M P
CS Institut fur Hygiene, University of Innsbruck, Austria.
SO FEMS microbiology immunology, (1990 Sep) 2 (2) 103-10.
Journal code: 8901230. ISSN: 0920-8534.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 199101
ED Entered STN: 19910322
Last Updated on STN: 19970203
Entered Medline: 19910129

L4 ANSWER 282 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 96
AN 1990:137344 CAPLUS
DN 112:137344
TI Human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1) ***antibodies***
IN Katinger, Hermann; Von Baehr, Ruediger; Jungbauer, Alois; Porstmann, Tomas; Steindl, Franz J.; Grunow, Roland; Buchacher, Andrea
PA CL Pharma A.-G., Austria
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8904370	A1	19890518	WO 1988-EP1072	19881114
	W: JP, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 355140	A1	19900228	EP 1989-900809	19881114
	EP 355140	B1	19960320		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02502251	T2	19900726	JP 1989-500718	19881114
	AT 135743	E	19960415	AT 1989-900809	19881114
	US 5831034	A	19981103	US 1994-293842	19940822
	US 5753503	A	19980519	US 1994-347966	19941201
PRAI	US 1987-120489	A	19871113		
	WO 1988-EP1072	W	19881114		
	US 1990-583505	B1	19900917		
	US 1991-693730	B1	19910430		
	US 1993-97170	B1	19930723		

L4 ANSWER 283 OF 374 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 1990:125644 TOXCENTER
CP Copyright 2004 ACS
DN CA1215137344R
TI Human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1) ***antibodies***
AU Katinger, Hermann; Von Baehr, Ruediger; Jungbauer, Alois; Porstmann, Tomas; Steindl, Franz J.; Grunow, Roland; Buchacher, Andrea
CS ASSIGNEE: CL Pharma A.-G.
PI WO 894370 A1 18 May 1989
SO (1989) PCT Int. Appl., 35 pp.
CODEN: PIXXD2.
CY AUSTRIA
DT Patent
FS CAPLUS
OS CAPLUS 1990:137344
LA English
ED Entered STN: 20011116
Last Updated on STN: 20021022

L4 ANSWER 284 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 97
AN 1989:514312 BIOSIS
DN PREV198988130455; BA88:130455
TI T-CELL RECEPTOR V-BETA-5 USAGE DEFINES REACTIVITY TO A HUMAN T-CELL RECEPTOR MONOCLONAL ***ANTIBODY*** .
AU LIPOLDOVA M [Reprint author]; BOYLSTON A W; YSSEL H; OWEN M J
CS IMPERIAL CANCER RES FUND, ST BARTHOLOMEW'S HOSP, DOMINION HOUSE, BARTHOLOMEW CLOSE, LONDON EC1A 7BE, UK
SO Immunogenetics, (1989) Vol. 30, No. 3, pp. 162-168.
CODEN: IMNGBK. ISSN: 0093-7711.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 15 Nov 1989
Last Updated on STN: 15 Nov 1989

L4 ANSWER 285 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 98
AN 1989:495013 BIOSIS
DN PREV198988121550; BA88:121550
TI THE EXPRESSION OF COLORECTAL CARCINOMA-ASSOCIATED ANTIGENS IN THE NORMAL COLONIC MUCOSA AN IMMUNOHISTOCHEMICAL ANALYSIS OF REGIONAL DISTRIBUTION.
AU WOLF B C [Reprint author]; SALEM R R; SEARS H F; HORST D A; LAVIN P T; HERLYN M; ITZKOWITZ S H; SCHLOM J; STEEL G D JR
CS LAB CANCER BIOL, NEW ENGLAND DEACONESS HOSP, 50 BINNEY ST, BOSTON, MASS 02115, USA
SO American Journal of Pathology, (1989) Vol. 135, No. 1, pp. 111-120.
CODEN: AJPAA4. ISSN: 0002-9440.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 2 Nov 1989
Last Updated on STN: 2 Nov 1989

L4 ANSWER 286 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 99
AN 1988:439941 BIOSIS
DN PREV198886092039; BA86:92039
TI ANTIGEN- ***ANTIBODY*** INTERACTION SYNTHETIC PEPTIDES DEFINE LINEAR ANTIGENIC DETERMINANTS RECOGNIZED BY MONOCLONAL ***ANTIBODIES*** DIRECTED TO THE CYTOPLASMIC CARBOXYL TERMINUS OF RHODOPSIN.
AU HODGES R S [Reprint author]; HEATON R J; PARKER J M R; MOLDAY L; MOLDAY R S
CS DEP BIOCHEM, UNIV ALBERTA, EDMONTON, ALBERTA T6G 2H7, CAN
SO Journal of Biological Chemistry, (1988) Vol. 263, No. 24, pp. 11768-11775.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 4 Oct 1988
Last Updated on STN: 4 Oct 1988

L4 ANSWER 287 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN

DN 109:124927
TI The mechanism of inhibition of the calcium-magnesium-ATPase by monoclonal ***antibodies***
AU Colyer, J.; Michelangeli, F.; Lee, A. G.; East, J. M.
CS Dep. Biochem., Univ. Southampton, Southampton, SO9 3TU, UK
SO Biochemical Society Transactions (1988), 16(6), 967-8
CODEN: BCSTB5; ISSN: 0300-5127
DT Journal
LA English

L4 ANSWER 288 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:488831 CAPLUS
DN 109:88831
TI Effect of monoclonal ***antibodies*** raised against calcium-magnesium ATPase from rabbit skeletal muscle sarcoplasmic reticulum on ATPase activity and its correlation with epitope location
AU Mata, Ana M.; Colyer, John; Tunwell, Richard E. A.; Lee, Anthony G.; East, J. Malcolm
CS Dep. Biochem., Univ. Southampton, Southampton, SO9 3TU, UK
SO Biochemical Society Transactions (1988), 16(5), 771-2
CODEN: BCSTB5; ISSN: 0300-5127
DT Journal
LA English

L4 ANSWER 289 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 100
AN 1989:27208 BIOSIS
DN PREV198987015208; BA87:15208
TI PRODUCTION OF MONOCLONAL ***ANTIBODIES*** AGAINST HUMAN ERYTHROPOIETIN AND THEIR USE IN THE PURIFICATION OF HUMAN URINARY ERYTHROPOIETIN.
AU MIYAZAKI H [Reprint author]; KOZUTSUMI H; KATO T; HOSHI S; TAMURA S; KUBOTA M; SUZUKI T
CS PHARM LAB, KIRIN BREWERY CO LTD, MAEBASHI, GUNMA 371, JPN
SO Journal of Immunological Methods, (1988) Vol. 113, No. 2, pp. 261-268.
CODEN: JIMMBG. ISSN: 0022-1759.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 20 Dec 1988
Last Updated on STN: 20 Dec 1988

L4 ANSWER 290 OF 374 LIFESCI COPYRIGHT 2004 CSA on STN
AN 88:57297 LIFESCI
TI Production of monoclonal ***antibodies*** against human erythropoietin and their use in the purification of human urinary erythropoietin.
AU Miyazaki, H.; Kozutsumi, H.; Kato, T.; Hoshi, S.; Tamura, S.; Kubota, M.; Suzuki, T.
CS Pharm. Lab., Kirin Brewery Co., Ltd., Maebashi, Gunma 371, Japan
SO J. IMMUNOL. METHODS., (1988) vol. 113, no. 3, pp. 261-267.
DT Journal
FS F
LA English
SL English

L4 ANSWER 291 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 101
AN 1987:634639 CAPLUS
DN 107:234639
TI Immunometric assay for high-molecular-weight carcinoembryonic antigen, kits for the immunoassay, and their use in colorectal cancer diagnosis
IN Schoemaker, Hubert J. P.; Brennan, Suzanne E.; Schlom, Jeffrey; Brock, Paul
PA Centocor, Inc., USA
SO Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 225709	A2	19870616	EP 1986-308212	19861022
	EP 225709	A3	19880907		
	EP 225709	B1	19920527		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 790261	A0	19880601	US 1985-790261	19851022
	JP 62201364	A2	19870905	JP 1986-251574	19861022

	AT 76690	E	19920615	AT 1986-308212	19861022
PRAI	US 1985-790261	A	19851022		
	EP 1986-308212	A	19861022		

L4 ANSWER 292 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 102
AN 1987:65782 BIOSIS
DN PREV198783034108; BA83:34108
TI T CELL CLONES WHICH SHARE T CELL RECEPTOR EPITOPES DIFFER IN PHENOTYPE FUNCTION AND SPECIFICITY.
AU YSSEL H [Reprint author]; BLANCHARD D; BOYLSTON A; DE VRIES J E; SPITS H
CS UNICET, CENTRE DE RECHERCHES, 27 CHEMIN DES PEUPLIERS, BP 11, F-69572 DARDILLY, FR
SO European Journal of Immunology, (1986) Vol. 16, No. 10, pp. 1187-1194. CODEN: EJIMAF. ISSN: 0014-2980.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 24 Jan 1987
Last Updated on STN: 24 Jan 1987

L4 ANSWER 293 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 103
AN 1986:378452 BIOSIS
DN PREV198682073428; BA82:73428
TI PROPERTIES OF A PANEL OF MONOCLONAL ***ANTIBODIES*** WHICH REACT WITH THE HUMAN T CELL ANTIGEN RECEPTOR ON THE LEUKEMIC LINE HPB-ALL AND A SUBSET OF NORMAL PERIPHERAL BLOOD T LYMPHOCYTES.
AU BOYLSTON A W [Reprint author]; BORST J; YSSEL H; BLANCHARD D; SPITS H; DE VRIES J E
CS PATHOL DEP, ST MARY'S HOSP MED SCH, LONDON W2 1PG, ENGLAND, UK
SO Journal of Immunology, (1986) Vol. 137, No. 2, pp. 741-744. CODEN: JOIMA3. ISSN: 0022-1767.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 20 Sep 1986
Last Updated on STN: 20 Sep 1986

L4 ANSWER 294 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1986:286053 BIOSIS
DN PREV198682029916; BA82:29916
TI THE USE OF A MONOCLONAL ***ANTIBODY*** SPECIFIC FOR THE AMINO-TERMINAL REGION OF SOUTHERN BEAN MOSAIC VIRUS AS A PROBE OF VIRUS STRUCTURE.
AU MACKENZIE D J [Reprint author]; TREMAINE J H
CS RESEARCH STN, AGRIC CAN, 6660 NW MARINE DR, VANCOUVER, BRITISH COLUMBIA, CAN V6T 1X2
SO Journal of General Virology, (1986) Vol. 67, No. 4, pp. 727-736. CODEN: JGVIAY. ISSN: 0022-1317.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 4 Jul 1986
Last Updated on STN: 4 Jul 1986

L4 ANSWER 295 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 104
AN 1986:171816 BIOSIS
DN PREV198681082232; BA81:82232
TI HUMAN T CELL LINES DIFFERING IN PHENOTYPE AND SPECIFICITY ARE REACTIVE WITH THE SAME ANTI-IDIOTYPIC ***ANTIBODY*** .
AU BORST J [Reprint author]; BOYLSTON A W; DE VRIES J E; SPITS H
CS DIV IMMUNOLOGY, NETH CANCER INST, ANTONI VAN LEEUWENHOEK HUIS, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETH
SO Journal of Immunology, (1986) Vol. 136, No. 2, pp. 601-608. CODEN: JOIMA3. ISSN: 0022-1767.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 26 Apr 1986
Last Updated on STN: 26 Apr 1986

L4 ANSWER 296 OF 374 LIFESCI COPYRIGHT 2004 CSA on STN
AN 86:33498 LIFESCI

Listeria monocytogenes : Phenotype, specific proliferation, lymphokine production, and protective capacity in vivo.
AU Stolpmann, R.M.; Sperling, U.; Hahn, H.
CS Inst. Med. Mikrobiol., Freie Univ., Berlin, FRG
SO CELL. IMMUNOL., (1986) vol. 101, no. 2, pp. 548-557.
DT Journal
FS J; F
LA English
SL English

L4 ANSWER 297 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 105
AN 1987:85748 BIOSIS
DN PREV198783044326; BA83:44326
TI A FAMILY OF T CELL RECEPTOR MOLECULES EXPRESSED ON T CELL CLONES WITH DIFFERENT SPECIFICITIES FOR ALLOMAJOR HISTOCOMPATIBILITY ANTIGENS.
AU BORST J [Reprint author]; SPITS H; VOORDOUW A; DE VRIES E; BOYLSTON A; DE VRIES J E
CS DIV IMMUNOL, NETHERLANDS CANCER INST PLESMANLAAN 121, 10666 CX AMSTERDAM, NETHERLANDS
SO Human Immunology, (1986) Vol. 17, No. 4, pp. 426-442.
CODEN: HUIMDQ. ISSN: 0198-8859.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 7 Feb 1987
Last Updated on STN: 7 Feb 1987

L4 ANSWER 298 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1987:420274 CAPLUS
DN 107:20274
TI Detection in plasma of derivatives of crosslinked fibrin, using monoclonal ***antibodies***
AU Whitaker, A. N.; Masci, P. P.; Dunstan, A.; Elms, M. J.; Bunce, I. H.; Bundesen, P. J.; Rylatt, D. B.; Webber, A. J.
CS Princess Alexandra Hosp., Univ. Queensland, Queensland, Australia
SO International Congress Series (1986), 722(Fibrinogen Its Deriv.), 265-72
CODEN: EXMDA4; ISSN: 0531-5131
DT Journal
LA English

L4 ANSWER 299 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 106
AN 1986:258982 BIOSIS
DN PREV198682013731; BA82:13731
TI DIFFERENTIAL IMMUNOGOLD-DEXTRAN LABELING OF BOVINE AND FROG ROD AND CONE CELLS USING MONOCLONAL ***ANTIBODIES*** AGAINST BOVINE RHODOPSIN.
AU HICKS D [Reprint author]; MOLDAY R S
CS DEPARTMENT BIOCHEMISTRY, UNIVERSITY BRITISH COLUMBIA, VANCOUVER, BC V6T 1W5, CANADA
SO Experimental Eye Research, (1986) Vol. 42, No. 1, pp. 55-72.
CODEN: EXERA6. ISSN: 0014-4835.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 21 Jun 1986
Last Updated on STN: 21 Jun 1986

L4 ANSWER 300 OF 374 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1985-37973 DRUGU P M
TI Rationale for Development of a Synthetic Vaccine Against Plasmodium Falciparum Malaria.
AU Zavala F; Tam J P; Hollingdale M R; Cochrane A H; Quakyi I; Nussenzweig R S
LO New York, New York, Rockville, Maryland, United States; Legon, Gha
SO Science (228, No. 4706, 1436-40, 1985) 2 Fig. 2 Tab. 23 Ref.
CODEN: SCIEAS ISSN: 0036-8075
AV Department of Medical and Molecular Parasitology, New York University Medical Center, New York 10021, U.S.A. (7 authors).
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L4 ANSWER 301 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on

AN 1985:407367 BIOSIS
DN PREV198580077359; BA80:77359
TI GROWTH OF NORMAL HUMAN T LYMPHOCYTES INDUCED BY MONOCLONAL ***ANTIBODY*** TO THE T CELL ANTIGEN RECEPTOR.
AU BOYLSTON A W [Reprint author]; COSFORD P
CS DEP PATHOLOGY, ST MARY'S HOSPITAL MED SCH, NORFOLK PLACE, PADDINGTON, LONDON W21PG, GB, UK
SO European Journal of Immunology, (1985) Vol. 15, No. 7, pp. 738-742. CODEN: EJIMAF. ISSN: 0014-2980.
DT Article
FS BA
LA ENGLISH

L4 ANSWER 302 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 108
AN 1985:388721 BIOSIS
DN PREV198580058713; BA80:58713
TI DETERMINANT HETEROGENEITY OF L-1 L-2 AND L-3 ANTIGEN MOLECULES ON HUMAN T CELLS AS DEFINED BY MONOCLONAL ***ANTIBODIES*** AND THEIR ROLES IN T CELL-MEDIATED IMMUNE FUNCTIONS.
AU TAKEI T [Reprint author]; ISHII Y
CS DEP PATHOL, SAPPORO MED COLL
SO Sapporo Medical Journal, (1985) Vol. 54, No. 3, pp. 281-300. CODEN: SIZSAR. ISSN: 0036-472X.
DT Article
FS BA
LA JAPANESE

L4 ANSWER 303 OF 374 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN DUPLICATE 109
AN 85:580 BIOBUSINESS
DN 0010784
TI A MORE SPECIFIC, SIMILAR RADIOIMMUNOASSAY FOR CARCINOEMBRYONIC ANTIGEN, WITH USE OF MONOCLONAL ***ANTIBODIES*** .
AU LIU Y-S V; TOBIAS R J; ZURAWSKI V R JR
CS CENTOCOR, 244 GREAT VALLEY PARKWAY, MALVERN, PA. 19355.
SO CLINICAL CHEMISTRY, (1985) VOL.31, NO.2, P.191-195.
FS NONUNIQUE
LA ENGLISH

L4 ANSWER 304 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1985:308182 BIOSIS
DN PREV198579088178; BA79:88178
TI A MORE SPECIFIC SIMILAR RADIOIMMUNOASSAY FOR CARCINOEMBRYONIC ANTIGEN WITH USE OF MONOCLONAL ***ANTIBODIES*** .
AU LIU Y-S V [Reprint author]; TOBIAS R J; ZURAWSKI V R JR
CS CENTOCOR, 244 GREAT VALLEY PARKWAY, MALVERN, PA 19355, USA
SO Clinical Chemistry, (1985) Vol. 31, No. 2, pp. 191-195. CODEN: CLCHAU. ISSN: 0009-9147.
DT Article
FS BA
LA ENGLISH

L4 ANSWER 305 OF 374 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 110
AN 1983:195706 BIOSIS
DN PREV198375045706; BA75:45706
TI ORGANIZATION OF RHOD OPSIN AND A HIGH MOLECULAR WEIGHT GLYCO PROTEIN IN ROD PHOTO RECEPTOR DISC MEMBRANES USING MONO CLONAL ***ANTIBODIES*** .
AU MACKENZIE D [Reprint author]; MOLDAY R S
CS DEP BIOCHEMISTRY, UNIV BRITISH COLUMBIA, VANCOUVER, BRITISH COLUMBIA V6T 1W5 CANADA
SO Journal of Biological Chemistry, (1982) Vol. 257, No. 12, pp. 7100-7105. CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
FS BA
LA ENGLISH

L4 ANSWER 306 OF 374 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1969:479219 CAPLUS
DN 71:79219
TI Quantitative studies of the specificity of antipneumococcal ***antibodies*** , types III and VIII. IV. Binding of labeled hexasaccharides derived from S3 by anti-S3 ***antibodies*** and their

AU Katz, Mōshe; Pappenheimer, Alwin M., Jr.
CS Harvard Univ., Cambridge, MA, USA
SO Journal of Immunology (1969), 103(3), 491-5
CODEN: JOIMA3; ISSN: 0022-1767
DT Journal
LA English

L4 ANSWER 307 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR54947 Protein DGENE
TI Amplifying nucleic acid by contacting engineered nucleic acid strand having predetermined sequence at one end and sequence complementary to predetermined sequence at other end, with primer having predetermined sequence -
IN Bowdish K S; Frederickson S; Maruyama T; Lin Y; Renshaw M
PA (ALEX-N) ALEXION PHARM INC.
PI WO 2003025202 A2 20030327 68p
AI WO 2002-US29889 20020919
PRAI US 2001-323455P 20010919
DT Patent
LA English
OS 2003-313359 [30]
DESC IgG light chain clone HBL4a ***3D6*** SEQ ID NO:173.

L4 ANSWER 308 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR54930 Protein DGENE
TI Amplifying nucleic acid by contacting engineered nucleic acid strand having predetermined sequence at one end and sequence complementary to predetermined sequence at other end, with primer having predetermined sequence -
IN Bowdish K S; Frederickson S; Maruyama T; Lin Y; Renshaw M
PA (ALEX-N) ALEXION PHARM INC.
PI WO 2003025202 A2 20030327 68p
AI WO 2002-US29889 20020919
PRAI US 2001-323455P 20010919
DT Patent
LA English
OS 2003-313359 [30]
DESC IgG lambda clone HBL4a ***3D6*** SEQ ID NO:156.

L4 ANSWER 309 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58275 Protein DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
CR N-PSDB: ABZ24633; ABZ24635
DESC Humanised ***3D6*** ***antibody*** heavy chain.

L4 ANSWER 310 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58274 Protein DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
CR N-PSDB: ABZ24632; ABZ24634
DESC Humanised ***3D6*** ***antibody*** light chain.

L4 ANSWER 311 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58273 Protein DGENE

for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Humanised ***3D6*** ***antibody*** heavy chain.

L4 ANSWER 312 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58272 Protein DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Humanised ***3D6*** ***antibody*** light chain.

L4 ANSWER 313 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58271 Protein DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Humanised ***3D6*** ***antibody*** heavy chain variable region.

L4 ANSWER 314 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58270 Protein DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Humanised ***3D6*** ***antibody*** light chain variable region.

L4 ANSWER 315 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58269 Protein DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]

L4 ANSWER 316 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58268 Protein DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Humanised ***3D6*** ***antibody*** light chain variable region.

L4 ANSWER 317 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58267 Peptide DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse monoclonal ***antibody*** ***3D6*** heavy chain CDR3.

L4 ANSWER 318 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58266 Peptide DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse monoclonal ***antibody*** ***3D6*** heavy chain CDR2.

L4 ANSWER 319 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58265 Peptide DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse monoclonal ***antibody*** ***3D6*** heavy chain CDR1.

L4 ANSWER 320 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58264 Peptide DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426

DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse monoclonal ***antibody*** ***3D6*** light chain CDR3.

L4 ANSWER 321 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58263 Peptide DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse monoclonal ***antibody*** ***3D6*** light chain CDR2.

L4 ANSWER 322 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP58262 Peptide DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse monoclonal ***antibody*** ***3D6*** light chain CDR1.

L4 ANSWER 323 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABG76936 Protein DGENE
TI Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has ***3D6*** /10D5 variable region complementarity determining regions and variable framework region from human acceptor immunoglobulin -
IN Basi G; Saldanha J; Yednock T
PA (NEUR-N) NEURALAB LTD.
(AMHP) WYETH.
PI WO 2002046237 A2 20020613 171p
AI WO 2001-US46587 20011206
PRAI US 2000-251892P 20001206
DT Patent
LA English
OS 2002-519658 [55]
DESC Humanised ***antibody*** associated protein #5.

L4 ANSWER 324 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABG76930 Protein DGENE
TI Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has ***3D6*** /10D5 variable region complementarity determining regions and variable framework region from human acceptor immunoglobulin -
IN Basi G; Saldanha J; Yednock T
PA (NEUR-N) NEURALAB LTD.
(AMHP) WYETH.
PI WO 2002046237 A2 20020613 171p
AI WO 2001-US46587 20011206
PRAI US 2000-251892P 20001206
DT Patent
LA English
OS 2002-519658 [55]
DESC Humanised ***antibody*** associated protein #4.

L4 ANSWER 325 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABG76929 Protein DGENE
TI Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has ***3D6*** /10D5 variable region

human acceptor immunoglobulin -
IN Basi G; Saldanha J; Yednock T
PA (NEUR-N) NEURALAB LTD.
(AMHP) WYETH.
PI WO 2002046237 A2 20020613 171p
AI WO 2001-US46587 20011206
PRAI US 2000-251892P 20001206
DT Patent
LA English
OS 2002-519658 [55]
DESC Humanised ***antibody*** associated protein #3.

L4 ANSWER 326 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABG76927 Protein DGENE
TI Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has ***3D6*** /10D5 variable region complementarity determining regions and variable framework region from human acceptor immunoglobulin -
IN Basi G; Saldanha J; Yednock T
PA (NEUR-N) NEURALAB LTD.
(AMHP) WYETH.
PI WO 2002046237 A2 20020613 171p
AI WO 2001-US46587 20011206
PRAI US 2000-251892P 20001206
DT Patent
LA English
OS 2002-519658 [55]
DESC Humanised ***antibody*** associated protein #2.

L4 ANSWER 327 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABG76926 Protein DGENE
TI Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has ***3D6*** /10D5 variable region complementarity determining regions and variable framework region from human acceptor immunoglobulin -
IN Basi G; Saldanha J; Yednock T
PA (NEUR-N) NEURALAB LTD.
(AMHP) WYETH.
PI WO 2002046237 A2 20020613 171p
AI WO 2001-US46587 20011206
PRAI US 2000-251892P 20001206
DT Patent
LA English
OS 2002-519658 [55]
DESC Humanised ***antibody*** associated protein #1.

L4 ANSWER 328 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAW19507 protein DGENE
TI Testing compounds for an effect on an Alzheimer's disease marker - uses non-human transgenic animals which can control expression of major forms of beta-amyloid precursor protein
IN Games K D; McConlogue L C; Rydel R E; Schenk D B; Seubert P A
PA (ATHE-N) ATHENA NEUROSCIENCES INC.
PI WO 9640896 A1 19961219 139p
AI WO 1996-US9857 19960607
PRAI US 1995-480653 19950607
DT Patent
LA English
OS 1997-052309 [05]
DESC Immunogen for raising monoclonal ***antibody*** ***3D6*** for A-beta recognition.

L4 ANSWER 329 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAW19494 protein DGENE
TI Transgenic mammal comprising DNA encoding A-beta-contg. protein - useful as animal model to test potential Alzheimer's disease treatments
IN McConlogue L C; Seubert P A
PA (ATHE-N) ATHENA NEUROSCIENCES INC.
PI WO 9640895 A1 19961219 116p
AI WO 1996-US9679 19960607
PRAI US 1995-486538 19950607
US 1995-486018 19950607
DT Patent
LA English
OS 1997-052308 [05]

A-beta recognition.

L4 ANSWER 330 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52521 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 CDR-H2.

L4 ANSWER 331 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52537 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 heavy chain complementarity determining region 1.

L4 ANSWER 332 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52536 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 heavy chain complementarity determining region 1.

L4 ANSWER 333 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52535 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 heavy chain complementarity determining region 1.

L4 ANSWER 334 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52534 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** light chain complementarity determining region 3.

L4 ANSWER 335 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52533 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 light chain complementarity determining region 3.

L4 ANSWER 336 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52532 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 light chain complementarity determining region 3.

L4 ANSWER 337 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52531 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 light chain complementarity determining region 3.

L4 ANSWER 338 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52530 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent

OS 1994-120230 [15]
DESC ***3D6*** light chain complementarity determining region 2.

L4 ANSWER 339 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52529 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 light chain complementarity determining region 2.

L4 ANSWER 340 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52528 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 light chain complementarity determining region 2.

L4 ANSWER 341 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52527 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 light chain complementarity determining region 2.

L4 ANSWER 342 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52526 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** light chain complementarity determining region 1.

L4 ANSWER 343 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52525 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies***

V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 light chain complementarity determining region 1.

L4 ANSWER 344 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52524 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 light chain complementarity determining region 1.

L4 ANSWER 345 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52523 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 light chain complementarity determining region 1.

L4 ANSWER 346 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52522 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC F19.9 CDR-H2.

L4 ANSWER 347 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52546 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909

LA English
OS 1994-120230 [15]
DESC ***3D6*** heavy chain complementarity determining region 3.

L4 ANSWER 348 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52545 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 heavy chain complementarity determining region 3.

L4 ANSWER 349 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52544 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 heavy chain complementarity determining region 3.

L4 ANSWER 350 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52543 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 heavy chain complementarity determining region 3.

L4 ANSWER 351 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52542 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** heavy chain complementarity determining region 2.

L4 ANSWER 352 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52541 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised

with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 heavy chain complementarity determining region 2.

L4 ANSWER 353 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52540 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 heavy chain complementarity determining region 2.

L4 ANSWER 354 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52539 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 heavy chain complementarity determining region 2.

L4 ANSWER 355 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR52538 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised ***antibody*** forms - for producing non-human ***antibodies*** with improved therapeutic efficiency by presenting human surface on V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** heavy chain complementarity determining region 1.

L4 ANSWER 356 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR20059 Protein DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 - contains variable region of ***antibody*** derived from ***3D6*** cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F
PA (JUNG-I) JUNGBAUER A.
PI WO 9118983 A 19911212 52p
AI WO 1991-1000067 19910528
PRAI AT 1990-1178 19900529
DT Patent

OS 1992-007468 [01]
CR N-PSDB: AAQ20068
DESC Recombinant sc3D6 anti-HIV gp160 ***antibody*** .

L4 ANSWER 357 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR20058 Protein DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 - contains variable region of ***antibody*** derived from ***3D6*** cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F
PA (JUNG-I) JUNGBAUER A.
PI WO 9118983 A 19911212 52p
AI WO 1991-1000067 19910528
PRAI AT 1990-1178 19900529
DT Patent
LA German
OS 1992-007468 [01]
CR N-PSDB: AAQ20067
DESC Light chain of ***3D6*** anti-HIV ***antibody*** .

L4 ANSWER 358 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR20057 Protein DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 - contains variable region of ***antibody*** derived from ***3D6*** cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F
PA (JUNG-I) JUNGBAUER A.
PI WO 9118983 A 19911212 52p
AI WO 1991-1000067 19910528
PRAI AT 1990-1178 19900529
DT Patent
LA German
OS 1992-007468 [01]
CR N-PSDB: AAQ20066
DESC Heavy chain of ***3D6*** anti-HIV ***antibody*** .

L4 ANSWER 359 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABZ24637 DNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse heavy chain variable region 3' PCR primer.

L4 ANSWER 360 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABZ24636 DNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse light chain variable region 3' PCR primer.

L4 ANSWER 361 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABZ24635 cDNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M

PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
CR P-PSDB: ABP58275
DESC Humanised ***3D6*** ***antibody*** heavy chain gene.

L4 ANSWER 362 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABZ24634 DNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
CR P-PSDB: ABP58274
DESC Humanised ***3D6*** ***antibody*** light chain gene.

L4 ANSWER 363 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABZ24633 cDNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
CR P-PSDB: ABP58275
DESC Humanised ***3D6*** ***antibody*** heavy chain cDNA.

L4 ANSWER 364 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABZ24632 cDNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful for treating Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
CR P-PSDB: ABP58274
DESC Humanised ***3D6*** ***antibody*** light chain cDNA.

L4 ANSWER 365 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ20068 DNA DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 - contains variable region of ***antibody*** derived from ***3D6*** cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F
PA (JUNG-I) JUNGBAUER A.
PI WO 9118983 A 19911212 52p
AI WO 1991-1000067 19910528
PRAI AT 1990-1178 19900529
DT Patent
LA German
OS 1992-007468 [01]
CR P-PSDB: AAR20059
DESC Encodes recombinant sc3D6 anti-HIV gp160 ***antibody*** .

L4 ANSWER 366 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ20067 DNA DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 - contains variable region of ***antibody*** derived from ***3D6*** cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F
PA (JUNG-I) JUNGBAUER A.
PI WO 9118983 A 19911212 52p
AI WO 1991-1000067 19910528
PRAI AT 1990-1178 19900529
DT Patent
LA German
OS 1992-007468 [01]
CR P-PSDB: AAR20058
DESC Encodes light chain of ***3D6*** anti-HIV ***antibody*** .

L4 ANSWER 367 OF 374 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ20066 DNA DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 - contains variable region of ***antibody*** derived from ***3D6*** cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F
PA (JUNG-I) JUNGBAUER A.
PI WO 9118983 A 19911212 52p
AI WO 1991-1000067 19910528
PRAI AT 1990-1178 19900529
DT Patent
LA German
OS 1992-007468 [01]
CR P-PSDB: AAR20057
DESC Encodes heavy chain of ***3D6*** ***antibody*** .

L4 ANSWER 368 OF 374 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): A21387 GenBank (R)
GenBank ACC. NO. (GBN): A21387
GenBank VERSION (VER): A21387.1 GI:583511
CAS REGISTRY NO. (RN): 389191-84-8
SEQUENCE LENGTH (SQL): 776
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Patent
DATE (DATE): 12 Jul 1994
DEFINITION (DEF): Plasmid DNA with human cDNA insert.
SOURCE: synthetic construct.
ORGANISM (ORGN): synthetic construct
artificial sequence
NUCLEIC ACID COUNT (NA): 184 a 178 c 221 g 193 t
REFERENCE: 1 (bases 1 to 776)
AUTHOR (AU): .
TITLE (TI): RECOMBINANT PROTEIN WHICH BINDS TO A COMPLEX VIRAL ANTIGEN OF HIV-1
JOURNAL (SO): Patent: WO 9118983-A 3 12-DEC-1991;

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..776	/organism="synthetic construct" /db-xref="taxon:32630"
CDS	14..760	/codon-start=1 /transl-table=11 /product="Fv-fragment of antibody 3D6" /protein-id="CAA01551.1" /db-xref="GI:583512" /translation="MEVQLVESGGGLVQPGRSLR LSCAASGFTFNDYAMHWVRQAPGK GLEWVSGISWDSSSIGYADSVKGRFTISRDNAKN SLYLQMNSLRAEDMALYYCVKGRD YYDSGGYFTVAFDIWGQGTMVTVSSGGGGSGGGG SGGGGSDIQMTQSPSTLSASVGDR VTITCRASQSISRWLAWYQQKPGKVPKLLIYKAS SLESGVPSRFSGSGSGTEFTLTIS SLQPDDFATYYCQQYNSYSFGPGTKVDIKR"

SEQUENCE (SEQ):

```
  61 caggtccctg agactcctcc gtgcagcctc tggattcacc tttaatgatt atgccatgca
 121 ctgggtccgg caagctccag ggaagggcct ggagtgggtc tcaggtataa gttgggatag
 181 tagtagtata ggctatgcgg actctgtgaa gggccgattc accatctcca gagacaacgc
 241 caagaactcc ctgtatctgc aaatgaacag tctgagagct gaggacatgg ccttatatta
 301 ctgtgtaaaa ggcagagatt actatgatag tggtggttat ttcacggttg cttttgatat
 361 ctggggccaa gggacaatgg tcaccgtctc ttcaggtggc ggtggctcgg gcggtggtgg
 421 gtcgggtggc ggcggatctg acatccagat gacccagtct ccttccaccc tgtctgcatc
 481 tgtaggagac agagtcacca tcacttgccg ggccagtcag agtattagta ggtggttggc
 541 ctggtatcag cagaaaccag ggaaagtccc taagctcctg atctataagg catctagttt
 601 agaaagtggg gtcccatcaa ggttcagcgg cagtggatct gggacagaat tcactctcac
 661 catcagcagc ctgcagcctg atgattttgc aacttattac tgccaacagt ataatagtta
 721 ttctttcggc cctgggacca aagtggatat caaacgataa gcttctgcac catctg
```

L4 ANSWER 369 OF 374 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): A21386 GenBank (R)
GenBank ACC. NO. (GBN): A21386
GenBank VERSION (VER): A21386.1 GI:583509
CAS REGISTRY NO. (RN): 389191-83-7
SEQUENCE LENGTH (SQL): 945
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Patent
DATE (DATE): 12 Jul 1994
DEFINITION (DEF): Plasmid DNA with human cDNA insert.
SOURCE: synthetic construct.
ORGANISM (ORGN): synthetic construct
artificial sequence
NUCLEIC ACID COUNT (NA): 229 a 274 c 226 g 216 t
REFERENCE: 1 (bases 1 to 945)
AUTHOR (AU): .
TITLE (TI): RECOMBINANT PROTEIN WHICH BINDS TO A COMPLEX VIRAL ANTIGEN OF HIV-1
JOURNAL (SO): Patent: WO 9118983-A 2 12-DEC-1991;

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..945	/organism="synthetic construct" /db-xref="taxon:32630"
CDS	28..732	/codon-start=1 /transl-table=11 /product="3D6 antibody light chain" /protein-id="CAA01550.1" /db-xref="GI:583510" /translation="MDMRVPAQLLGLLLLWLPGA KCDIQMTQSPSTLSASVGDRVTIT CRASQSISRWLAWYQQKPGKVPKLLIYKASSLES GVPSRFSGSGSGTEFTLTISSLQP DDFATYYCQQYNSYSFGPGTKVDIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFY PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC"

SEQUENCE (SEQ):

```
   1 gtgaattcga gctcggtacc ccacagcatg gacatgaggg tccccgctca gctcctgggg
  61 ctcctgctgc tctggctccc aggtgccaaa tgtgacatcc agatgaccca gtctccttcc
 121 accctgtctg catctgtagg agacagagtc accatcactt gccgggccag tcagagtatt
 181 agtaggtggt tggcctggta tcagcagaaa ccagggaaag tccctaagct cctgatctat
 241 aaggcatcta gtttagaaag tggggtccca tcaaggttca gcggcagtgg atctgggaca
 301 gaattcactc tcaccatcag cagcctgcag cctgatgatt ttgcaactta ttactgccaa
 361 cagtataata gttattcttt cggccctggg accaaagtgg atatcaaacg aactgtggct
 421 gcaccatctg tcttcatctt cccgccatct gatgagcagt tgaaatctgg aactgcctct
 481 gttgtgtgcc tgctgaataa cttctatccc agagaggcca aagtacagtg gaaggtggat
 541 aacgccctcc aatcgggtaa ctcccaggag agtgtcacag agcaggacag caaggacagc
 601 acctacagcc tcagcagcac cctgacgctg agcaaagcag actacgagaa acacaaagtc
 661 tacgcctgcg aagtcaccca tcagggcctg agctcgcccg tcacaaagag cttcaacagg
 721 ggagagtgtt agcacctgct cctcagttcc agcctgaccc cctcccatcc tttggcctct
 781 gaccctttt ccacagggga cctacccta ttgcggtcct ccagctcatc tttcacctca
 841 ccccctcct cctccttggc tttaattatg ctaatgttgg aggagaatga ataaataaag
 901 tgaatgggga tcctctagag tcgacctgca ggcatgcaag cttgg
```

L4 ANSWER 370 OF 374 GENBANK.RTM. COPYRIGHT 2004 on STN

GenBank ACC. NO. (GBN): A21385
GenBank VERSION (VER): A21385.1 GI:583507
CAS REGISTRY NO. (RN): 389191-86-0
SEQUENCE LENGTH (SQL): 1549
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Patent
DATE (DATE): 19 Dec 1994
DEFINITION (DEF): Plasmid DNA with human cDNA insert.
SOURCE: synthetic construct.
ORGANISM (ORGN): synthetic construct
artificial sequence
NUCLEIC ACID COUNT (NA): 362 a 463 c 417 g 307 t
REFERENCE: 1 (bases 1 to 1549)
AUTHOR (AU): .
TITLE (TI): RECOMBINANT PROTEIN WHICH BINDS TO A COMPLEX VIRAL ANTIGEN OF HIV-1
JOURNAL (SO): Patent: WO 9118983-A 1 12-DEC-1991;

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..1549	/organism="synthetic construct" /db-xref="taxon:32630"
CDS	101..1528	/codon-start=1 /transl-table=11 /product="heavy chain antibody 3D6" /protein-id="CAA01549.1" /db-xref="GI:583508" /translation="MELGLSWIFLLAILKGVQCE VQLVESGGGLVQPGRSLRLSCAAS GFTFNDYAMHWVRQAPGKGLEWVSGISWDSSSIG YADSVKGRFTISRDNAKNSLYLQM NSLRAEDMALYYCVKGRDYYDSGGYFTVAFDIWG QGTMVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK"

SEQUENCE (SEQ):

```
     1 gtgaattcga gctcggtacc cggggatcct ctagagtccc agccctgaga ttcccaggtg
    61 tttccattca gtgatcagca ctgaacacag aggactcacc atggagttgg gactgagctg
   121 gattttcctt ttggctattt taaaaggtgt ccagtgtgaa gtgcagctgg tggagtctgg
   181 gggaggcttg gtacagcctg gcaggtccct gagactctcc tgtgcagcct ctggattcac
   241 ctttaatgat tatgccatgc actgggtccg gcaagctcca gggaagggcc tggagtgggt
   301 ctcaggtata agttgggata gtagtagtat aggctatgcg gactctgtga agggccgatt
   361 caccatctcc agagacaacg ccaagaactc cctgtatctg caaatgaaca gtctgagagc
   421 tgaggacatg gccttatatt actgtgtaaa aggcagagat tactatgata gtggtggtta
   481 tttcacggtt gcttttgata tctggggcca agggacaatg gtcaccgtct cttcagcctc
   541 caccaagggc ccatcggtct tccccctggc accctcctcc aagagcacct ctgggggcac
   601 agcagccctg ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa
   661 ctcaggcgcc ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact
   721 ctactccctc agcagcgtgg tgaccgtgcc ctccagcagc ttgggcaccc agacctacat
   781 ctgcaacgtg aatcacaagc ccagcaacac caaggtggac aagaaagttg agcccaaatc
   841 ttgtgacaaa actcacacat gcccaccgtg cccagcacct gaactcctgg ggggaccgtc
   901 agtcttcctc ttccccccaa aacccaagga caccctcatg atctcccgga ccctgaggt
   961 cacatgcgtg gtggtggacg tgagccacga agaccctgag gtcaagttca actggtacgt
  1021 ggacggcgtg gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaactccac
  1081 gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta
  1141 caagtgcaag gtctccaaca aagccctccc agcccccatc gagaaaacca tctccaaagc
  1201 caaagggcag ccccgagaac cacaggtgta caccctgccc ccatcccggg atgagctgac
  1261 caagaaccag gtcagcctga cctgcctggt caaaggcttc tatcccagcg acatcgccgt
  1321 ggagtgggag agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga
  1381 ctccgacggc tccttcttcc tctacagcaa gctcaccgtg gacaagagca ggtggcagca
  1441 ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa
  1501 gagcctctcc ctgtctccgg gtaaatgaga cctgcaggca tgcaagctt
```

LOCUS (LOC): MUSIGVHC GenBank (R)
GenBank ACC. NO. (GBN): D14172
GenBank VERSION (VER): D14172.1 GI:784932
CAS REGISTRY NO. (RN): 384577-20-2
SEQUENCE LENGTH (SQL): 341
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Rodents
DATE (DATE): 24 Jan 2003
DEFINITION (DEF): Mus musculus mRNA, immunoglobulin heavy chain variable region (anti-CD8 monoclonal ***antibody***), partial sequence, clone:TD- ***3D6*** .
KEYWORDS (ST): VH region
SOURCE: Mus musculus (house mouse)
ORGANISM (ORGN): Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus
NUCLEIC ACID COUNT (NA): 97 a 83 c 89 g 72 t
COMMENT:
On Apr 26, 1995 this sequence version replaced gi:498370.
REFERENCE: 1 (bases 1 to 341)
AUTHOR (AU): Sato,T.; Kon,S.
TITLE (TI): Analysis of the immunoglobulin heavy chain variable region of hybridomas producing anti-CD8 monoclonal antibodies
JOURNAL (SO): Sapporo Med. J., 62, 31-41 (1993)
OTHER SOURCE (OS): CA 121:80571
REFERENCE: 2 (bases 1 to 341)
AUTHOR (AU): Kon,S.
TITLE (TI): Direct Submission
JOURNAL (SO): Submitted (25-JAN-1993) Shinichiro Kon, Sapporo Medical College, Department of Pathology; South1, West17, Chuo-ku, Sapporo 060, Japan (Tel:011-611-2111(ex.2311), Fax:011-643-2310)

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..341	/organism="Mus musculus" /strain="BALB/c" /db-xref="taxon:10090" /clone="TD-3D6" /cell-type="hybridoma (TD series)"
V-region	<1..>341	/product="anti-CD8 monoclonal antibody" /db-xref="IMGT/LIGM:D14172"
misc-feature	1..89	/note="FR1"
misc-feature	90..104	/note="CDR1"
misc-feature	105..146	/note="FR2"
misc-feature	147..197	/note="CDR2"
misc-feature	198..293	/note="FR3"
misc-feature	294..317	/note="CDR3"
misc-feature	318..341	/note="FR4"

SEQUENCE (SEQ):
1 aggtccaact gcagcagtct ggagctgaac tgatgaagcc tggggcctca gtgaagatat
61 cctgcaaggc tactggcaac acattcagaa ccaactggat agagtgggta aaacagaggc
121 ctggacatgg ccttgagtgg attggagaga ttttacctgg aagtggtagt accaactacc
181 atgagaagtt caaggataag gccacattca ctgcagacat atcctccaac acagcctaca
241 tacaactcag cagcctgaca tctgaggact ctgccgtcta ttactgtgca agactgagtg
301 attccaagtt tgcttactgg ggcgcaggga ccacggtcac c

L4 ANSWER 372 OF 374 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): HS3D6LCV GenBank (R)
GenBank ACC. NO. (GBN): X53612
GenBank VERSION (VER): X53612.1 GI:23868
CAS REGISTRY NO. (RN): 140555-39-1
SEQUENCE LENGTH (SQL): 381
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Primates
DATE (DATE): 3 Apr 1995
DEFINITION (DEF): Human mRNA for ***3D6*** light chain variable region.

```
 ORGANISM (ORGN):          Homo sapiens
                           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
                           Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini;
                           Hominidae; Homo
NUCLEIC ACID COUNT (NA): 92 a   101 c   95 g   93 t
COMMENT:
     This comes from serum of a HIV-1 positive individual.
REFERENCE:                 1  (bases 1 to 381)
   AUTHOR (AU):            Rueker,F.
   TITLE (TI):             Direct Submission
   JOURNAL (SO):           Submitted (26-JUN-1990) Rueker F., Institut fuer
                           Angewandte Mikrobiologie, Universitaet fuer
                           Bodenkultur, Peter Jordanstr. 82, A-1190 Wien, Austria
REFERENCE:                 2  (bases 1 to 381)
   AUTHOR (AU):            Felgenhauer,M.; Kohl,J.; Ruker,F.
   TITLE (TI):             Nucleotide sequences of the cDNAs encoding the
                           V-regions of H- and L-chains of a human monoclonal
                             ***antibody***   specific to HIV-1-gp41
   JOURNAL (SO):           Nucleic Acids Res., 18 (16), 4927 (1990)
   OTHER SOURCE (OS):      CA 113:166692

FEATURES (FEAT):
  Feature Key       Location                  Qualifier
==============+=====================+================================
source          1..381                    /organism="Homo sapiens"
                                          /isolate="monoclonal antibody 3D6"
                                          /db-xref="taxon:9606"
                                          /cell-line="3D6."
                                          /cell-type="rearranged
                                          lymphoblastoid"
sig-peptide     1..66
CDS             1..>381                   /codon-start=1
                                          /product="kappa light chain
                                          V-region"
                                          /protein-id="CAA37674.1"
                                          /db-xref="GI:762937"
                                          /translation="MDMRVPAQLLGLLLLWLPGA
                                          KCDIQMTQSPSTLSASVGDRVTIT
                                          CRASQSISRWLAWYQQKPGKVPKLLIYKASSLES
                                          GVPSRFSGSGSGTEFTLTISSLQP
                                          DDFATYYCQQYNSYSFGPGTKVDIK"
V-region        67..>381                  /note="variable region (AA 23 -
                                          127)"

SEQUENCE (SEQ):
     1 atggacatga gggtccccgc tcagctcctg gggctcctgc tgctctggct cccaggtgcc
    61 aaatgtgaca tccagatgac ccagtctcct tccaccctgt ctgcatctgt aggagacaga
   121 gtcaccatca cttgccgggc cagtcagagt attagtaggt ggttggcctg gtatcagcag
   181 aaaccaggga aagtccctaa gctcctgatc tataaggcat ctagtttaga aagtggggtc
   241 ccatcaaggt tcagcggcag tggatctggg acagaattca ctctcaccat cagcagcctg
   301 cagcctgatg attttgcaac ttattactgc caacagtata atagttattc tttcggccct
   361 gggaccaaag tggatatcaa a

L4   ANSWER 373 OF 374    GENBANK.RTM.  COPYRIGHT 2004 on STN

LOCUS (LOC):               HS3D6HCV     GenBank (R)
GenBank ACC. NO. (GBN):    X53613
GenBank VERSION (VER):     X53613.1  GI:23865
CAS REGISTRY NO. (RN):     139841-87-5
SEQUENCE LENGTH (SQL):     435
MOLECULE TYPE (CI):        mRNA; linear
DIVISION CODE (CI):        Primates
DATE (DATE):               3 Apr 1995
DEFINITION (DEF):          Human mRNA for   ***3D6***   heavy chain variable
                           region.
SOURCE:                    human.
 ORGANISM (ORGN):          Homo sapiens
                           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
                           Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini;
                           Hominidae; Homo
NUCLEIC ACID COUNT (NA): 99 a   87 c   130 g   119 t
COMMENT:
     This comes from serum of a HIV-1 positive individual.
REFERENCE:                 1  (bases 1 to 435)
   AUTHOR (AU):            Rueker,F.
```

JOURNAL (SO): Submitted (26-JUN-1990) Rueker F., Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Peter Jordanstr. 82, A-1190 Wien, Austria

REFERENCE: 2 (bases 1 to 435)
AUTHOR (AU): Felgenhauer,M.; Kohl,J.; Ruker,F.
TITLE (TI): Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of a human monoclonal ***antibody*** specific to HIV-1-gp41
JOURNAL (SO): Nucleic Acids Res., 18 (16), 4927 (1990)
OTHER SOURCE (OS): CA 113:166692

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..435	/organism="Homo sapiens" /isolate="monoclonal antibody 3D6" /db-xref="taxon:9606" /cell-line="3D6." /cell-type="rearranged lymphoblastoid"
sig-peptide	1..57	
CDS	1..>435	/codon-start=1 /product="kappa light chain V-region" /protein-id="CAA37675.1" /db-xref="GI:762936" /translation="MELGLSWIFLLAILKGVQCE VQLVESGGGLVQPGRSLRLSCAAS GFTFNDYAMHWVRQAPGKGLEWVSGISWDSSSIG YADSVKGRFTISRDNAKNSLYLQM NSLRAEDMALYYCVKGRDYYDSGGYFTVAFDIWG QGTMVTVSS"
V-region	58..>435	/note="variable region (AA 20 - 145)"

SEQUENCE (SEQ):

```
     1 atggagttgg gactgagctg gattttcctt ttggctattt taaaaggtgt ccagtgtgaa
    61 gtgcagctgg tggagtctgg gggaggcttg gtacagcctg gcaggtccct gagactctcc
   121 tgtgcagcct ctggattcac ctttaatgat tatgccatgc actgggtccg gcaagctcca
   181 gggaagggcc tggagtgggt ctcaggtata agttgggata gtagtagtat aggctatgcg
   241 gactctgtga agggccgatt caccatctcc agagacaacg ccaagaactc cctgtatctg
   301 caaatgaaca gtctgagagc tgaggacatg gccttatatt actgtgtaaa aggcagagat
   361 tactatgata gtggtggtta tttcacggtt gcttttgata tctggggcca agggacaatg
   421 gtcaccgtct cttca
```

L4 ANSWER 374 OF 374 NTIS COPYRIGHT 2004 NTIS on STN
AN 1988(15):00270 NTIS Order Number: PB88-167978/XAB
TI Immunometric Assay for High Molecular Weight Carcinoembryonic Antigen. Patent Application
IN Schlom, J.
PA Department of Health and Human Services, Washington, DC. (068119000)
NR PB88-167978/XAB; PAT-APPL-6-790 261
26p; Filed 22 Oct 85
AI US 1985-790261 19851022
DT Patent
CY United States
LA English
AV This Government-owned invention available for U.S. licensing and, possibly, for foreign licensing. Copy of application available NTIS. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)605-6900; and email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.
NTIS Prices: PC A03/MF A01
OS GRA&I8811
STN INTERNATIONAL LOGOFF AT 15:10:29 ON 14 DEC 2004